IL-7 binding proteins and their use in medical therapy

JP2023551935A5Inactive Publication Date: 2024-12-04GLAXOSMITHKLINE INTPROP DEV LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023533733
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-02
Filing Date
2021-11-30
Publication Date
2024-12-04
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Pathogenic CD4+ T cells, particularly T H1 and T H17 subsets, contribute to autoimmune diseases like multiple sclerosis by producing inflammatory cytokines, and IL-7 is crucial for their survival and activation, necessitating the development of antagonists to inhibit the IL-7/IL-7R pathway for therapeutic intervention.

Method used

IL-7 binding proteins, such as antibodies or antigen-binding fragments, are developed to bind specifically to human IL-7 residues, inhibiting its interaction with the IL-7R, thereby blocking signaling pathways and reducing cytokine production and T cell activation.

Benefits of technology

The IL-7 binding proteins effectively inhibit IL-7-dependent signaling, reducing inflammation and autoimmune responses, offering therapeutic potential for conditions like multiple sclerosis, rheumatoid arthritis, Crohn's disease, and other autoimmune disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000100_0000
    Figure 00000100_0000
  • Figure 00000100_0001
    Figure 00000100_0001
  • Figure 00000100_0002
    Figure 00000100_0002
Patent Text Reader

Abstract

Provided herein are interleukin-7 (IL-7) binding proteins, pharmaceutical compositions and their uses in the treatment or prevention of diseases or conditions.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This disclosure relates to interleukin-7 (IL-7) binding proteins. This disclosure also relates to methods for treating diseases or disorders with IL-7 binding proteins, the use of IL-7 binding proteins, pharmaceutical compositions comprising IL-7 binding proteins, and methods for producing the same. Other aspects of this disclosure will become apparent from the following description. [Background technology]

[0002] Both altered autoimmune T cell responses and dysfunction of the immune system's regulatory network play important roles in human autoimmune conditions such as multiple sclerosis (MS) and rheumatoid arthritis (Kuchroo et al., (2002) Annu. Rev. Immunol. 20:101-123; Sospedra and Martin (2005) Annu. Rev. Immunol. 23: 683-747; Toh and Miossec (2007) Curr. Opin. Rheumatol. 19:284-288).

[0003] The etiology and pathogens of MS remain unknown, but generally, T H 1 and T H It is thought to be an autoimmune disease in which pathogenic, autoreactive T cells such as 17 cells play a crucial role. There is evidence that these effector T cells are activated in vivo during the course of the disease and are caused by central nervous system (CNS) inflammation. There is also evidence that in the lesions of experimental autoimmune encephalomyelitis (EAE) and MS, these T cells mediate the destruction of myelin-expressing cells during the active phase of the disease. On the other hand, in typical MS patients, pathogenic T cells H 1 and T H Regulatory T cells (T reg ) is deficient, further shifting the immune system towards a pro-inflammatory state.

[0004] IL-7 and its receptor (IL-7R) are known to play crucial roles in T cell and B cell development and homeostasis, primarily in the thymic environment. In humans, IL-7 is essential for T cell development in the thymus and for the survival of memory T cells and naive T cells in the periphery. Indeed, thymic stromal cells, the fetal thymus, and bone marrow are sites of IL-7 production.

[0005] IL-7 is a bundle of four helices, exhibiting a conserved up-up-down-down cytokine structure. Based on the research by McElroy et al. (Structure, 2009, 17:54-65), the helices of IL-7 extend from amino acids 10-26 (Helix A), 53-63 (Helix B), 74-91 (Helix C), and 128-146 (Helix D), starting from the one closest to the N-terminus. A mini-helix is ​​thought to exist between Helix A and Helix B, extending to amino acids 40-44. For the purposes of this disclosure, helices A, B, C, and D are referred to as Helix 1, 3, 4, and 5, and the mini-helix is ​​referred to as Helix 2. Therefore, the loops that interconnect the helices extend from amino acids 27–39 ("loop 1" between helices 1 and 2), 45–52 ("loop 2" between helices 2 and 3), 64–73 ("loop 3" between helices 3 and 4), and 92–127 ("loop 4" between helices 4 and 5). The "N-terminal loop" extends from amino acids 1–9, and the "C-terminal loop" extends from amino acids 147–152.

[0006] The IL-7 receptor consists of two subunits: CD127 and a common chain (γ chain or γc) shared by the IL-2, IL-4, IL-9, IL-15, and IL-21 receptors. CD127 is also known as IL-7 receptor α (IL-7Rα) and p90 IL-7R. Human CD127 (Swiss Prot accession number P16871) has a total of 459 amino acids (a 20-amino acid signal sequence). Human CD127 consists of an extracellular domain of 219 amino acids, a transmembrane domain of 25 amino acids, and an intracellular domain of 195 amino acids. IL-7Rα and γc are required for signal transduction. While the crystal structure of the IL-7 / IL-7Rα ECD (extracellular domain) complex has been elucidated (McElroy et al., cited above), information on the interaction between IL-7 and the functional IL-7Rα / γc receptor complex is limited to date. Although the IL-7 residues crucial in this interaction have not been determined, helix A (helix 1 in this specification) and helix D (helix 5 in this specification) are generally predicted to be involved in the binding of IL-7 to γc.

[0007] The binding of IL-7 to the IL-7R complex activates multiple signaling pathways, including the activation of JAK kinases 1 and 3, leading to the phosphorylation and activation of STAT5. This pathway is essential for the survival of T cell precursors developing in the thymus, as STAT5 activation is required for the induction of the anti-apoptotic protein Bcl-2 and the prevention of the entry of the pro-apoptotic protein Bax into mitochondria. Another IL-7R-mediated pathway is the activation of PI3 kinase, which in turn leads to the phosphorylation and retention of the pro-apoptotic protein BAD (BCL2-associated agonist of cell death) in the cytoplasm. [Overview of the project] [Problems that the invention aims to solve]

[0008] Pathogenic CD4 in multiple sclerosis (MS) + T cells are primarily T H1 and T H derived from 17 subsets and reflected by the production of inflammatory cytokines (such as IFN-γ, IL-17, and GM-CSF) from these cells. These cytokines contribute to blood-brain barrier dysfunction, inflammation, and the activation of resident astrocytes and microglial cells. IL-7 can induce the Th1 and Th 17 phenotype, and effector memory T cells depend on IL-7 for survival and proliferation. The pathogenic autoreactive T cells in MS are maintained by the memory T cell pool, and IL-7 is important for its generation, proliferation, and activation. Therefore, it is desirable to develop antagonists of the IL-7 / IL-7R pathway. Such antagonists are useful therapeutically in the treatment of MS and other inflammatory and / or autoimmune diseases and disorders, particularly those in which an increase in T H 1 and / or T H 17 cells is observed.

Means for Solving the Problems

[0009] As used herein, an IL-7 binding protein, such as an IL-7 binding antibody or an antigen-binding fragment thereof, is disclosed.

[0010] In one aspect of the invention, an IL-7 binding protein that binds to one or more amino acid residues within the amino acid sequence of human IL-7 shown in SEQ ID NO: 12 is provided. In one embodiment, the IL-7 binding protein protects residues 67-81 (SEQ ID NO: 12) of IL-7 from deuterium exchange in HDX-MS analysis. In a further embodiment, the IL-7 binding protein protects residues 67-80 (SEQ ID NO: 16) of IL-7 from deuterium exchange in HDX-MS analysis.

[0011] In another aspect of the present invention, an IL-7 binding protein is provided that binds adjacent to the IL-7Rα binding site to human IL-7 with a KD of 100 nM or less as measured by surface plasmon resonance assay. In some embodiments, the IL-7 binding protein inhibits the binding of IL-7 to IL-7R as measured by an in vitro competitive binding assay determined using surface plasmon resonance assay. In other embodiments, the IL-7 binding protein further comprises one or more of the following: CDRH1 shown in SEQ ID NO: 6, CDRH2 shown in SEQ ID NO: 7, CDRH3 shown in SEQ ID NO: 8, CDRL1 shown in SEQ ID NO: 9, CDRL2 shown in SEQ ID NO: 10, and / or CDRL3 shown in SEQ ID NO: 11.

[0012] In a further aspect of the present invention, the IL-7 binding protein comprises CDRH1 shown in SEQ ID NO: 6, CDRH2 shown in SEQ ID NO: 7, CDRH3 shown in SEQ ID NO: 8, CDRL1 shown in SEQ ID NO: 9, CDRL2 shown in SEQ ID NO: 10, and CDRL3 shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises V having at least 90% identity with the amino acid sequence shown in SEQ ID NO: 4. H V having at least 90% identity with the amino acid sequence shown in the domain and / or SEQ ID NO: 5 L It comprises a domain. In another embodiment, the IL-7 binding protein is V shown in SEQ ID NO: 4. H Domain and V shown in Sequence ID No. 5 LThe IL-7-binding protein comprises a domain. In some embodiments, the IL-7-binding protein comprises a constant region such that the IL-7-binding protein has reduced ADCC and / or complement activation or reduced effector function. In some embodiments, the IL-7-binding protein comprises a heavy chain Fc domain having alanine residues at positions 235 and 237 according to EU numbering. In other embodiments, the IL-7-binding protein comprises a scaffold selected from the group consisting of human IgG1 isotype and human IgG4 isotype. In one embodiment, the IL-7-binding protein is a human IgG1 isotype. In another embodiment, the IL-7-binding protein is a monoclonal antibody. In some embodiments, the monoclonal antibody is a human, humanized, or chimeric antibody. In other embodiments, the IL-7-binding protein comprises a heavy chain having at least 90% identity with the amino acid sequence shown in SEQ ID NO: 2 and a light chain having at least 90% identity with the amino acid sequence shown in SEQ ID NO: 3. In one embodiment, the IL-7 binding protein comprises a heavy chain shown in SEQ ID NO: 2 and a light chain shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein binds to IL-7 at a KD of 50 nM or less, 10 nM or less, 1 nM or less, or 0.1 nM or less. In another embodiment, the IL-7 binding protein binds to IL-7 and (i) has an IC of 1 nM or less. 50 Therefore, it inhibits IL-7-dependent IFN-γ or IL-10 secretion from peripheral blood mononuclear cells, and / or (ii) IC12 is less than 1 nM. 50 This inhibits IL-7-dependent STAT5 phosphorylation in CD4+ T cells. In some embodiments, the IL-7-binding protein inhibits CD4 + T cells and / or CD8 + Inhibits T cell signaling, activation, cytokine production, and proliferation.

[0013] In one aspect of the present invention, a nucleic acid encoding an IL-7 binding protein is provided. In another aspect of the present invention, an expression vector comprising a nucleic acid sequence encoding an IL-7 binding protein is provided. In a further aspect of the present invention, a host cell comprising a nucleic acid sequence encoding an IL-7 binding protein or an expression vector comprising a nucleic acid sequence encoding an IL-7 binding protein is provided. In yet another aspect of the present invention, an IL-7 binding protein expressed by a host cell is provided.

[0014] Another aspect of the present invention provides a method for producing an IL-7 binding protein, comprising the steps of: maintaining a host cell in a culture medium, the host cell comprising a nucleic acid sequence encoding an IL-7 binding protein or an expression vector comprising a nucleic acid sequence encoding an IL-7 binding protein; and isolating or purifying the IL-7 binding protein produced by the host cell.

[0015] In a further aspect of the present invention, an IL-7 binding protein is provided that competes with the IL-7 binding proteins disclosed herein for binding to IL-7.

[0016] In yet another aspect of the present invention, a pharmaceutical composition is provided comprising a pharmaceutically acceptable carrier or excipient and an IL-7 binding protein, wherein the IL-7 binding protein exhibits binding to IL-7 in an epitope comprising at least five consecutive amino acids from the sequence shown in SEQ ID NO: 12 or SEQ ID NO: 16. In yet another aspect of the present invention, a pharmaceutical composition is provided comprising an IL-7 binding protein and a pharmaceutically acceptable carrier or excipient.

[0017] Another aspect of the present invention provides an IL-7 binding protein for use in therapy. One aspect of the present invention provides a method for treating an autoimmune and / or inflammatory condition in a subject requiring it, comprising the step of administering to the subject a therapeutically effective amount of an IL-7 binding protein or a pharmaceutical composition. One aspect of the present invention provides an IL-7 binding protein for use in the treatment of an autoimmune and / or inflammatory condition. Another aspect of the present invention provides the use of an IL-7 binding protein in the manufacture of a pharmaceutical for the treatment of an autoimmune and / or inflammatory condition. In some embodiments, the autoimmune and / or inflammatory condition is multiple sclerosis, Sjögren's syndrome, rheumatoid arthritis, Crohn's disease, ulcerative colitis, or lupus erythematosus. In some embodiments, multiple sclerosis is clinically isolated syndrome, relapsing-remitting, primary progressive, or secondary progressive.

[0018] In a further aspect of the present invention, a kit comprising an IL-7 binding protein and instructions for use is provided.

[0019] In one aspect of the present invention, an IL-7 binding protein is provided comprising CDRH1 shown in SEQ ID NO: 26, CDRH2 shown in SEQ ID NO: 27, CDRH3 shown in SEQ ID NO: 28, CDRL1 shown in SEQ ID NO: 29, CDRL2 shown in SEQ ID NO: 30, and CDRL3 shown in SEQ ID NO: 31. In some embodiments, the IL-7 binding protein has at least 90% identity with the amino acid sequence shown in SEQ ID NO: 25. H V having at least 90% identity with the domain and / or the amino acid sequence shown in SEQ ID NO: 24 L It comprises a domain. In another embodiment, the IL-7 binding protein is V shown in SEQ ID NO: 25. H Domain and V shown in Sequence ID No. 24 L It includes a domain.

[0020] In one aspect of the present invention, an IL-7 binding protein is provided comprising CDRH1 shown in SEQ ID NO: 34, CDRH2 shown in SEQ ID NO: 35, CDRH3 shown in SEQ ID NO: 36, CDRL1 shown in SEQ ID NO: 37, CDRL2 shown in SEQ ID NO: 38, and CDRL3 shown in SEQ ID NO: 39. In some embodiments, the IL-7 binding protein has at least 90% identity with the amino acid sequence shown in SEQ ID NO: 33. H V having at least 90% identity with the domain and / or the amino acid sequence shown in SEQ ID NO: 32 L It comprises a domain. In another embodiment, the IL-7 binding protein is V shown in SEQ ID NO: 33. H Domain and V as shown in Sequence ID No. 32 L It includes a domain.

[0021] In one aspect of the present invention, an IL-7 binding protein is provided comprising CDRH1 shown in SEQ ID NO: 42, CDRH2 shown in SEQ ID NO: 43, CDRH3 shown in SEQ ID NO: 44, CDRL1 shown in SEQ ID NO: 45, CDRL2 shown in SEQ ID NO: 46, and CDRL3 shown in SEQ ID NO: 47. In some embodiments, the IL-7 binding protein has at least 90% identity with the amino acid sequence shown in SEQ ID NO: 41. H V having at least 90% identity with the domain and / or the amino acid sequence shown in SEQ ID NO: 40 L It comprises a domain. In another embodiment, the IL-7 binding protein is V shown in SEQ ID NO: 41. H Domain and V shown in Sequence ID No. 40 L It includes a domain.

[0022] In some embodiments, the IL-7 binding protein or its antigen-binding fragment binds to one or more residues in the amino acid sequence of human IL-7 shown in SEQ ID NO: 12. In some embodiments, the IL-7 binding protein protects residues 67-81 (SEQ ID NO: 12) of IL-7 from deuterium exchange during HDX-MS analysis. In some embodiments, the IL-7 binding protein or its antigen-binding fragment binds to one or more residues in the amino acid sequence of human IL-7 shown in SEQ ID NO: 16. In some embodiments, the IL-7 binding protein protects residues 67-80 (SEQ ID NO: 16) of IL-7 from deuterium exchange during HDX-MS analysis. In some embodiments, the IL-7 binding protein binds to an epitope comprising the amino acid sequence shown in SEQ ID NO: 12. In some embodiments, the IL-7 binding protein binds to an epitope comprising at least 50%, 60%, 70%, 80%, 90%, or 95% identity with the amino acid sequence shown in SEQ ID NO: 12. In some embodiments, the IL-7 binding protein comprises a variable region light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises at least one of the following: (a) a heavy chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 6, (b) a heavy chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 7, or (c) a heavy chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the IL-7 binding protein comprises at least one of the following: (a) a light chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 9, (b) a light chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 10, or (c) a light chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region light chain having the amino acid sequence shown in SEQ ID NO: 5.In some embodiments, the IL-7 binding protein comprises a heavy chain CDR1 comprising the amino acid sequence shown in SEQ ID NO: 6, a heavy chain CDR2 comprising the amino acid sequence shown in SEQ ID NO: 7, and a heavy chain CDR3 comprising the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 comprising the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 comprising the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 comprising the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain comprising the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a light chain comprising the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 2 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein is an antibody or its antigen-binding portion. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the monoclonal antibody is an IgG antibody. In some embodiments, the antibody is an IgG1 isotype antibody. In some embodiments, the monoclonal antibody is an IgG4 isotype antibody. In some embodiments, the IL-7 binding protein comprises a constant region such that the IL-7 binding protein has reduced ADCC and / or complement activation or reduced effector function.In some embodiments, the IL-7 binding protein comprises a heavy chain Fc domain having an alanine residue at position 235 and / or 237 according to EU numbering. In some embodiments, the IL-7 binding protein is a human, humanized, or chimeric antibody. In some embodiments, the IL-7 binding protein is a humanized antibody. In some embodiments, the IL-7 binding protein is a human antibody. In some embodiments, the IL-7 binding protein binds to and neutralizes IL-7. In some embodiments, the IL-7 binding protein binds to circulating IL-7. In some embodiments, the IL-7 binding protein binds to IL-7 and induces IL-7-dependent IFN-γ or IL-10 secretion at a minimum IC50 of 1 nM. 50 It inhibits IL-7. In some embodiments, the IL-7 binding protein is an isolated IL-7 binding protein. In some embodiments, the IL-7 binding protein binds to IL-7 and inhibits IL-7-dependent STAT5 phosphorylation in CD4+ T cells with an IC of less than 1 nM. 50 It inhibits CD4. In some embodiments, the IL-7 binding protein is a reversible dimer. In some embodiments, the IL-7 binding protein is a dimer. In some embodiments, the IL-7 binding protein is a monomer. In some embodiments, the IL-7 binding protein is CD4 + T cells and / or CD8 +It inhibits T cell signaling, activation, cytokine production, and proliferation. In some embodiments, the IL-7 binding protein is for use in therapy. Furthermore, nucleic acids encoding the IL-7 binding protein are also disclosed. In some embodiments, the nucleic acid comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 13 encoding the light chain. In some embodiments, the nucleic acid comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 14 encoding the heavy chain. In some embodiments, the nucleic acid comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 14 encoding the heavy chain. In some embodiments, the nucleic acid further comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 15 encoding the signal peptide. In some embodiments, a vector comprising nucleic acid is disclosed herein. In some embodiments, the vector comprises a promoter that functions in mammalian cells. Also disclosed are host cells comprising nucleic acid. In some embodiments, the host cell is a CHO cell. This specification further discloses a method for producing an IL-7 binding protein, comprising the steps of maintaining host cells in a culture medium to produce the IL-7 binding protein, and isolating or purifying the IL-7 binding protein produced by the host cells. In some embodiments, this specification discloses a pharmaceutical composition comprising an IL-7 binding protein. In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition further comprises at least one additional therapeutic agent. In some embodiments, the pharmaceutical composition has a pH of 4.5 to 7.0. In some embodiments, the pharmaceutical composition has a pH of 5.5, 6.0, 6.2, or 6.5. In some embodiments, the pharmaceutical composition or IL-7 binding protein can be used in a method for treating an autoimmune and / or inflammatory condition in a subject requiring it, comprising the step of administering a therapeutically effective amount of the pharmaceutical composition or IL-7 binding protein to the subject.In some embodiments, administration is via arterial, subcutaneous, intradermal, intratumoral, intralymph node, intramedullary, intramuscular, intravenous, or intraperitoneal administration. In some embodiments, administration is subcutaneous. In some embodiments, the therapeutically effective dose is at least about 0.1 mg / kg, 0.5 mg / kg, 1 mg / kg, 3 mg / kg, 5 mg / kg, 10 mg / kg, 20 mg / kg, 30 mg / kg, or 40 mg / kg. In some embodiments, the therapeutically effective dose is administered to the subject at least approximately twice daily or once every 1 to 60 days. In some embodiments, the therapeutically effective dose is administered to the subject once every 4 weeks. In some embodiments, the autoimmune and / or inflammatory condition is Sjögren's syndrome. In some embodiments, the autoimmune and / or inflammatory condition is rheumatoid arthritis. In some embodiments, the autoimmune and / or inflammatory condition is inflammatory bowel disease (IBD). In some embodiments, the autoimmune and / or inflammatory condition is multiple sclerosis. In some embodiments, multiple sclerosis is clinically isolated syndrome, relapsing-remitting, primary or secondary progressive. In some embodiments, the autoimmune and / or inflammatory condition is Crohn's disease. In some embodiments, the autoimmune and / or inflammatory condition is ulcerative colitis. In some embodiments, the autoimmune and / or inflammatory condition is lupus erythematosus. In some embodiments, the autoimmune and / or inflammatory condition is diabetes mellitus, e.g., type 1 diabetes mellitus. In some embodiments, the IL-7 binding protein is used in the manufacture of pharmaceuticals for the treatment of autoimmune and / or inflammatory conditions. In some embodiments, a compound comprising the IL-7 binding protein is for use in the treatment of autoimmune and / or inflammatory conditions. In some embodiments, the IL-7 binding protein is used for the diagnosis of a disease or condition. In some embodiments, the IL-7 binding protein is used for the diagnosis of autoimmune and / or inflammatory conditions. In some embodiments, the IL-7 binding protein is bound to a portion or its antigenic fragment. In some embodiments, that portion is IL-7 or a fragment thereof.In some embodiments, the IL-7 binding protein is attached directly or indirectly to a solid support. In some embodiments, the IL-7 binding protein is included in the kit along with instructions for use. In some embodiments, the solid support is included in the kit.

[0023] This specification discloses IL-7-binding proteins or antigen-binding fragments thereof that bind to human IL-7 with a KD of 100 nM or less. In some embodiments, the IL-7-binding protein binds to human IL-7 adjacent to the IL-7Rα binding site. In some embodiments, the IL-7-binding protein inhibits the binding of IL-7 to IL-7R when measured by an in vitro competitive binding assay. In some embodiments, the competitive binding assay is an immunoassay. In some embodiments, the competitive binding assay is a surface plasmon resonance assay. In some embodiments, the competitive binding assay is, for example, ELISA or radioimmunoassay. In some embodiments, the IL-7-binding protein comprises a variable region light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises at least one of the following: (a) a heavy chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 6, (b) a heavy chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 7, or (c) a heavy chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the IL-7 binding protein comprises at least one of the following: (a) a light chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 9, (b) a light chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 10, or (c) a light chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region light chain having the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 6, a heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 7, and a heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 8.In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a light chain having the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain having the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 2 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein is an antibody or its antigen-binding portion. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the monoclonal antibody is an IgG antibody. In some embodiments, the antibody is an IgG1 isotype antibody. In some embodiments, the monoclonal antibody is an IgG4 isotype antibody. In some embodiments, the IL-7 binding protein comprises a constant region such that the IL-7 binding protein has reduced ADCC and / or complement activation or reduced effector function. In some embodiments, the IL-7 binding protein comprises a heavy chain Fc domain having an alanine residue at positions 235 and / or 237 according to EU numbering. In some embodiments, the IL-7 binding protein is a human, humanized, or chimeric antibody. In some embodiments, the IL-7 binding protein is a humanized antibody.In some embodiments, the IL-7 binding protein is a human antibody. In some embodiments, the IL-7 binding protein binds to and neutralizes IL-7. In some embodiments, the IL-7 binding protein binds to circulating IL-7. In some embodiments, the IL-7 binding protein is an isolated IL-7 binding protein. In some embodiments, the IL-7 binding protein binds to IL-7 and reduces IL-7-dependent IFN-γ or IL-10 secretion from peripheral blood mononuclear cells to 1 nM or less IC50. 50 This inhibits IL-7. In some embodiments, the IL-7-binding protein binds to IL-7 and inhibits IL-7-dependent STAT5 phosphorylation in CD4+ T cells at IC50 below 1 nM. 50 It inhibits CD4. In some embodiments, the IL-7 binding protein is CD4 + T cells and / or CD8 +It inhibits T cell signaling, activation, cytokine production, and proliferation. In some embodiments, the IL-7 binding protein is a reversible dimer. In some embodiments, the IL-7 binding protein is a dimer. In some embodiments, the IL-7 binding protein is a monomer. In some embodiments, the IL-7 binding protein is for use in therapy. Furthermore, nucleic acids encoding the IL-7 binding protein are also disclosed. In some embodiments, the nucleic acid comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 13 encoding the light chain. In some embodiments, the nucleic acid comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 14 encoding the heavy chain. In some embodiments, the nucleic acid comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 14 encoding the heavy chain. In some embodiments, the nucleic acid further comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 15 encoding the signal peptide. In some embodiments, vectors comprising nucleic acids are disclosed herein. In some embodiments, the vector comprises a promoter that functions in mammalian cells. Also disclosed are host cells comprising nucleic acids. In some embodiments, the host cells are CHO cells. Further disclosed herein are methods for producing IL-7 binding proteins, comprising the steps of maintaining host cells in a culture medium to produce IL-7 binding proteins, and isolating or purifying the IL-7 binding proteins produced by the host cells. In some embodiments herein, pharmaceutical compositions comprising IL-7 binding proteins are disclosed. In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition further comprises at least one additional therapeutic agent. In some embodiments, the pharmaceutical composition has a pH of 4.5 to 7.0. In some embodiments, the pharmaceutical composition has a pH of 5.5, 6.0, 6.2, or 6.5.In some embodiments, the pharmaceutical composition or IL-7 binding protein can be used in a method for treating an autoimmune and / or inflammatory condition in a subject requiring its use, the method comprising the step of administering a therapeutically effective amount of the pharmaceutical composition or IL-7 binding protein to the subject. In some embodiments, the administration is transarterial, subcutaneous, intradermal, intratumoral, intralymph node, intramedullary, intramuscular, intravenous, or intraperitoneal. In some embodiments, the administration is subcutaneous. In some embodiments, the therapeutically effective amount is at least about 0.1 mg / kg, 0.5 mg / kg, 1 mg / kg, 3 mg / kg, 5 mg / kg, 10 mg / kg, 20 mg / kg, 30 mg / kg, or 40 mg / kg. In some embodiments, the therapeutically effective amount is administered to the subject at least twice daily or once every 1 to 60 days. In some embodiments, the therapeutically effective amount is administered to the subject once every 4 weeks. In some embodiments, the autoimmune and / or inflammatory condition is Sjögren's syndrome. In some embodiments, the autoimmune and / or inflammatory condition is IBD. In some embodiments, the autoimmune and / or inflammatory condition is rheumatoid arthritis. In some embodiments, the autoimmune and / or inflammatory condition is multiple sclerosis. In some embodiments, multiple sclerosis is clinically isolated syndrome, relapsing-remitting, primary progressive or secondary progressive. In some embodiments, the autoimmune and / or inflammatory condition is Crohn's disease. In some embodiments, the autoimmune and / or inflammatory condition is ulcerative colitis. In some embodiments, the autoimmune and / or inflammatory condition is lupus erythematosus. In some embodiments, the autoimmune and / or inflammatory condition is diabetes mellitus, e.g., type 1 diabetes mellitus. In some embodiments, the IL-7 binding protein is used in the manufacture of pharmaceuticals for the treatment of autoimmune and / or inflammatory conditions. In some embodiments, compounds comprising an IL-7 binding protein are provided for use in the treatment of autoimmune and / or inflammatory conditions. In some embodiments, IL-7 binding proteins are used for the diagnosis of diseases or conditions.In some embodiments, IL-7 binding proteins are used for the diagnosis of autoimmune and / or inflammatory conditions. In some embodiments, the IL-7 binding protein is bound to a moiety or an antigenic fragment thereof. In some embodiments, the moiety is IL-7 or a fragment thereof. In some embodiments, the IL-7 binding protein is attached directly or indirectly to a solid support. In some embodiments, the IL-7 binding protein is included in the kit along with instructions for use. In some embodiments, the solid support is included in the kit.

[0024] This specification discloses an IL-7 binding protein comprising a variable region light chain having at least 95% identity with the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises at least one of (a) a heavy chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 6, (b) a heavy chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 7, or (c) a heavy chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the IL-7 binding protein comprises a variable region light chain having the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 6, a heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 7, and a heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a light chain having the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain having the amino acid sequence shown in SEQ ID NO: 2.In some embodiments, the IL-7 binding protein comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 2 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein is an antibody or its antigen-binding portion. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the monoclonal antibody is an IgG antibody. In some embodiments, the antibody is an IgG1 isotype antibody. In some embodiments, the monoclonal antibody is an IgG4 isotype antibody. In some embodiments, the IL-7 binding protein comprises a constant region such that the IL-7 binding protein has reduced ADCC and / or complement activation or reduced effector function. In some embodiments, the IL-7 binding protein comprises a heavy chain Fc domain having an alanine residue at positions 235 and / or 237 according to EU numbering. In some embodiments, the IL-7 binding protein is a human, humanized, or chimeric antibody. In some embodiments, the IL-7 binding protein is a humanized antibody. In some embodiments, the IL-7 binding protein is a human antibody. In some embodiments, the IL-7 binding protein binds to and neutralizes IL-7. In some embodiments, the IL-7 binding protein binds to native IL-7. In some embodiments, the IL-7 binding protein binds to circulating IL-7. In some embodiments, the IL-7 binding protein binds to IL-7 and stimulates IL-7-dependent IFN-γ or IL-10 secretion from peripheral blood mononuclear cells to an IC5 of 1 nM or less. 50 It inhibits IL-7. In some embodiments, the IL-7 binding protein is an isolated IL-7 binding protein. In some embodiments, the IL-7 binding protein binds to IL-7 and inhibits IL-7-dependent STAT5 phosphorylation in CD4+ T cells with an IC of less than 1 nM. 50 It inhibits CD4. In some embodiments, the IL-7 binding protein is CD4 + T cells and / or CD8 +It inhibits T cell signaling, activation, cytokine production, and proliferation. In some embodiments, the IL-7 binding protein is a reversible dimer. In some embodiments, the IL-7 binding protein is a dimer. In some embodiments, the IL-7 binding protein is a monomer. In some embodiments, the IL-7 binding protein is for use in therapy. Furthermore, nucleic acids encoding the IL-7 binding protein are also disclosed. In some embodiments, the nucleic acid comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 13 encoding the light chain. In some embodiments, the nucleic acid comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 14 encoding the heavy chain. In some embodiments, the nucleic acid comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 14 encoding the heavy chain. In some embodiments, the nucleic acid further comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 15 encoding the signal peptide. In some embodiments, vectors comprising nucleic acids are disclosed herein. In some embodiments, the vector comprises a promoter that functions in mammalian cells. Also disclosed are host cells comprising nucleic acids. In some embodiments, the host cells are CHO cells. Further disclosed herein are methods for producing IL-7 binding proteins, comprising the steps of maintaining host cells in a culture medium to produce IL-7 binding proteins, and isolating or purifying the IL-7 binding proteins produced by the host cells. In some embodiments herein, pharmaceutical compositions comprising IL-7 binding proteins are disclosed. In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition further comprises at least one additional therapeutic agent. In some embodiments, the pharmaceutical composition has a pH of 4.5 to 7.0. In some embodiments, the pharmaceutical composition has a pH of 5.5, 6.0, 6.2, or 6.5.In some embodiments, the pharmaceutical composition or IL-7 binding protein can be used in a method for treating an autoimmune and / or inflammatory condition in a subject requiring its use, the method comprising the step of administering a therapeutically effective amount of the pharmaceutical composition or IL-7 binding protein to the subject. In some embodiments, the administration is transarterial, subcutaneous, intradermal, intratumoral, intralymph node, intramedullary, intramuscular, intravenous, or intraperitoneal. In some embodiments, the administration is subcutaneous. In some embodiments, the therapeutically effective amount is at least about 0.1 mg / kg, 0.5 mg / kg, 1 mg / kg, 3 mg / kg, 5 mg / kg, 10 mg / kg, 20 mg / kg, 30 mg / kg, or 40 mg / kg. In some embodiments, the therapeutically effective amount is administered to the subject at least twice daily or once every 1 to 60 days. In some embodiments, the therapeutically effective amount is administered to the subject once every 4 weeks. In some embodiments, the autoimmune and / or inflammatory condition is Sjögren's syndrome. In some embodiments, the autoimmune and / or inflammatory condition is rheumatoid arthritis. In some embodiments, the autoimmune and / or inflammatory condition is IBD. In some embodiments, the autoimmune and / or inflammatory condition is multiple sclerosis. In some embodiments, multiple sclerosis is clinically isolated syndrome, relapsing-remitting, primary progressive, or secondary progressive. In some embodiments, the autoimmune and / or inflammatory condition is Crohn's disease. In some embodiments, the autoimmune and / or inflammatory condition is ulcerative colitis. In some embodiments, the autoimmune and / or inflammatory condition is lupus erythematosus. In some embodiments, the autoimmune and / or inflammatory condition is diabetes mellitus, e.g., type 1 diabetes mellitus. In some embodiments, the IL-7 binding protein is used in the manufacture of pharmaceuticals for the treatment of autoimmune and / or inflammatory conditions. In some embodiments, compounds comprising the IL-7 binding protein are for use in the treatment of autoimmune and / or inflammatory conditions. In some embodiments, IL-7 binding proteins are used for the diagnosis of disease or pathological conditions.In some embodiments, IL-7 binding proteins are used for the diagnosis of autoimmune and / or inflammatory conditions. In some embodiments, the IL-7 binding protein is bound to a moiety or an antigenic fragment thereof. In some embodiments, the moiety is IL-7 or a fragment thereof. In some embodiments, the IL-7 binding protein is attached directly or indirectly to a solid support. In some embodiments, the IL-7 binding protein is included in the kit along with instructions for use. In some embodiments, the solid support is included in the kit.

[0025] This specification discloses an IL-7 binding protein or an antigen-binding fragment thereof comprising a heavy chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 6, a heavy chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 7, and a heavy chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the IL-7 binding protein comprises a variable region light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a variable region light chain having the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 6, a heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 7, and a heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a light chain having the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain having the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 2 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 3.In some embodiments, the IL-7 binding protein is an antibody or its antigen-binding portion. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the monoclonal antibody is an IgG antibody. In some embodiments, the antibody is an IgG1 isotype antibody. In some embodiments, the monoclonal antibody is an IgG4 isotype antibody. In some embodiments, the IL-7 binding protein comprises a constant region so that the IL-7 binding protein has reduced ADCC and / or complement activation or reduced effector function. In some embodiments, the IL-7 binding protein comprises a heavy chain Fc domain having an alanine residue at positions 235 and / or 237 according to EU numbering. In some embodiments, the IL-7 binding protein is a human, humanized, or chimeric antibody. In some embodiments, the IL-7 binding protein is a humanized antibody. In some embodiments, the IL-7 binding protein is a human antibody. In some embodiments, the IL-7 binding protein binds to and neutralizes IL-7. In some embodiments, the IL-7 binding protein binds to native IL-7. In some embodiments, the IL-7 binding protein binds to circulating IL-7. In some embodiments, the IL-7 binding protein is an isolated IL-7 binding protein. In some embodiments, the IL-7 binding protein binds to IL-7 and stimulates IL-7-dependent IFN-γ or IL-10 secretion from peripheral blood mononuclear cells to an IC of 1 nM or less. 50 This inhibits IL-7. In some embodiments, the IL-7-binding protein binds to IL-7 and inhibits IL-7-dependent STAT5 phosphorylation in CD4+ T cells at IC50 below 1 nM. 50 It inhibits CD4. In some embodiments, the IL-7 binding protein is CD4 + T cells and / or CD8 +It inhibits T cell signaling, activation, cytokine production, and proliferation. In some embodiments, the IL-7 binding protein is a reversible dimer. In some embodiments, the IL-7 binding protein is a dimer. In some embodiments, the IL-7 binding protein is a monomer. In some embodiments, the IL-7 binding protein is for use in therapy. Furthermore, nucleic acids encoding the IL-7 binding protein are also disclosed. In some embodiments, the nucleic acid comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 13 encoding the light chain. In some embodiments, the nucleic acid comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 14 encoding the heavy chain. In some embodiments, the nucleic acid comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 14 encoding the heavy chain. In some embodiments, the nucleic acid further comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 15 encoding the signal peptide. In some embodiments, vectors comprising nucleic acids are disclosed herein. In some embodiments, the vector comprises a promoter that functions in mammalian cells. Also disclosed are host cells comprising nucleic acids. In some embodiments, the host cells are CHO cells. Furthermore, a method for producing an IL-7 binding protein is disclosed herein, comprising the steps of maintaining host cells in a culture medium to produce an IL-7 binding protein, and isolating or purifying the IL-7 binding protein produced by the host cells. In some embodiments, a pharmaceutical composition comprising an IL-7 binding protein is disclosed herein. In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition further comprises at least one additional therapeutic agent. In some embodiments, the pharmaceutical composition has a pH of 4.5 to 7.0. In some embodiments, the pharmaceutical composition has a pH of 5.5, 6.0, 6.2, or 6.5.In some embodiments, the pharmaceutical composition or IL-7 binding protein can be used in a method for treating an autoimmune and / or inflammatory condition in a subject requiring its use, the method comprising the step of administering a therapeutically effective amount of the pharmaceutical composition or IL-7 binding protein to the subject. In some embodiments, the administration is transarterial, subcutaneous, intradermal, intratumoral, intralymph node, intramedullary, intramuscular, intravenous, or intraperitoneal. In some embodiments, the administration is subcutaneous. In some embodiments, the therapeutically effective amount is at least about 0.1 mg / kg, 0.5 mg / kg, 1 mg / kg, 3 mg / kg, 5 mg / kg, 10 mg / kg, 20 mg / kg, 30 mg / kg, or 40 mg / kg. In some embodiments, the therapeutically effective amount is administered to the subject at least twice daily or once every 1 to 60 days. In some embodiments, the therapeutically effective amount is administered to the subject once every 4 weeks. In some embodiments, the autoimmune and / or inflammatory condition is Sjögren's syndrome. In some embodiments, the autoimmune and / or inflammatory condition is rheumatoid arthritis. In some embodiments, the autoimmune and / or inflammatory condition is IBD. In some embodiments, the autoimmune and / or inflammatory condition is multiple sclerosis. In some embodiments, multiple sclerosis is clinically isolated syndrome, relapsing-remitting, primary progressive, or secondary progressive. In some embodiments, the autoimmune and / or inflammatory condition is Crohn's disease. In some embodiments, the autoimmune and / or inflammatory condition is ulcerative colitis. In some embodiments, the autoimmune and / or inflammatory condition is lupus erythematosus. In some embodiments, the autoimmune and / or inflammatory condition is diabetes mellitus, e.g., type 1 diabetes mellitus. In some embodiments, the IL-7 binding protein is used in the manufacture of pharmaceuticals for the treatment of autoimmune and / or inflammatory conditions. In some embodiments, compounds comprising the IL-7 binding protein are for use in the treatment of autoimmune and / or inflammatory conditions. In some embodiments, IL-7 binding proteins are used for the diagnosis of diseases or conditions.In some embodiments, IL-7 binding proteins are used for the diagnosis of autoimmune and / or inflammatory conditions. In some embodiments, the IL-7 binding protein is bound to a moiety or an antigenic fragment thereof. In some embodiments, the moiety is IL-7 or a fragment thereof. In some embodiments, the IL-7 binding protein is attached directly or indirectly to a solid support. In some embodiments, the IL-7 binding protein is included in the kit along with instructions for use. In some embodiments, the solid support is included in the kit.

[0026] This specification discloses an IL-7 binding protein or an antigen-binding fragment thereof comprising a light chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a variable region light chain having the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 6, a heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 7, and a heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a light chain having the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain having the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 2 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 3.In some embodiments, the IL-7 binding protein is an antibody or its antigen-binding portion. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the monoclonal antibody is an IgG antibody. In some embodiments, the antibody is an IgG1 isotype antibody. In some embodiments, the monoclonal antibody is an IgG4 isotype antibody. In some embodiments, the IL-7 binding protein comprises a constant region so that the IL-7 binding protein has reduced ADCC and / or complement activation or reduced effector function. In some embodiments, the IL-7 binding protein comprises a heavy chain Fc domain having an alanine residue at positions 235 and / or 237 according to EU numbering. In some embodiments, the IL-7 binding protein is a human, humanized, or chimeric antibody. In some embodiments, the IL-7 binding protein is a humanized antibody. In some embodiments, the IL-7 binding protein binds to and neutralizes IL-7. In some embodiments, the IL-7 binding protein binds to native IL-7. In some embodiments, the IL-7 binding protein binds to circulating IL-7. In some embodiments, the IL-7 binding protein is an isolated IL-7 binding protein. In some embodiments, the IL-7 binding protein binds to IL-7 and stimulates IL-7-dependent IFN-γ or IL-10 secretion from peripheral blood mononuclear cells to an IC of 1 nM or less. 50 This inhibits IL-7. In some embodiments, the IL-7-binding protein binds to IL-7 and inhibits IL-7-dependent STAT5 phosphorylation in CD4+ T cells at IC50 below 1 nM. 50 It inhibits CD4. In some embodiments, the IL-7 binding protein is CD4 + T cells and / or CD8 +It inhibits T cell signaling, activation, cytokine production, and proliferation. In some embodiments, the IL-7 binding protein is a reversible dimer. In some embodiments, the IL-7 binding protein is a dimer. In some embodiments, the IL-7 binding protein is a monomer. In some embodiments, the IL-7 binding protein is for use in therapy. Furthermore, nucleic acids encoding the IL-7 binding protein are also disclosed. In some embodiments, the nucleic acid comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 13 encoding the light chain. In some embodiments, the nucleic acid comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 14 encoding the heavy chain. In some embodiments, the nucleic acid comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 14 encoding the heavy chain. In some embodiments, the nucleic acid further comprises a sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 15 encoding the signal peptide. In some embodiments, vectors comprising nucleic acids are disclosed herein. In some embodiments, the vector comprises a promoter that functions in mammalian cells. Also disclosed are host cells comprising nucleic acids. In some embodiments, the host cells are CHO cells. Furthermore, a method for producing an IL-7 binding protein is disclosed herein, comprising the steps of maintaining host cells in a culture medium to produce an IL-7 binding protein, and isolating or purifying the IL-7 binding protein produced by the host cells. In some embodiments, a pharmaceutical composition comprising an IL-7 binding protein is disclosed herein. In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition further comprises at least one additional therapeutic agent. In some embodiments, the pharmaceutical composition has a pH of 4.5 to 7.0. In some embodiments, the pharmaceutical composition has a pH of 5.5, 6.0, 6.2, or 6.5.In some embodiments, the pharmaceutical composition or IL-7 binding protein can be used in a method for treating an autoimmune and / or inflammatory condition in a subject requiring its use, the method comprising the step of administering a therapeutically effective amount of the pharmaceutical composition or IL-7 binding protein to the subject. In some embodiments, the administration is transarterial, subcutaneous, intradermal, intratumoral, intralymph node, intramedullary, intramuscular, intravenous, or intraperitoneal. In some embodiments, the administration is subcutaneous. In some embodiments, the therapeutically effective amount is at least about 0.1 mg / kg, 0.5 mg / kg, 1 mg / kg, 3 mg / kg, 5 mg / kg, 10 mg / kg, 20 mg / kg, 30 mg / kg, or 40 mg / kg. In some embodiments, the therapeutically effective amount is administered to the subject at least twice daily or once every 1 to 60 days. In some embodiments, the therapeutically effective amount is administered to the subject once every 4 weeks. In some embodiments, the autoimmune and / or inflammatory condition is Sjögren's syndrome. In some embodiments, the autoimmune and / or inflammatory condition is rheumatoid arthritis. In some embodiments, the autoimmune and / or inflammatory condition is IBD. In some embodiments, the autoimmune and / or inflammatory condition is multiple sclerosis. In some embodiments, multiple sclerosis is clinically isolated syndrome, relapsing-remitting, primary progressive, or secondary progressive. In some embodiments, the autoimmune and / or inflammatory condition is Crohn's disease. In some embodiments, the autoimmune and / or inflammatory condition is ulcerative colitis. In some embodiments, the autoimmune and / or inflammatory condition is lupus erythematosus. In some embodiments, the autoimmune and / or inflammatory condition is diabetes mellitus, e.g., type 1 diabetes mellitus. In some embodiments, the IL-7 binding protein is used in the manufacture of pharmaceuticals for the treatment of autoimmune and / or inflammatory conditions. In some embodiments, compounds comprising the IL-7 binding protein are for use in the treatment of autoimmune and / or inflammatory conditions. In some embodiments, IL-7 binding proteins are used for the diagnosis of diseases or conditions.In some embodiments, IL-7 binding proteins are used for the diagnosis of autoimmune and / or inflammatory conditions. In some embodiments, the IL-7 binding protein is bound to a moiety or an antigenic fragment thereof. In some embodiments, the moiety is IL-7 or a fragment thereof. In some embodiments, the IL-7 binding protein is attached directly or indirectly to a solid support. In some embodiments, the IL-7 binding protein is included in the kit along with instructions for use. In some embodiments, the solid support is included in the kit.

[0027] This specification discloses pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an IL-7 binding protein or an antigen-binding fragment thereof, wherein the IL-7 binding protein or the antigen-binding fragment exhibits binding specificity to IL-7 in an epitope comprising at least five consecutive amino acids from the sequence shown in SEQ ID NO: 12. In some embodiments, the IL-7 binding protein exhibits binding specificity in an epitope comprising at least five consecutive amino acids from a sequence having at least about 50%, 60%, 70%, 80%, 90%, or 95% identity with the amino acid sequence shown in SEQ ID NO: 12. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a variable region light chain having the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 6, a heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 7, and a heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having the amino acid sequence shown in SEQ ID NO: 4.In some embodiments, the IL-7 binding protein comprises a light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a light chain having the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain having the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain having the amino acid sequence shown in SEQ ID NO: 2 and a light chain having the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein is an antibody or its antigen-binding portion. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the monoclonal antibody is an IgG antibody. In some embodiments, the antibody is an IgG1 isotype antibody. In some embodiments, the monoclonal antibody is an IgG4 isotype antibody. In some embodiments, the IL-7 binding protein comprises a constant region such that the IL-7 binding protein has reduced ADCC and / or complement activation or reduced effector function. In some embodiments, the IL-7 binding protein comprises a heavy chain Fc domain having an alanine residue at positions 235 and / or 237 according to EU numbering. In some embodiments, the IL-7 binding protein is a human, humanized, or chimeric antibody. In some embodiments, the IL-7 binding protein is a humanized antibody. In some embodiments, the IL-7 binding protein is a human antibody. In some embodiments, the IL-7 binding protein binds to and neutralizes IL-7. In some embodiments, the IL-7 binding protein binds to native IL-7. In some embodiments, the pharmaceutical composition further comprises at least one additional therapeutic agent. In some embodiments, the pharmaceutical composition has a pH of 4.5 to 7.0. In some embodiments, the pharmaceutical composition has a pH of 5.5, 6.0, 6.2, or 6.5.In some embodiments, the pharmaceutical composition can be used in a method for treating an autoimmune and / or inflammatory condition in a subject requiring it, the method comprising the step of administering a therapeutically effective amount of the pharmaceutical composition to the subject. In some embodiments, the administration is transarterial, subcutaneous, intradermal, intratumoral, intralymph node, intramedullary, intramuscular, intravenous, or intraperitoneal. In some embodiments, the administration is subcutaneous. In some embodiments, the therapeutically effective amount is at least about 0.1 mg / kg, 0.5 mg / kg, 1 mg / kg, 3 mg / kg, 5 mg / kg, 10 mg / kg, 20 mg / kg, 30 mg / kg, or 40 mg / kg. In some embodiments, the therapeutically effective amount is administered to the subject at least twice daily or once every 1 to 60 days. In some embodiments, the therapeutically effective amount is administered to the subject once every 4 weeks. In some embodiments, the autoimmune and / or inflammatory condition is Sjögren's syndrome. In some embodiments, the autoimmune and / or inflammatory condition is rheumatoid arthritis. In some embodiments, the autoimmune and / or inflammatory condition is IBD. In some embodiments, the autoimmune and / or inflammatory condition is multiple sclerosis. In some embodiments, multiple sclerosis is clinically isolated syndrome, relapsing-remitting, primary progressive or secondary progressive. In some embodiments, the autoimmune and / or inflammatory condition is Crohn's disease. In some embodiments, the autoimmune and / or inflammatory condition is ulcerative colitis. In some embodiments, the autoimmune and / or inflammatory condition is lupus erythematosus. In some embodiments, the autoimmune and / or inflammatory condition is diabetes mellitus, e.g., type 1 diabetes mellitus. In some embodiments, the pharmaceutical composition is included in the kit along with instructions for use. In some embodiments, the pharmaceutical composition is a stable liquid aqueous pharmaceutical formulation comprising 20-150 mg / mL of the anti-human IL-7 binding protein described herein, an isotonic agent, a surfactant, and a buffer system with a pH of 4.0-8.0.

[0028] This specification discloses methods for treating autoimmune and / or inflammatory conditions by administering an IL-7 binding protein or an antigen-binding fragment thereof to a subject. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a variable region light chain having the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 6, a heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 7, and a heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a light chain having the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain having the amino acid sequence shown in SEQ ID NO: 2.In some embodiments, the IL-7 binding protein comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 2 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein is an antibody or its antigen-binding portion. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the monoclonal antibody is an IgG antibody. In some embodiments, the antibody is an IgG1 isotype antibody. In some embodiments, the monoclonal antibody is an IgG4 isotype antibody. In some embodiments, the IL-7 binding protein comprises a constant region such that the IL-7 binding protein has reduced ADCC and / or complement activation or reduced effector function. In some embodiments, the IL-7 binding protein comprises a heavy chain Fc domain having an alanine residue at positions 235 and / or 237 according to EU numbering. In some embodiments, the IL-7 binding protein is a human, humanized, or chimeric antibody. In some embodiments, the IL-7 binding protein is a humanized antibody. In some embodiments, the IL-7 binding protein is a human antibody. In some embodiments, the IL-7 binding protein binds to and neutralizes IL-7. In some embodiments, the IL-7 binding protein binds to native IL-7. In some embodiments, administration is transarterial, subcutaneous, intradermal, intratumoral, intralymph node, intramedullary, intramuscular, intravenous, or intraperitoneal. In some embodiments, administration is subcutaneous. In some embodiments, the therapeutically effective dose is at least about 0.1 mg / kg, 0.5 mg / kg, 1 mg / kg, 3 mg / kg, 5 mg / kg, 10 mg / kg, 20 mg / kg, 30 mg / kg, or 40 mg / kg. In some embodiments, the therapeutically effective dose is administered to the subject at least approximately twice daily or once every 1 to 60 days. In some embodiments, the therapeutically effective dose is administered to the subject once every 4 weeks. In some embodiments, the autoimmune and / or inflammatory condition is Sjögren's syndrome. In some embodiments, the autoimmune and / or inflammatory condition is rheumatoid arthritis.In some embodiments, the autoimmune and / or inflammatory condition is IBD. In some embodiments, the autoimmune and / or inflammatory condition is multiple sclerosis. In some embodiments, multiple sclerosis is clinically isolated syndrome, relapsing-remitting, primary progressive, or secondary progressive. In some embodiments, the autoimmune and / or inflammatory condition is Crohn's disease. In some embodiments, the autoimmune and / or inflammatory condition is ulcerative colitis. In some embodiments, the autoimmune and / or inflammatory condition is lupus erythematosus. In some embodiments, the autoimmune and / or inflammatory condition is diabetes mellitus, e.g., type 1 diabetes mellitus.

[0029] This specification discloses the use of IL-7 binding proteins or antigen-binding fragments thereof in the manufacture of pharmaceuticals for the treatment of autoimmune and / or inflammatory conditions. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a variable region light chain having the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 6, a heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 7, and a heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a light chain having the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain having the amino acid sequence shown in SEQ ID NO: 2.In some embodiments, the IL-7 binding protein comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 2 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein is an antibody or its antigen-binding portion. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the monoclonal antibody is an IgG antibody. In some embodiments, the antibody is an IgG1 isotype antibody. In some embodiments, the monoclonal antibody is an IgG4 isotype antibody. In some embodiments, the IL-7 binding protein comprises a constant region such that the IL-7 binding protein has reduced ADCC and / or complement activation or reduced effector function. In some embodiments, the IL-7 binding protein comprises a heavy chain Fc domain having an alanine residue at positions 235 and / or 237 according to EU numbering. In some embodiments, the IL-7 binding protein is a human, humanized, or chimeric antibody. In some embodiments, the IL-7 binding protein is a humanized antibody. In some embodiments, the IL-7 binding protein is a human antibody. In some embodiments, the IL-7 binding protein binds to and neutralizes IL-7. In some embodiments, the IL-7 binding protein binds to native IL-7. In some embodiments, the autoimmune and / or inflammatory condition is Sjögren's syndrome. In some embodiments, the autoimmune and / or inflammatory condition is rheumatoid arthritis. In some embodiments, the autoimmune and / or inflammatory condition is IBD. In some embodiments, the autoimmune and / or inflammatory condition is multiple sclerosis. In some embodiments, multiple sclerosis is clinically isolated syndrome, relapsing-remitting, primary progressive, or secondary progressive. In some embodiments, the autoimmune and / or inflammatory condition is Crohn's disease. In some embodiments, the autoimmune and / or inflammatory condition is ulcerative colitis. In some embodiments, the autoimmune and / or inflammatory condition is lupus erythematosus. In some embodiments, the autoimmune and / or inflammatory condition is diabetes mellitus, e.g., type 1 diabetes mellitus.

[0030] This specification discloses IL-7 binding proteins or antigen-binding fragments thereof for use in the treatment of autoimmune and / or inflammatory conditions. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a variable region light chain having the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 6, a heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 7, and a heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a light chain having the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain having the amino acid sequence shown in SEQ ID NO: 2.In some embodiments, the IL-7 binding protein comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 2 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein is an antibody or its antigen-binding portion. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the monoclonal antibody is an IgG antibody. In some embodiments, the antibody is an IgG1 isotype antibody. In some embodiments, the monoclonal antibody is an IgG4 isotype antibody. In some embodiments, the IL-7 binding protein comprises a constant region such that the IL-7 binding protein has reduced ADCC and / or complement activation or reduced effector function. In some embodiments, the IL-7 binding protein comprises a heavy chain Fc domain having an alanine residue at positions 235 and / or 237 according to EU numbering. In some embodiments, the IL-7 binding protein is a human, humanized, or chimeric antibody. In some embodiments, the IL-7 binding protein is a humanized antibody. In some embodiments, the IL-7 binding protein is a human antibody. In some embodiments, the IL-7 binding protein binds to and neutralizes IL-7. In some embodiments, the IL-7 binding protein binds to native IL-7. In some embodiments, the autoimmune and / or inflammatory condition is Sjögren's syndrome. In some embodiments, the autoimmune and / or inflammatory condition is rheumatoid arthritis. In some embodiments, the autoimmune and / or inflammatory condition is IBD. In some embodiments, the autoimmune and / or inflammatory condition is multiple sclerosis. In some embodiments, multiple sclerosis is clinically isolated syndrome, relapsing-remitting, primary progressive, or secondary progressive. In some embodiments, the autoimmune and / or inflammatory condition is Crohn's disease. In some embodiments, the autoimmune and / or inflammatory condition is ulcerative colitis. In some embodiments, the autoimmune and / or inflammatory condition is lupus erythematosus. In some embodiments, the autoimmune and / or inflammatory condition is diabetes mellitus, e.g., type 1 diabetes mellitus.

[0031] This specification discloses the use of IL-7 binding proteins or antigen-binding fragments thereof for the diagnosis of diseases or pathological conditions. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a variable region light chain having the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 6, a heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 7, and a heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a light chain having the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain having the amino acid sequence shown in SEQ ID NO: 2.In some embodiments, the IL-7 binding protein comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 2 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein is an antibody or its antigen-binding portion. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the monoclonal antibody is an IgG antibody. In some embodiments, the antibody is an IgG1 isotype antibody. In some embodiments, the monoclonal antibody is an IgG4 isotype antibody. In some embodiments, the IL-7 binding protein comprises a constant region such that the IL-7 binding protein has reduced ADCC and / or complement activation or reduced effector function. In some embodiments, the IL-7 binding protein comprises a heavy chain Fc domain having an alanine residue at positions 235 and / or 237 according to EU numbering. In some embodiments, the IL-7 binding protein is a human, humanized, or chimeric antibody. In some embodiments, the IL-7 binding protein is a humanized antibody. In some embodiments, the IL-7 binding protein is a human antibody. In some embodiments, the IL-7 binding protein binds to and neutralizes IL-7. In some embodiments, the IL-7 binding protein binds to native IL-7. In some embodiments, the disease or condition is an autoimmune and / or inflammatory condition. In some embodiments, the autoimmune and / or inflammatory condition is Sjögren's syndrome. In some embodiments, the autoimmune and / or inflammatory condition is rheumatoid arthritis. In some embodiments, the autoimmune and / or inflammatory condition is IBD. In some embodiments, the autoimmune and / or inflammatory condition is multiple sclerosis. In some embodiments, multiple sclerosis is clinically isolated syndrome, relapsing-remitting, primary progressive, or secondary progressive. In some embodiments, the autoimmune and / or inflammatory condition is Crohn's disease. In some embodiments, the autoimmune and / or inflammatory condition is ulcerative colitis. In some embodiments, the autoimmune and / or inflammatory condition is lupus erythematosus.In some embodiments, the autoimmune and / or inflammatory condition is diabetes, e.g., type 1 diabetes. In some embodiments, detection of binding of the IL-7 binding protein disclosed herein serves as an indicator of the presence of IL-7. In some embodiments, IL-7 levels are measured in or from a sample obtained from the subject. In some embodiments, the measurement of IL-7 levels can be carried out by methods and assays known in the Art. In some embodiments, IL-7 levels are compared to a reference level of IL-7. In some embodiments, the reference level serves as an indicator of normal, non-disease, disease, or disease stage. In some embodiments, IL-7 levels are measured multiple times in or from multiple samples obtained from the subject.

[0032] This specification discloses solid-phase supports comprising an IL-7 binding protein or an antigen-binding fragment thereof. In some embodiments, the solid-phase support is an array. In some embodiments, the IL-7 binding protein is directly or indirectly attached to the solid-phase support. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 6, a heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 7, and a heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 comprising the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 comprising the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 comprising the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain comprising the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a light chain comprising the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 2.In some embodiments, the IL-7 binding protein comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 2 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein is an antibody or its antigen-binding portion. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the monoclonal antibody is an IgG antibody. In some embodiments, the antibody is an IgG1 isotype antibody. In some embodiments, the monoclonal antibody is an IgG4 isotype antibody. In some embodiments, the IL-7 binding protein comprises a constant region such that the IL-7 binding protein has reduced ADCC and / or complement activation or reduced effector function. In some embodiments, the IL-7 binding protein comprises a heavy chain Fc domain having an alanine residue at positions 235 and / or 237 according to EU numbering. In some embodiments, the IL-7 binding protein is a human, humanized, or chimeric antibody. In some embodiments, the IL-7 binding protein is a humanized antibody. In some embodiments, the IL-7 binding protein is a human antibody. In some embodiments, the IL-7 binding protein binds to and neutralizes IL-7. In some embodiments, the IL-7 binding protein binds to native IL-7. In some embodiments, the device comprises a solid support and a processor for detecting a signal, the signal being an indicator of binding to a portion of the IL-7 binding protein. In some embodiments, the IL-7 binding protein is included in the kit along with instructions for use. In some embodiments, the solid support is included in the kit.

[0033] Furthermore, this specification discloses syringes or autoinjector devices comprising an IL-7 binding protein or an antigen-binding fragment thereof. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a variable region light chain having the amino acid sequence shown in SEQ ID NO: 5. In some embodiments, the IL-7 binding protein comprises a heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 6, a heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 7, and a heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the IL-7 binding protein comprises a light chain CDR1 having the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a variable region heavy chain having the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the IL-7 binding protein comprises a light chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a light chain having the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein comprises a heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the IL-7 binding protein comprises a heavy chain having the amino acid sequence shown in SEQ ID NO: 2.In some embodiments, the IL-7 binding protein comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 2 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-7 binding protein is an antibody or its antigen-binding portion. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the monoclonal antibody is an IgG antibody. In some embodiments, the antibody is an IgG1 isotype antibody. In some embodiments, the monoclonal antibody is an IgG4 isotype antibody. In some embodiments, the IL-7 binding protein comprises a constant region such that the IL-7 binding protein has reduced ADCC and / or complement activation or reduced effector function. In some embodiments, the IL-7 binding protein comprises a heavy chain Fc domain having an alanine residue at positions 235 and / or 237 according to EU numbering. In some embodiments, the IL-7 binding protein is a human, humanized, or chimeric antibody. In some embodiments, the IL-7 binding protein is a humanized antibody. In some embodiments, the IL-7 binding protein is a human antibody. In some embodiments, the IL-7 binding protein binds to and neutralizes IL-7. In some embodiments, the IL-7 binding protein binds to native IL-7. In some embodiments, a syringe or autoinjector device is included in the kit along with instructions for use.

[0034] Other aspects and embodiments of this disclosure will become apparent from the following detailed description.

[0035] Novel features of the present invention are particularly set forth in the appended claims. A better understanding of the features and advantages of the present invention can be obtained by referring to the following detailed description and accompanying drawings illustrating exemplary embodiments in which the principles of the present invention are used. [Brief explanation of the drawing]

[0036] [Figure 1A]Figure 1A shows the DRSPAI-L7B concentrations in (iv) animals administered the target doses of DRSPAI-L7B: 0.1 mg / kg, 1 mg / kg, or 10 mg / kg. [Figure 1B] Figure 1B shows the concentrations after weekly subcutaneous administration of a repeated target dose of 30 mg / kg, specifically the concentration after the first administration. Serum samples were collected at the indicated time, and DRSPAI-L7B was quantified by Gyrolab immunoassay. [Figure 1C] Figure 1C shows the concentrations after weekly subcutaneous administration of a repeated target dose of 30 mg / kg, specifically the concentration after the fourth administration. Serum samples were collected at the indicated time, and DRSPAI-L7B was quantified by Gyrolab immunoassay. [Figure 2A] Figure 2A shows the percentage of pSTAT5 inhibition in whole blood obtained from healthy donors stimulated with IL-7 in the presence of DRSPAI-L7B. [Figure 2B] Figure 2B shows the STAT5 phosphorylation of CD8+ T cells from peripheral blood mononuclear cells (PBMCs) obtained from healthy donors or IBD patients stimulated with rhIL-7 in the presence of DRSPAI-L7B or anti-RSV antibody (isotype control). [Figure 2C] Figure 2C shows the STAT5 phosphorylation of CD4+ T cells from peripheral blood mononuclear cells (PBMCs) obtained from healthy donors or IBD patients stimulated with rhIL-7 in the presence of DRSPAI-L7B or anti-RSV antibody (isotype control). [Figure 2D] Figure 2D shows the STAT5 phosphorylation of CD3+ T cells from peripheral blood mononuclear cells (PBMCs) obtained from healthy donors or IBD patients stimulated with rhIL-7 in the presence of DRSPAI-L7B or anti-RSV antibody (isotype control). [Figure 3A] Figure 3A shows the inhibition of IFN-γ secretion by healthy donor PBMCs treated with gradually increasing concentrations of DRSPAI-L7B in the presence of rhIL-7 and anti-CD3. [Figure 3B]Figure 3B shows the inhibition of IL-10 secretion by healthy donor PBMCs treated with gradually increasing concentrations of DRSPAI-L7B in the presence of rhIL-7 and anti-CD3. [Figure 3C] Figure 3C shows the inhibition of IL-2 by DRSPAI-L7B in the presence of rhIL-7 and anti-CD3. [Figure 3D] Figure 3D shows the inhibition of IL-2 by DRSPAI-L7B in the presence of rhIL-7 and anti-CD3. [Figure 3E] Figure 3E shows the inhibition of IL-2 by DRSPAI-L7B in the presence of rhIL-7 and anti-CD3. [Figure 3F] Figure 3F shows the inhibition of IL-2 by DRSPAI-L7B in the presence of rhIL-7 and anti-CD3. [Figure 3G] Figure 3G shows the inhibition of IL-2 by DRSPAI-L7B in the presence of rhIL-7 and anti-CD3. [Figure 4A] Figure 4A shows the inhibition of IL-17 in CD4+ Tmem cells isolated from healthy donor blood after incubation with IL-7 in the presence of DRSPAI-L7B following the addition of phorbol myristate acetate (PMA) / ionomycin. [Figure 4B] Figure 4B shows the TNFα inhibition of CD4+ Tmem cells isolated from healthy donor blood after adding PMA / ionomycin and incubating them with IL-7 in the presence of DRSPAI-L7B. [Figure 4C] Figure 4C shows the inhibition of IL-6 in CD4+ Tmem cells isolated from healthy donor blood after adding PMA / ionomycin and incubating them with IL-7 in the presence of DRSPAI-L7B. [Figure 4D] Figure 4D shows the inhibition of IL-10 in CD4+ Tmem cells isolated from healthy donor blood after adding PMA / ionomycin and incubating them with IL-7 in the presence of DRSPAI-L7B. [Figure 4E]Figure 4E shows the INFγ inhibition of CD4+ Tmem cells isolated from healthy donor blood after adding PMA / ionomycin and incubating them with IL-7 in the presence of DRSPAI-L7B. [Figure 4F] Figure 4F shows the CCL3 inhibition of CD4+ Tmem cells isolated from healthy donor blood incubated with IL-7 in the presence of DRSPAI-L7B supplemented with PMA / ionomycin. [Figure 5A] Figure 5A shows profiles of CD4+ lymphocytes from healthy controls and MS patients, profiled by flow cytometry based on CD45RO, CCR7, CD127, and CD25 expression on the cell surface. [Figure 5B] Figure 5B shows profiles of CD8+ lymphocytes from healthy controls and MS patients, profiled by flow cytometry based on CD45RO, CCR7, CD127, and CD25 expression on the cell surface. [Figure 5C] Figure 5C shows profiles of regulatory T cells from healthy controls and MS patients, profiled by flow cytometry based on CD45RO, CCR7, CD127, and CD25 expression on the cell surface. [Figure 6A] Figure 6A shows the STAT5 phosphorylation of CD4+ T cells from PBMCs obtained from healthy donors or MS patients stimulated with rhIL-7 in the presence of DRSPAI-L7B or anti-RSV antibody (isotype control). [Figure 6B] Figure 6B shows the STAT5 phosphorylation of CD8+ T cells from PBMCs obtained from healthy donors or MS patients stimulated with rhIL-7 in the presence of DRSPAI-L7B or anti-RSV antibody (isotype control). [Figure 7A] Figure 7A shows a linear plot of IL-7 levels in serum samples from healthy controls (HC, n=10), Crohn's disease (n=15), ulcerative colitis (UC, n=15), systemic lupus erythematosus (SLE, n=15), and primary Sjögren's syndrome (pSS, n=15). [Figure 7B] Figure 7B shows a logarithmic plot of IL-7 levels in serum samples from healthy controls (HC, n=10), Crohn's disease (n=15), ulcerative colitis (UC, n=15), systemic lupus erythematosus (SLE, n=15), and primary Sjögren's syndrome (pSS, n=15). [Modes for carrying out the invention]

[0037] Inhibition of IL-7 receptor-mediated signaling offers a promising therapeutic intervention for the treatment of autoimmune and / or inflammatory diseases. In some embodiments herein, IL-7-binding proteins are disclosed that reduce B cell activation, decrease autoantibody production, and / or reduce B cell antigen presentation. In some embodiments, the IL-7-binding proteins disclosed herein bind to IL-7 and inhibit IL-7 receptor-mediated signaling, thereby inhibiting regulatory T cells (T reg ) does not restrict the development or function of CD4. In some embodiments, the IL-7 binding protein disclosed herein is CD4 + T cells and CD8 + It inhibits both T cell signaling, activation, cytokine production, and proliferation. In some embodiments, blocking IL-7-binding proteins in IL-7-mediated signaling reduces the inflammatory response.

[0038] IL-7 binding protein The term "IL-7-mediated signaling," as used herein, refers to the biological effects induced by the IL-7 receptor complex upon binding of its ligand, IL-7. Therefore, IL-7-mediated signaling is not necessarily limited to, but includes, IL-7-induced phosphorylation of STAT-5 and IL-7-induced T H 17 Cell expansion and IL-7-induced T H This includes one or more, or all, of the 17 surviving cells.

[0039] The term "IL-7-binding protein," as used herein, refers to antibodies and other protein constructs, such as domains, that can bind to IL-7. The terms "IL-7-binding protein" and "anti-IL-7 antigen-binding protein" are used interchangeably herein. This does not include native congener receptors.

[0040] The term “antibody” is used herein in its broadest sense to refer to molecules having an immunoglobulin-like domain (e.g., IgG, IgM, IgA, IgD, or IgE), and includes monoclonal antibodies, recombinant antibodies, polyclonal antibodies, chimeric antibodies, human antibodies, humanized antibodies, multispecific antibodies (including bispecific antibodies), and heteroconjugate antibodies; single variable domains (e.g., domain antibodies (DAB)), antigen-binding antibody fragments, Fab, F(ab')2, Fv, disulfide-linked Fv, single-chain Fv, disulfide-linked scFv, diabodies, TANDAB, etc., and any of the above variations (for an overview of alternative “antibody” forms, see Holliger and Hudson, Nature Biotechnology, 2005, Vol 23, No. 9, 1126–1136).

[0041] In some embodiments, the IL-7 binding protein disclosed herein may be derived from rats, mice, primates (e.g., cynomolgus monkeys, Old World monkeys, or great apes) or humans. The IL-7 binding protein may be human, humanized, or chimeric antibodies. The IL-7 binding protein may include a constant region, which may be any isotype or subclass. The constant region may be the constant region of an IgG isotype, e.g., IgG1, IgG2, IgG3, IgG4 or a variant thereof. The constant region of the IL-7 binding protein may be IgG1. In some embodiments, the IL-7 binding protein is an IgG1k antibody.

[0042] As used herein, "approximately" means plus or minus 10%.

[0043] The terms “full,” “whole,” and “intact” antibodies, as used interchangeably herein, refer to heterotetrameric glycoproteins. Intact antibodies consist of two identical heavy chains (HC) and two identical light chains (LC) linked by covalent disulfide bonds. This H2L2 structure folds to form three functional domains comprising two antigen-binding fragments known as “Fab” fragments and an “Fc” crystalline fragment. The Fab fragment consists of a variable heavy chain (VH) or variable light chain (VL) as a variable domain at the amino terminus, and CH1 (heavy chain) and CL (light chain) as constant domains at the carboxyl terminus. The Fc fragment consists of two domains formed by the dimerization of paired CH2 and CH3 regions. Fc can evoke effector function by binding to receptors on immune cells or by binding to C1q, the first component of the classical complement pathway. The five classes of antibodies, IgM, IgA, IgG, IgE, and IgD, are defined by different heavy chain amino acid sequences called μ, α, γ, ε, and δ, respectively, where each heavy chain can be paired with a κ or λ light chain. The majority of antibodies in serum belong to the IgG class, and human IgG has four isotypes (IgG1, IgG2, IgG3, and IgG4), whose sequences differ mainly in the hinge region. In some embodiments, the IL-7 binding protein disclosed herein is human IgG1. In some embodiments, the IL-7 binding protein disclosed herein is a disulfide-linked α2β2 tetramer. In some embodiments, the IL-7 binding protein disclosed herein comprises two light chains (κ) and two heavy (IgG1) chains.

[0044] Fully human antibodies can be obtained using various methods, such as using a yeast-based library or transgenic animals (e.g., mice) capable of producing a repertoire of human antibodies. Yeast that displays human antibodies that bind to the target antigen on its surface can be selected by methods based on FACS (fluorescence-activated cell sorting) or by capture onto beads using labeled antigens. Transgenic animals modified to express human immunoglobulin genes can be immunized with the target antigen, and antigen-specific human antibodies can be isolated using B-cell sorting techniques. Human antibodies produced using such techniques can then be characterized for desirable properties such as affinity, developability, and selectivity.

[0045] In some embodiments, alternative antibody forms may be used. These alternative antibody forms include alternative scaffolds on which one or more CDRs of an IL-7 antibody can be positioned on a scaffold or backbone of a suitable non-immunoglobulin protein, such as an affibody, SpA scaffold, LDL receptor class A domain, avimer (see, for example, U.S. Patent Applications Publications 2005 / 0053973, 2005 / 0089932, and 2005 / 0164301), or EGF domain.

[0046] The term "domain" refers to a folded polypeptide structure that maintains its tertiary structure independently of the rest of the polypeptide. Generally, domains contribute to distinct functional properties of a polypeptide. Often, domains can be added, removed, or transferred to other polypeptides without losing the function of the rest of the protein and / or the domain itself.

[0047] The term "single variable domain" refers to a folded polypeptide domain containing sequences specific to antibody variable domains. Therefore, a "single variable domain" includes a fully antibody variable domain (e.g., V H , V HH and V L) and modified antibody variable domains (e.g., antibody variable domains in which one or more loops are replaced by sequences not specific to the antibody variable domain), truncated antibody variable domains, or antibody variable domains containing N or C-terminal extensions, as well as folded fragments of variable domains that retain at least the binding activity and specificity of the full-length domain. A single variable domain can bind to an antigen or epitope independently of different variable regions or domains. A “domain antibody” or “DAB” may be considered the same as a “single variable domain”. A single variable domain may be a human single variable domain, but furthermore, single variable domains from other species, e.g., rodents (e.g., as disclosed in WO00 / 29004A1), and V from the families Scaridae and Camelidae. HH Includes DAB. V of the camel family. HH This is an immunoglobulin monovariate polypeptide derived from species including camels, llamas, alpacas, dromedary camels, and guanacos, which produces heavy-chain antibodies that naturally lack light chains. HH A domain may be humanized by standard techniques available in the art, and such a domain is considered a “single variable domain.” As used herein, V H V of the camelid family HH Includes the domain.

[0048] Antigen-binding fragments, IL-7-binding protein fragments, functional fragments, biologically active fragments, or immunologically effective fragments may include a partial heavy chain or light chain variable sequence. The fragments are at least 5, 6, 8, or 10 amino acid lengths. Alternatively, the fragments are at least 15, at least 20, at least 50, at least 75, or at least 100 amino acid lengths.

[0049] Antigen-binding fragments may be provided by locating one or more CDRs on a non-antibody protein scaffold. “Protein scaffold” as used herein includes, but is not limited to, immunoglobulin (Ig) scaffolds, such as an IgG scaffold which may be a quadruple-chain or double-chain antibody, or an IgG scaffold which may consist only of the Fc region of an antibody, or an IgG scaffold which may consist of one or more constant regions derived from an antibody (which may be of human or primate origin), or an IgG scaffold which may be an artificial chimera of human and primate constant regions.

[0050] The protein scaffold can be an Ig scaffold, for example, an IgG or IgA scaffold. The IgG scaffold contains the antibody domains (i.e., CH1, CH2, CH3, V). H , V L The IL-7 binding protein may consist of some or all of the following: The IL-7 binding protein may consist of an IgG scaffold selected from IgG1, IgG2, IgG3, IgG4, or IgG4PE. For example, the scaffold may be IgG1. The scaffold may consist of, or contain, or be a part of, the Fc region of the antibody.

[0051] Protein scaffolds may be derivatives of scaffolds selected from the group consisting of CTLA-4, lipocalin, protein A-derived molecules such as the Z-domain (afibody, SpA) and A-domain (avimer / maxibody) of proteins; heat shock proteins such as GroEl and GroES; transferrin (transbody); ankyrin repeat protein (DARPin); peptide aptamers; C-type lectin domains (tetranectin); human γ-crystallin and human ubiquitin (afirin); PDZ domains; scorpion toxin Knitz-type domains of human protease inhibitors; and fibronectin / adnectin; and those subjected to protein engineering to obtain binding to antigens other than natural ligands.

[0052] As used herein, the term "antagonist antibody" refers to an antibody or fragment thereof that can completely or partially inhibit the biological activity of an antigen to which it binds (e.g., IL-7) by, for example, completely or partially blocking its binding to a ligand or by reducing the biological activity of the antigen.

[0053] The "antigen-binding site" refers to the region of an antigen-binding protein that can specifically bind to an antigen. This can be a single variable domain or a V-domain found in standard antibodies. H / V L It can be a pair of domains. Single-chain Fv(ScFv) domains can also provide antigen-binding sites.

[0054] The term “chimeric antigen receptor” ("CAR"), as used herein, refers to an extracellular antigen-binding domain (usually a monoclonal antibody or its fragments, e.g., a V in scFv form). H Domain and V L CARs refer to genetically engineered receptors consisting of a domain (derived from a T cell), and sometimes a spacer region, a transmembrane region, and one or more intracellular effector domains. CARs have also been called chimeric T cell receptors or chimeric immune receptors (CIRs). CARs are commonly introduced into hematopoietic cells, such as T cells, to redirect T cell specificity to desired cell surface antigens, thereby obtaining CAR-T therapeutics.

[0055] A "humanized antibody" refers to a type of genetically engineered antibody in which its CDR is derived from a non-human donor immunoglobulin, and the remaining immunoglobulin-derived portion of the molecule is derived from one or more human immunoglobulins. In addition, framework support residues may be modified to preserve binding affinity (see, e.g., Queen et al. Proc. Natl Acad Sci USA, 86:10029-10032 (1989), Hodgson et al. Bio / Technology, 9:421 (1991)). A suitable human acceptor antibody may be selected from conventional databases, e.g., the KABAT database, the Los Alamos database, and the Swiss Protein database, based on homology to the nucleotide and amino acid sequences of the donor antibody. Human antibodies characterized by homology (based on amino acids) to the framework region of the donor antibody may be suitable for providing a heavy chain constant region and / or heavy chain variable framework region for donor CDR insertion. A suitable acceptor antibody capable of donating a constant or variable framework region of the light chain can also be selected. It should be noted that the acceptor antibody heavy and light chains do not need to originate from the same acceptor antibody. Several methods for producing such humanized antibodies are described in the prior art literature (see, for example, EP-A-0239400 and EP-A-054951).

[0056] The term "spacer region," as used herein, refers to an oligopeptide or polypeptide that functions to ligate a transmembrane domain to a target-binding domain. This region is sometimes called a "hinge region" or "stalk region." The size of the spacer is variable depending on the position of the target epitope in order to maintain a set distance (e.g., 14 nM) at CAR:target binding.

[0057] As used herein, the term "transmembrane domain" refers to the portion of a CAR molecule that crosses the cell membrane.

[0058] The term “intracellular effector domain” (also called “signaling domain”), as used herein, refers to a domain within a CAR that is responsible for intracellular signaling after the antigen-binding domain has bound to a target. The intracellular effector domain is responsible for activating at least one of the normal effector functions of the immune cell on which the CAR is expressed. For example, the effector function of a T cell may be cytolytic activity or helper activity, including cytokine secretion.

[0059] V disclosed herein H and / or V L Those skilled in the art will recognize that the domain can be introduced into CAR-T therapy drugs, for example, in the form of scFv.

[0060] In some embodiments, the IL-7 binding proteins of this disclosure exhibit cross-reactivity between human IL-7 and IL-7 from other species, such as cynomolgus monkey IL-7. In some embodiments, the IL-7 binding proteins of the present invention specifically bind to human and cynomolgus monkey IL-7. This is particularly useful in drug discovery, where it is generally necessary to test lead drug candidates in mouse systems before testing drugs in humans. Providing drugs that can bind to both human and macaque monkeys allows for examining the results in these systems and performing controlled comparisons of data using the same drug. This eliminates the complexity of having to find a drug that acts on macaque monkey IL-7 and another drug that acts on human IL-7, and also eliminates the need to compare human and macaque results using non-identical drugs. Cross-reactivity between different species used in disease models such as dogs or mice is also anticipated.

[0061] In some cases, the difference in binding affinity of the IL-7 binding protein to cynomolgus monkey IL-7 and to human IL-7 is at least 2-fold or 5-fold. In some embodiments, the IL-7 binding proteins disclosed herein are species-specific.

[0062] Affinity, also known as "binding affinity," is the strength of binding at a single binding site. That is, affinity is the strength of binding at a single binding site between one molecule, e.g., the IL-7 binding protein of this disclosure, and another molecule, e.g., its target antigen. The binding affinity between the IL-7 binding protein and its target can be determined by equilibrium methods (e.g., enzyme-linked immunosorbent assay (ELISA) or radioimmunoassay (RIA)) or kinetic methods (e.g., surface plasmon resonance analysis using a BIACORE instrument). For example, the BIACORE method described in Example 2 can be used to measure binding affinity.

[0063] Avidity, also known as functional affinity, is the cumulative strength of binding at multiple interaction sites. For example, it is the total strength of binding to each other at multiple sites of two (or more (e.g., in the case of bispecific or multispecific molecules)) molecules, and may take interaction valence into consideration.

[0064] In some embodiments, the equilibrium dissociation constant (KD) of the interaction between the IL-7 binding protein and IL-7 is less than or equal to about 100 nM, less than or equal to about 10 nM, less than or equal to about 2 nM, or less than or equal to about 1 nM. Alternatively, the KD may be about 5 to about 10 nM; or about 1 to about 2 nM. The KD may be about 1 pM to about 500 pM; or about 500 pM to about 1 nM. In some embodiments, the equilibrium dissociation constant (KD) of the interaction between the IL-7 binding protein and IL-7 is less than or equal to 100 nM, less than or equal to 10 nM, less than or equal to 2 nM, or less than or equal to 1 nM. Alternatively, the KD may be 5 to 10 nM; or 1 to 2 nM. The KD may be 1 pM to 500 pM; or 500 pM to 1 nM. Those skilled in the art will understand that a smaller KD value indicates stronger binding. The reciprocal of KD (i.e., 1 / KD) is M -1This is the equilibrium association constant (KA) in units of . Those skilled in the art will understand that a larger KA value indicates stronger binding. In some embodiments, the KD of the IL-7 binding proteins disclosed herein is about 30 to 90 pM. In some embodiments, the KD of the IL-7 binding proteins disclosed herein is about 30 to about 80 pM, about 30 to about 70 pM, about 30 to about 60 pM, about 30 to about 50 pM, about 30 to about 55 pM, or about 30 to about 40 pM. In some embodiments, the KD of the IL-7 binding proteins disclosed herein is about 40 to about 80 pM, about 40 to about 70 pM, about 40 to about 60 pM, about 40 to about 50 pM, or about 40 to about 55 pM. In some embodiments, the KD of the IL-7 binding proteins disclosed herein is about 30 to about 55 pM. In some embodiments, the KD of the IL-7 binding proteins disclosed herein is about 31, about 34, about 46, about 53, about 69, about 73, about 75, or about 87 pM. In some embodiments, the KD of the IL-7 binding proteins disclosed herein is about 31, about 34, about 46, about 53, about 69, about 73, about 75, or about 87 pM. In some embodiments, the KD of the IL-7 binding proteins disclosed herein is about 34 pM. In some embodiments, the KD of the IL-7 binding proteins disclosed herein is about 67 pM. In some embodiments, the KD of the IL-7 binding proteins disclosed herein is about 30 to about 55 pM at 25°C. In some embodiments, the KD of the IL-7 binding proteins disclosed herein is about 36 pM at about 25°C. In some embodiments, the KD of the IL-7 binding proteins disclosed herein is about 45 to about 90 pM. In some embodiments, the KD of the IL-7 binding protein disclosed herein is about 45 to about 90 pM at 37°C. In some embodiments, the KD of the IL-7 binding protein disclosed herein is about 67 pM at 37°C. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 30 to 90 pM. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 30 to 80 pM, 30 to 70 pM, 30 to 60 pM, 30 to 50 pM, 30 to 55 pM, or 30 to 40 pM.In some embodiments, the KD of the IL-7 binding protein disclosed herein is 40–80 pM, 40–70 pM, 40–60 pM, 40–50 pM, or 40–55 pM. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 30–55 pM. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 31, 34, 46, 53, 69, 73, 75, or 87 pM. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 31, 34, 46, 69, 75, or 87 pM. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 34 pM. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 67 pM. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 30–55 pM at 25°C. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 36 pM at 25°C. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 45–90 pM. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 45–90 pM at 37°C. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 67 pM at 37°C.

[0065] In some embodiments, the KD of the IL-7 binding protein disclosed herein is 31, 34, 46, 53, 69, 73, 75, or 87 pM ± 15%. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 31, 34, 46, 69, 75, or 87 pM ± 15%. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 34 pM ± 15%. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 67 pM ± 15%. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 30 to 55 pM at 25°C. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 36 pM ± 15% at 25°C. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 45 to 90 pM. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 45–90 pM at 37°C. In some embodiments, the KD of the IL-7 binding protein disclosed herein is 67 pM ± 15% at 37°C.

[0066] Those skilled in the art will understand that surface plasmon resonance (SPR) is a suitable method for measuring binding affinity and determining binding rate (see, for example, Day et al., Direct comparison of binding equilibrium, thermodynamic, and rate constants determined by surface- and solution-based biophysical methods, Protein Science (2002), 11:1017-1025; and, Hearty et al, “Measuring antibody-antigen binding kinetics using surface plasmon resonance” Methods Mol Biol (2012) 907:411-4).

[0067] The dissociation rate constant (kd) or "off-rate" represents the stability of the IL-7 binding protein-IL-7 complex, i.e., the rate at which the complex decays per second. For example, a kd of 0.01 seconds -1 corresponds to 1% of the complex decaying per second. In certain embodiments, the dissociation rate constant (kd) is about 1×10 -3 seconds -1 or less, about 1×10 -4 seconds -1 or less, about 1×10 -5 seconds -1 or less or about 1×10 -6 seconds -1 or less. The kd can be about 1×10 -5 seconds -1 to about 1×10 -4 seconds -1 ; or about 1×10 -4 seconds -1 to about 1×10 -3 seconds -1 In some embodiments, the kd of the IL-7 binding protein disclosed herein is about 2.06×10 -4 seconds -1 or less, about 1.58×10 -4 seconds -1 or less, about 1.7×10 -4 seconds -1 or less, about 5.68×10 -4 seconds -1 or less, about 6.78×10 -4 seconds -1 or less, about 8.26×10 -4 seconds -1 or less or about 5.15×10 -4 seconds -1 or less. In some embodiments, the kd of the IL-7 binding protein disclosed herein is about 1.58×10 -4 seconds -1 or less. In some embodiments, the kd of the IL-7 binding protein disclosed herein is about 5.68×10 -4 seconds -1 or less. In some embodiments, the kd of the IL-7 binding protein disclosed herein is about 2.06×10 -4 seconds at 25°C-1 Below, approximately 1.58×10 -4 seconds -1 The following or approximately 1.7 × 10 -4 seconds -1 The following applies: In some embodiments, the kd of the IL-7 binding protein disclosed herein is approximately 5.68 × 10⁻¹⁴ at 37°C. -4 seconds -1 Below, approximately 6.78×10 -4 seconds -1 Below, approximately 8.26×10 -4 seconds -1 The following or approximately 5.15 × 10 -4 seconds -1 The following applies:

[0068] In one embodiment, the dissociation rate constant (kd) is 1 × 10⁻⁶. -3 seconds -1 Below, 1 x 10 -4 seconds -1 Below, 1 x 10 -5 seconds -1 The following or 1 x 10 -6 seconds -1 The following applies: kd is 1 × 10 -5 seconds -1 ~1 × 10 -4 seconds -1 ; or 1 × 10 -4 seconds -1 ~1 × 10 -3 seconds -1 It is possible. In some embodiments, the kd of the IL-7 binding protein disclosed herein is 2.06 × 10⁻⁶. -4 seconds -1 Below, 1.58 × 10 -4 seconds -1 Below, 1.7 × 10 -4 seconds -1 Below, 5.68 × 10 -4 seconds -1 Below, 6.78 × 10 -4 seconds -1 Below, 8.26 × 10 -4 seconds -1 The following or 5.15 × 10 -4 seconds -1 The following applies: In some embodiments, the kd of the IL-7 binding protein disclosed herein is 1.58 × 10⁻⁶. -4 seconds-1 In some embodiments, the kd of the IL-7 binding protein disclosed herein is 5.68 × 10⁻⁶. -4 seconds -1 The following applies: In some embodiments, the kd of the IL-7 binding protein disclosed herein is 2.06 × 10⁻¹⁴ at 25°C. -4 seconds -1 Below, 1.58 × 10 -4 seconds -1 The following or 1.7 × 10 -4 seconds -1 The following applies: In some embodiments, the kd of the IL-7 binding protein disclosed herein is 5.68 × 10⁻¹⁴ at 37°C. -4 seconds -1 Below, 6.78 × 10 -4 seconds -1 Below, 8.26 × 10 -4 seconds -1 The following or 5.15 × 10 -4 seconds -1 The following applies:

[0069] The association rate constant (ka) or "on-rate" represents the rate of formation of the IL-7 binding protein-IL-7 complex. In some embodiments, the association rate constant (ka) is approximately 6.49 × 10⁻⁶. 6 M -1 seconds -1 , about 4.65×10 6 M -1 seconds -1 , about 3.17×10 6 M -1 seconds -1 , about 8.28×10 6 M -1 seconds -1 , about 1.47×10 7 M -1 seconds -1 , about 1.10×10 7 M -1 seconds -1 Or approximately 5.90 × 10 6 M -1 seconds -1 In one embodiment, the association rate constant (ka) is approximately 6.49 × 10⁻⁶ at 25°C. 6 M-1 seconds -1 , 4.65×10 6 M -1 seconds -1 Or approximately 3.17 × 10 6 M -1 seconds -1 In one embodiment, the association rate constant (ka) is approximately 8.28 × 10⁻⁶ at 37°C. 6 M -1 seconds -1 , about 1.47×10 7 M -1 seconds -1 , about 1.10×10 7 M -1 seconds -1 Or approximately 5.90 × 10 6 M -1 seconds -1 In one embodiment, the association rate constant (ka) is 6.49 × 10⁻⁶. 6 M -1 seconds -1 , 4.65×10 6 M -1 seconds -1 , 3.17 × 10 6 M -1 seconds -1 , 8.28×10 6 M -1 seconds -1 , 1.47 × 10 7 M -1 seconds -1 , 1.10 × 10 7 M -1 seconds -1 Or 5.90 × 10 6 M -1 seconds -1 In one embodiment, the association rate constant (ka) is 6.49 × 10⁻⁶ at 25°C. 6 M -1 seconds -1 , 4.65×10 6 M -1 seconds -1 Or 3.17 × 10 6 M -1 seconds -1 In one embodiment, the association rate constant (ka) is 8.28 × 10⁻⁶ at 37°C. 6 M -1 seconds -1 , 1.47 × 10 7 M-1 seconds -1 , 1.10 × 10 7 M -1 seconds -1 Or 5.90 × 10 6 M -1 seconds -1 That is the case.

[0070] As used herein, the term "neutralize" means that, in vitro or in vivo, the biological activity of IL-7 is reduced in the presence of an IL-7-binding protein as described herein compared to the IL-7 activity in the absence of the IL-7-binding protein. Neutralization may result from one or more of the following: blockage of IL-7 binding to its receptor, avoidance of IL-7 activating its receptor, downmodulation of IL-7 or its receptor, or an effect on effector function.

[0071] The reduction or inhibition of biological activity may be partial or complete. Neutralizing IL-7 binding proteins can neutralize IL-7 activity by lowering the B-cell activation threshold by at least 20%, 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% compared to IL-7 activity in the absence of the IL-7 binding protein. Neutralization can be determined or measured using one or more assays known to those skilled in the art or described herein. See, for example, Figures 2B, 2C, and 2D.

[0072] Those skilled in the art will see that the term “derived” is intended to define not only a source in the sense of the physical origin of the substance, but also a substance that is structurally identical to the substance but does not originate from the reference source.

[0073] "Isolated" means that a molecule, such as an IL-7 binding protein, has been removed from its naturally occurring environment. For example, a molecule may be purified from substances that normally coexist naturally. For instance, an IL-7 binding protein may be purified to at least 95%, 96%, 97%, 98%, or 99%, or more, relative to a culture medium containing the IL-7 binding protein. The IL-7 binding proteins and antibodies disclosed herein may be isolated IL-7 binding proteins and antibodies.

[0074] "CDR" is defined as the complementarity-determining region amino acid sequence of an antigen-binding protein. These are the hypervariable regions of the immunoglobulin heavy and light chains. The variable region of an immunoglobulin contains three heavy-chain CDRs and three light-chain CDRs (or CDR regions). Therefore, as used herein, "CDR" refers to all three heavy-chain CDRs, all three light-chain CDRs, all heavy-chain and light-chain CDRs, or at least two CDRs.

[0075] In this specification, amino acid residues in variable domain sequences and amino acid residues in variable domain regions within full-length antigen-binding sequences, such as amino acid residues in antibody heavy chain sequences or antibody light chain sequences, are numbered according to Kabat numbering rules. Similarly, the terms “CDR,” “CDRL1,” “CDRL2,” “CDRL3,” “CDRH1,” “CDRH2,” and “CDRH3” used in the examples also follow Kabat numbering rules. For further details, see Kabat et al., Sequences of Proteins of Immunological Interest, 4th edition, US Department of Health and Human Services, National Institutes of Health (1987).

[0076] variant It is obvious to those skilled in the art that there are alternative numbering rules for amino acid residues in variable domain sequences and full-length antibody sequences. There are also alternative numbering rules for CDR sequences, such as those presented, for example, in Chothia et al. (1989) Nature 342: 877-883. The structure and protein folding of IL-7 binding proteins imply that other residues are considered part of the CDR sequence, and this is understood to those skilled in the art.

[0077] Other numbering rules for CDR sequences available to those skilled in the art include the "AbM" method (University of Bath) and the "Contact" method (University College London). At least two of the Kabat, Chothia, AbM, and Contact methods can be used to determine the minimum overlapping region and obtain the "minimum binding unit." The minimum binding unit may be a portion of the CDR.

[0078] Table 1 below shows one definition for each CDR or binding unit using each numbering rule. In Table 1, the Kabat numbering scheme is used to number the variable domain amino acid sequences. Note that some CDR definitions may differ depending on the individual publication used.

[0079] [Table 1]

[0080] Therefore, an IL-7 binding protein is provided comprising one or a combination of the following CDRs: CDRH1 of SEQ ID NO: 6, CDRH2 of SEQ ID NO: 7, CDRH3 of SEQ ID NO: 8, CDRL1 of SEQ ID NO: 9, CDRL2 of SEQ ID NO: 10, and CDRL3 of SEQ ID NO: 11. The CDR may be modified by at least one amino acid substitution, deletion, or addition, and this variant IL-7 binding protein substantially retains the biological characteristics of the unmodified protein, such as binding to IL-7.

[0081] It will be recognized that each of the CDRs H1, H2, H3, L1, L2, and L3 may be modified individually or in combination with any other CDR in any permutation or combination. In one embodiment, a CDR is modified by the substitution, deletion, or addition of up to three amino acids, e.g., one or two amino acids, e.g., one amino acid. Generally, the modification is a substitution, in particular a conservative substitution, such as those shown in Table 2 below.

[0082] [Table 2]

[0083] For example, in a variant CDR, adjacent residues comprising the CDR as part of another definition, such as Kabat or Chothia, may be substituted with conserved amino acid residues. In some embodiments, an IL-7 binding protein comprising such a variant CDR may be referred to herein as a “functional CDR variant.”

[0084] Therefore, in another embodiment, the IL-7 binding protein provided herein is an IL-7 binding protein that binds to IL-7 and comprises CDRH3 of SEQ ID NO: 8 or its variant CDRH3. In one embodiment, the IL-7 binding protein comprises CDRH1 of SEQ ID NO: 6 or its variant CDRH1, CDRH2 of SEQ ID NO: 7 or its variant CDRH2, CDRH3 of SEQ ID NO: 8 or its variant CDRH3, CDRL1 of SEQ ID NO: 9 or its variant CDRL1, CDRL2 of SEQ ID NO: 10 or its variant CDRL2, and CDRL3 of SEQ ID NO: 11 or its variant CDRL3. In some embodiments, the IL-7 binding proteins disclosed herein, including those with one or more variant CDRs, can bind to IL-7 and can also neutralize IL-7 activity.

[0085] This specification discloses an IL-7-binding protein that binds to IL-7 and comprises the heavy chain variable region of SEQ ID NO: 4. The IL-7-binding protein may also comprise the light chain variable region of SEQ ID NO: 5. In some embodiments, the IL-7-binding protein binds to and neutralizes IL-7. In one embodiment, the IL-7-binding protein comprises the heavy chain variable region of SEQ ID NO: 4 and the light chain variable region of SEQ ID NO: 5.

[0086] CDRs L1, L2, L3, H1, H2, and H3 tend to exhibit one of a structurally finite number of canonical conformations. A specific canonical conformation class of a CDR is defined by both the length of the CDR and the loop packing, which is determined by residues (structural determination residues or SDRs) located at key positions in both the CDR and the framework region. Martin and Thornton (1996; J Mol Biol 263:800-815) developed an automated method for defining "key residue" canonical templates. They define the canonical class of a set of CDRs using cluster analysis and then identify the canonical template by analyzing buried hydrophobic residues, hydrogen-bonded residues, and conserved glycine and proline. CDRs of antibody sequences can be assigned to a canonical class by comparing the sequence to a key residue template and scoring each template using an identity matrix or similarity matrix.

[0087] Based on the canonical class of the DRSPAI-L7B antibody, functional antibody binding can be predicted to be maintained in the presence of the following CDR substitutions, where the amino acid before the Kabat number is the original amino acid sequence and the amino acid sequence after the Kabat number is the substituted amino acid.

[0088] CDRL1 Canonical: K24R S27aN, S27aD, S27aT, S27aE, S31N, S31T, S31K, S31G L27bV D27cL, D27cY, D27cV, D27cI, D27cS, D27cN, D27sF, D27cH, D27cG, D27cT Y32F, Y32N, Y32A, Y32H, Y32S, Y32R I33M, I33L, I33V, I33R N34H

[0089] CDRL2 Canonical: G51A

[0090] CDRL3カノニカル: Q89S、Q89G、Q89F、Q89L、Q90N、Q90H S91N、S91F、S91G、S91R、S91D、S91H、S91T、S91Y、S91V N92Y、N92W、N92T、N92S、N92R、N92Q、N92Q、N92H、N92A、N92D V93E、V93N、V93G、V93H、V93T、V93S、V93R、V93A D94Y、D94T、D94V、D94L、D94H、D94N、D94I、D94W、D94P、D94S L96P、L96Y、L96R、L96I、L96W、L96F

[0091] CDRH1カノニカル: Y32I、Y32H、Y32F、Y32T、Y32N、Y32C、Y32E、Y32D G33Y、G33A、G33W、G33T、G33L、G33V V34M、V34I、V34L、V34T、V34W H35E、H35N、H35Q、H35S、H35Y、H35T

[0092] CDRH2カノニカル: I51L、I51V、I51T、I51S、I51N、I51M G55D Y59L

[0093] CDRH3カノニカル: Y102H、Y102V、Y102I、Y102S、Y102D、Y102G

[0094] As described above, a specific canonical structural class of a CDR is defined by both the length of the CDR and the loop packing determined by residues at key positions in both the CDR and the framework region. Therefore, substitutions may be made to the framework residues of the IL-7 binding protein of the present invention based on the canonical class, while retaining a functional antibody. Such substitutions include the following (using Kabat numbering): Light chain: I, L, or V at position 2; Q, L, or E at position 3; M or L at position 4; I or V at position 48; and / or Heavy chain: V, I, or L at position 2; L or V at position 4; L, I, M, or V at position 20; T, A, V, G, or S at position 24; F, Y, T, or G at position 27; F, L, I, V, or S at position 29; W or Y at position 47; I, M, L, or V at position 48; I, L, F, M, or V at position 69; R, K, V, or I at position 71; A, L, V, Y, or F at position 78; L or M at position 80; Y or F at position 90; R, K, G, S, H, N, T, A, and / or L at position 94.

[0095] Therefore, the IL-7 binding protein may have any of the above substitutions at the aforementioned positions. Since multiple substitutions may exist for each variant CDR, each heavy chain or light chain variable region, each heavy chain or light chain, and each IL-7 binding protein, the IL-7 binding protein of the present invention may have any combination of substitutions, as long as the canonical structure of the CDR is maintained. To avoid doubt, the above substitutions should not be interpreted as limiting the CDR substitutions that may be performed while still retaining a functional anti-IL-7 antibody.

[0096] V disclosed herein H Or V LThe (or HC or LC) sequence may be a variant sequence having up to 10 amino acid substitutions, additions, or deletions. For example, a variant sequence may have 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid substitution, addition, or deletion. Sequence variations may exclude one or more CDRs or all CDRs, for example, CDR is V H Or V L (Also the same as the HC or LC sequence, the variation is V) H Or V L The CDR sequence is located in the remainder of the (or HC or LC) sequence, and therefore the CDR sequence is fixed and intact.

[0097] Alternatively, the heavy chain variable region may have 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, 99% or more, or 100% identity with the amino acid sequence shown in SEQ ID NO: 4; and the light chain variable region may have 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, 99% or more, or 100% identity with the amino acid sequence shown in SEQ ID NO: 5.

[0098] The heavy chain variable region may be a variant of the amino acid sequence shown in SEQ ID NO: 4, containing 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid substitution, insertion, or deletion. The light chain variable region may be a variant of the amino acid sequence shown in SEQ ID NO: 5, containing 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid substitution, insertion, or deletion.

[0099] In certain embodiments, the IL-7 binding protein described herein binds to IL-7 and comprises a combination of the heavy chain variable domain of SEQ ID NO: 4 and the light chain variable domain of SEQ ID NO: 5, or the IL-7 binding protein has a heavy chain variable domain and a light chain variable domain having at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 4 and SEQ ID NO: 5, respectively. In some embodiments, the IL-7 binding protein binds to and neutralizes IL-7.

[0100] Any of the heavy chain variable regions of IL-7 binding proteins described herein may be combined with a suitable constant region. Any of the light chain variable regions of IL-7 binding proteins may be combined with a suitable constant region. The constant regions disclosed herein may be human constant regions.

[0101] This disclosure also provides nucleic acid molecules encoding any one polypeptide sequence of the IL-7 binding proteins described herein. The nucleic acid molecule may comprise (i) one or more CDRH, heavy chain variable sequence, or full-length heavy chain sequence; and (ii) one or more CDRL, light chain variable sequence, or full-length light chain sequence, wherein (i) and (ii) reside in the same nucleic acid molecule. Alternatively, the nucleic acid molecule encoding the IL-7 binding protein described herein may comprise (a) one or more CDRH, heavy chain variable sequence, or full-length heavy chain sequence; or (b) one or more CDRL, light chain variable sequence, or full-length light chain sequence, wherein (a) and (b) reside in separate nucleic acid molecules. In some embodiments, the nucleic acid comprises a sequence having at least about 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the nucleic acid sequence shown in Sequence ID No. 13 encoding the light chain. In some embodiments, the nucleic acid comprises the nucleic acid sequence shown in Sequence ID No. 13 encoding the light chain. In some embodiments, the nucleic acid comprises a sequence having at least about 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the nucleic acid sequence shown in SEQ ID NO: 14, which codes for a heavy chain. In some embodiments, the nucleic acid comprises a sequence having at least about 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the nucleic acid sequence shown in SEQ ID NO: 15, which codes for a signal peptide.

[0102] IL-7 binding proteins such as those described above, for example, variants with partial sequence changes due to chemical modification and / or insertion, deletion, or substitution of one or more amino acid residues, or those having 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more or 99% or more identity with any of the above sequences, may exhibit efficacy up to 10 times or 5 times that of DRSPAI-L7B in terms of binding to IL-7, as shown by EC50 or surface plasmon resonance analysis. DRSPAI-L7B is a human IgG1 that strongly inhibits IL-7-mediated signaling (Kd 67pM) by binding to interleukin 7 (IL-7). DRSPAI-L7B is a disulfide-linked α2β2 tetramer consisting of two light (κ) chains and two heavy (IgG1) chains. The heavy chain constant region contains two point mutations, L235A and G237A (LAGA), which reduce mAb binding to the Fcγ receptor and prevent Fc-mediated effector function, including CDC and ADCC. DRSPAI-L7B comprises a heavy chain having the amino acids shown in SEQ ID NO: 2 and a light chain having the amino acids shown in SEQ ID NO: 3.

[0103] In some embodiments, the IL-7 binding protein described herein comprises a heavy chain having at least 80%, 85%, 90%, or 95% sequence identity with the amino acids shown in SEQ ID NO: 19, 21, or 23. In some embodiments, the IL-7 binding protein described herein comprises a heavy chain having the amino acids shown in SEQ ID NO: 19, 21, or 23. In some embodiments, the IL-7 binding protein described herein comprises a light chain having at least 80%, 85%, 90%, or 95% sequence identity with the amino acids shown in SEQ ID NO: 18, 20, or 22. In some embodiments, the IL-7 binding protein described herein comprises a light chain having the amino acids shown in SEQ ID NO: 18, 20, or 22. In some embodiments, the IL-7 binding protein disclosed herein comprises a heavy chain having the amino acids shown in SEQ ID NO: 19 and a light chain having the amino acids shown in SEQ ID NO: 18. In some embodiments, the IL-7 binding protein disclosed herein comprises a heavy chain having the amino acids shown in SEQ ID NO: 21 and a light chain having the amino acids shown in SEQ ID NO: 20. In some embodiments, the IL-7 binding protein disclosed herein comprises a heavy chain having the amino acids shown in SEQ ID NO: 23 and a light chain having the amino acids shown in SEQ ID NO: 22.

[0104] In some embodiments, DRSPAI-L7B reduces the survival and activation of pathogenic T cells and memory T cells in the periphery, inhibits the establishment and maintenance of tertiary lymphoid organs (TLOs) through its role in the development of lymphoid tissue-inducing cells (Lti) and ILC3s, and does not affect the number or function of regulatory T cells. In some embodiments, DRSPAI-L7B functions peripherally and reduces T cell transport to TLOs and the brain, thus not requiring penetration into the CNS. With respect to MS, in some embodiments, DRSPAI-L7B reduces inflammation and mitigates chronic autoimmunity, resulting in reduced relapse rates and delayed progression in both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS).

[0105] The term "epitope," as used herein, refers to a portion of an antigen that contacts a specific binding domain of an antigen-binding protein, and is also called a paratope. Epitopes may be linear or conformal / discontinuous. Conformal or discontinuous epitopes consist of amino acid residues separated by other sequences, i.e., amino acid residues that are not in a continuous sequence in the primary sequence of the antigen assembled by the three-dimensional folding of the polypeptide chain. The residues may come from different regions of the polypeptide chain but are in close proximity in the three-dimensional structure of the antigen. In the case of multimeric antigens, conformal or discontinuous epitopes may consist of residues from different peptide chains. The specific residues contained in an epitope can be determined by the three-dimensional structure obtained by computer modeling programs or by methods known in the art, such as X-ray crystallography. Epitope mapping can be performed using various techniques known to those skilled in the art, as described in publications such as Methods in Molecular Biology 'Epitope Mapping Protocols', Mike Schutkowski and Ulrich Reineke (volume 524, 2009) and Johan Rockberg and Johan Nilvebrant (volume 1785, 2018). Exemplary methods include peptide-based approaches such as pepscan, in which a series of overlapping peptides are screened for binding using techniques such as ELISA or in vitro display of a large library of peptide or protein variants, for example, by phages. Detailed epitope information can be determined by structural techniques including X-ray crystallography, solution nuclear magnetic resonance (NMR) spectroscopy, and cryo-electron microscopy (cryo-EM). Mutagenesis, such as alanine scanning, is an effective approach that uses analysis of binding loss for epitope mapping. Alternatively, a combination of hydrogen / deuterium exchange (HDX), proteolysis, and liquid chromatography-mass spectrometry (LC-MS) can be used to characterize discontinuities or conformational epitopes.

[0106] In one embodiment, an IL-7-binding protein is provided that binds to human IL-7 via one or more amino acid residues in SEQ ID NO: 1. In another embodiment, an IL-7-binding protein is provided that binds to human IL-7 via one or more amino acid residues in SEQ ID NO: 12. In yet another embodiment, an IL-7-binding protein is provided that binds to human IL-7 via one or more amino acid residues in SEQ ID NO: 16.

[0107] In another embodiment, an IL-7-binding protein is provided that protects the residue shown in SEQ ID NO: 12 of IL-7 from deuterium exchange in HDX-MS analysis. In one embodiment, an IL-7-binding protein is provided that protects residues 67-81 (SEQ ID NO: 1) of IL-7 from deuterium exchange in HDX-MS analysis. In some embodiments, the IL-7-binding protein binds to a sequence having at least about 50%, 60%, 70%, 80%, 90%, or 95% identity with the amino acid sequence shown in SEQ ID NO: 12. In some embodiments, the IL-7-binding protein binds to a sequence having at least about 50%, 60%, 70%, 80%, 90%, or 95% identity with the amino acid sequence shown in SEQ ID NO: 16. In some embodiments, the IL-7-binding protein binds to IL-7 at a site adjacent to the IL-7Rα and γ chain interaction site on the folded IL-7 protein. In some embodiments, the IL-7 binding protein exhibits binding specificity to IL-7 in an epitope comprising at least five consecutive amino acids from the sequence shown in SEQ ID NO: 12. In some embodiments, the IL-7 binding protein exhibits binding specificity to IL-7 in an epitope comprising at least five consecutive amino acids from the sequence shown in SEQ ID NO: 16. In some embodiments, the IL-7 binding protein exhibits binding specificity to IL-7 in an epitope comprising at least ten consecutive amino acids from the sequence shown in SEQ ID NO: 12. In some embodiments, the IL-7 binding protein exhibits binding specificity to IL-7 in an epitope comprising at least ten consecutive amino acids from the sequence shown in SEQ ID NO: 16.

[0108] In some embodiments, the affinity of an IL-7 binding protein for an antigen can be determined by a competitive binding assay. In some embodiments, the competitive binding assay is an immunoassay. In some embodiments, the competitive binding assay is, for example, an ELISA or a radioimmunoassay.

[0109] In some embodiments, the reduction or inhibition of biological activity may be partial or complete. The neutralizing IL-7 binding proteins disclosed herein neutralize the activity of IL-7 by at least 20%, 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% compared to the activity of IL-7 in the absence of the IL-7 binding protein. Neutralization can be determined or measured using one or more assays known to those skilled in the art or as described herein.

[0110] In some embodiments, the IL-7 binding proteins disclosed herein target membrane-bound IL-7 receptor α (CD127), which forms a heterodimeric receptor with the common γ chain (CD132) upon IL-7 binding. In some embodiments, the IL-7 binding proteins disclosed herein target soluble IL-7 receptor α (sCD127).

[0111] Competition between the IL-7 binding protein of the present invention and a reference IL-7 binding protein, such as a reference antibody or IL-7 receptor, can be determined by one or more techniques known to those skilled in the art, such as ELISA, FMAT, surface plasmon resonance (SPR), or ForteBio Octet biolayer interference (BLI). Such techniques are sometimes called epitope binning. There are several potential reasons for this competition; the two proteins may bind to the same or overlapping epitopes, steric inhibition of binding may be present, or the binding of the first protein to the antigen may cause a conformational change that prevents or reduces the binding of the second protein.

[0112] The reduction or inhibition of biological activity may be partial or complete. The neutralizing antigen-binding protein may neutralize the activity of the <target> by at least 20%, 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% compared to the activity of the <target> in the absence of the antigen-binding protein.

[0113] Neutralization can be determined or measured using one or more assays known to those skilled in the art or described herein.

[0114] Identity Percentage The "identity percentage" between the query nucleic acid sequence and the target nucleic acid sequence is a percentage-based "identity" value calculated over the entire length of the query sequence using a preferred algorithm or software such as BLASTN, FASTA, DNASTAR Lasergene, GeneDoc, Bioedit, EMBOSS needle, or EMBOSS infoalign, after pairwise global sequence alignment has been performed using a preferred algorithm or software such as BLASTN, FASTA, ClustalW, MUSCLE, MAFFT, EMBOSS Needle, T-Coffee, and DNASTAR Lasergene. Importantly, the query nucleic acid sequence may be described by a nucleic acid sequence specified in one or more claims of this specification.

[0115] The "identity percentage" between the query amino acid sequence and the target amino acid sequence is a percentage-based "identity" value calculated over the entire length of the query sequence using a preferred algorithm or software such as BLASTP, FASTA, DNASTAR Lasergene, GeneDoc, Bioedit, EMBOSS needle, or EMBOSS infoalign, after pairwise global sequence alignment using a preferred algorithm or software such as BLASTP, FASTA, ClustalW, MUSCLE, MAFFT, EMBOSS Needle, T-Coffee, and DNASTAR Lasergene. Importantly, the query nucleic acid sequence may be described by an amino acid sequence specified in one or more claims of this specification.

[0116] The query sequence may be 100% identical to the target sequence, or it may contain changes of up to a certain integer number of amino acids or nucleotides compared to the target sequence such that the identity percentage is less than 100%. For example, the query sequence may be at least 50, 60, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% identical to the target sequence. Such changes may include at least one amino acid deletion, substitution (including conserved and non-conserved substitutions) or insertion, and the changes may occur at the amino-terminal or carboxy-terminal position of the query sequence, or at any location individually scattered between those terminal positions, between amino acids or nucleotides in the query sequence, or at any location scattered in one or more consecutive groups in the query sequence.

[0117] The identity percentage may be determined over the entire length of the query sequence, including the CDR. Alternatively, the identity percentage may exclude one or more or all of the CDRs, for example, all of which are 100% identical to the target sequence, and the variation in identity percentage exists in the rest of the query sequence, e.g., the framework sequence, and therefore the CDR sequences are fixed and intact. In some embodiments, the variant sequence substantially retains the biological characteristics of an unmodified protein such as DRSPAI-L7B.

[0118] qualification Those skilled in the art will understand that post-translational modifications can occur during the production of IL-7-binding proteins, such as antibodies, in host cells. These may include, for example, cleavage of specific leader sequences, addition of various sugar moieties in various glycosylation patterns, non-enzymatic glycation, deamidation, oxidation, disulfide bond scrambling and other cysteine ​​variants (e.g., free sulfhydryl, racemized disulfide, thioether and trisulfide bonds), isomerization, C-terminal resync-clipping, and N-terminal glutamine cyclization. This disclosure encompasses the use of IL-7-binding proteins that have undergone or are subject to one or more post-translational modifications. Thus, each "IL-7-binding protein" or "antibody" of the present invention includes the above-defined "IL-7-binding protein" or "antibody" that has undergone post-translational modifications as described herein.

[0119] Glycation is a post-translational, non-enzymatic chemical reaction between reducing sugars such as glucose and free amine groups in proteins, and is commonly found at the ε-amine of lysine side chains or at the N-terminus of proteins. Glycation can only occur in the presence of reducing sugars during production and storage.

[0120] Deamidation is an enzymatic reaction that can occur during production and storage, primarily converting asparagine (N) to isoaspartate and aspartate (D) in an approximately 3:1 ratio. Therefore, this deamidation reaction relates to the isomerization of aspartate (D) to isoaspartate. Both asparagine deamidation and aspartate isomerization involve the intermediate succinimide. Deamidation can also occur at glutamine residues, albeit to a much lesser degree. Deamidation can occur at CDR, Fab (non-CDR region), or Fc region.

[0121] Oxidation can occur during production and storage (i.e., in the presence of oxidative conditions), resulting in covalent modifications of proteins, induced directly by reactive oxygen species or indirectly by reactions with secondary byproducts of oxidative stress. Oxidation primarily occurs at methionine residues, but can also occur at tryptophan and free cysteine ​​residues. Oxidation can occur in CDR, Fab (non-CDR), or Fc regions.

[0122] Sulfide bond scrambling can occur during production and under basic storage conditions. Under certain circumstances, disulfide bonds may be broken or improperly formed, resulting in unpaired cysteine ​​residues (-SH). These free (unpaired) sulfhydryl (-SH) can promote shuffling.

[0123] Thioether formation and racemization of disulfide bonds can occur under basic conditions during production or storage. Disulfide bridges are converted back to cysteine ​​residues via β-elimination through dehydroalanine and persulfide intermediates. Subsequently, the bridge between dehydroalanine and cysteine ​​leads to the formation of thioether bonds. Alternatively, free cysteine ​​residues may reform disulfide bonds with a mixture of D-cysteine ​​and L-cysteine.

[0124] Trisulfides arise from the insertion of a sulfur atom into a disulfide bond (Cys-SSS-Cys) and are formed in the presence of hydrogen sulfide in the cell culture.

[0125] N-terminal glutamine (Q) and glutamate (glutamic acid) (E) in the heavy and / or light chains can form pyroglutamates (pGlu) through cyclization. Most pGlu formation occurs in the production bioreactor, but it can also occur non-enzymatically depending on the pH and temperature of processing and storage conditions. Cyclization of N-terminal Q or E is commonly observed in naturally occurring human antibodies.

[0126] C-terminal lysine clipping is an enzymatic reaction catalyzed by carboxypeptidases and is commonly observed in recombinant and native human antibodies. Variants of this process include the removal of lysine from one or both heavy chains by cellular enzymes from recombinant host cells. Removal of remaining C-terminal lysine may occur upon administration to human subjects / patients.

[0127] The terms "peptide," "polypeptide," and "protein" refer to molecules comprising two or more amino acid residues, respectively. Peptides can be monomers or polymers.

[0128] In some embodiments, it may be desirable to modify the effector function of the IL-7 binding protein, for example, by increasing the ADCC or CDC, or the half-life. The IL-7 binding protein may have a half-life of at least 6 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 7 days, or at least 9 days in human or mouse animal models in vivo.

[0129] Mutations in the Fc effector portion of an antibody can be used to modulate antibody turnover by altering the affinity of the FcRn-antibody interaction. This can extend the antibody's half-life in vivo. Maximum dose and maximum administration frequency are determined in vivo. 50 This can be beneficial to the patient population as it can be achieved as a result of maintaining the effect for a longer period. Since killing cells expressing CD127 is undesirable, the Fc effector function of the antibody may be removed entirely or partially. This removal may result in an improved safety profile.

[0130] In some embodiments, IL-7 binding proteins comprising a constant domain may exhibit reduced ADCC and / or complement activation, or reduced effector function. The constant domain may comprise a naturally impaired constant domain of an IgG2 or IgG4 isotype or a mutated IgG1 constant domain. In some embodiments, the IL-7 binding proteins of the present invention may be Fc-impaired. Examples of preferred modifications are described in EP0307434. One method for achieving Fc impairment comprises alanine residue substitutions at positions 235 and 237 (EU index numbering) of the heavy chain constant domain, i.e., L235A and G237A (commonly referred to as "LAGA" mutations). Another example comprises alanine substitutions at positions 234 and 235 (EU index numbering), i.e., L234A and L235A (commonly referred to as "LALA" mutations). In some embodiments, the Fc effector function of the IL-7 binding proteins disclosed herein is impaired using LAGA mutations. Alternatively, the IL-7 binding protein may be Fc-undamaged and may not contain alanine substitutions at positions 235 and 237.

[0131] Additional modifications and mutations that reduce effector function include (with respect to IgG1 unless otherwise noted) glycosylated N297A or N297Q or N297G;L235E;IgG4:F234A / L235A; and chimeric IgG2 / IgG4. IgG2:H268Q / V309L / A330S / P331S, and IgG2:V234A / G237A / P238S / H268A / V309L / A330S / P331S may reduce FcγR and C1q binding ((Wang et al. 2018 and US8,961,967).

[0132] Other mutations that reduce effector function include: L234F / L235E / P331S; chimeric antibodies created using the CH1 and hinge regions from human IgG2 and the CH2 and CH3 regions from human IgG4; IgG2m4 based on an IgG2 isotype with four key amino acid residue changes (H268Q, V309L, A330S, and P331S) derived from IgG4; IgG2σ containing V234A / G237A / P238S / H268A / V309L / A330S / P331S substitutions to eliminate affinity for the Fcγ receptor and C1q complement protein; IgG2m4 (H268Q / V309L / A330S / P331S, changed to IgG4); IgG4 (S228P / L234A / L235A); huIgG1 L234A / L235A(AA); huIgG4 This includes S228P / L234A / L235A;IgG1σ(L234A / L235A / G237A / P238S / H268A / A330S / P331S);IgG4σ1(S228P / F234A / L235A / G237A / P238S); and IgG4σ2(S228P / F234A / L235A / G236 / G237A / P238S, with spaces indicating deletions) (Tam et al., Antibodies 2017, 6(3)).

[0133] In some embodiments, the IL-7 binding protein disclosed herein may comprise one or more modifications selected from constant domains that have been mutated such that the antibody exhibits enhanced effector function / ADCC and / or complement activation. Examples of suitable modifications are described in Shields et al. J. Biol. Chem (2001) 276:6591-6604, Lazar et al. PNAS (2006) 103:4005-4010 as well as US6737056, WO2004063351 and WO2004029207. The IL-7 binding protein may comprise a constant domain having a glycosylation profile that has been altered such that the IL-7 binding protein exhibits enhanced effector function / ADCC and / or complement activation. Examples of suitable methods for making IL-7 binding proteins with an altered glycosylation profile are described in WO2003 / 011878, WO2006 / 014679 and EP1229125.

[0134] Hosts and vectors The IL-7 binding protein may be made by any of several conventional techniques. For example, the IL-7 binding protein may be purified from cells that naturally express them (e.g., an antibody can be purified from the hybridoma that produces it), or it may be produced in a recombinant expression system.

[0135] Several different expression systems and purification methods can be used to generate the IL-7 binding protein of the present invention. Generally, a host cell is transformed with a recombinant expression vector encoding the desired antigen-binding protein. The expression vector may, depending on the expression system, be maintained by the host as a separate genetic element or may be integrated into the host's chromosome.

[0136] In some embodiments, an expression vector comprising a nucleic acid molecule is described herein. Also provided are recombinant host cells comprising the expression vectors described herein. The IL-7 binding proteins described herein can be produced in suitable host cells. A wide range of host cells can be used, for example, prokaryotes (e.g., Gram-negative or Gram-positive bacteria, e.g., Escherichia coli, Bacillus species, Pseudomonas species, Corynebacterium species) and eukaryotes (e.g., yeast (e.g., Saccharomyces cerevisiae, Pichia pastoris), fungi (e.g., Aspergillus species) or higher eukaryotes (e.g., insect cells and cell lines of mammalian origin). Examples of cell lines include Chinese hamster ovary (CHO) cells, PER.C6, HEK293, HeLa or NSO. In some embodiments, the host cells described herein are CHO cells, NSO myeloma cells, COS cells or SP2 cells. The host cell may be a non-human host cell. The host cell may be a non-embryonic host cell. Human cells can also be used, thus allowing modification of the human glycosylation pattern. Alternatively, other eukaryotic cell lines can also be used. In some embodiments, the selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and production and purification of the product are known in the art. In some embodiments, the host cell is a yeast strain. The host cell can be cultured in a culture medium, e.g., a serum-free culture medium. The IL-7 binding protein can be secreted by the host cell into the culture medium. The IL-7 binding protein can be purified to at least 95% or more (e.g., 98% or more) with respect to the culture medium containing the IL-7 binding protein.

[0137] The host cell can be an isolated host cell. The host cell is usually not part of a multicellular organism (e.g., a plant or an animal). The host cell can be a non-human host cell.

[0138] Suitable cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian host cells are known in the art.

[0139] A method for producing IL-7 binding protein as described herein may comprise the steps of culturing host cells and recovering the IL-7 binding protein. In one embodiment of the present invention, a method for producing IL-7 binding protein is provided, comprising the steps of maintaining host cells in a culture medium to produce IL-7 binding protein, and isolating or purifying the IL-7 binding protein produced by the host cells.

[0140] A transformed, transfected, or transduced recombinant host cell may comprise at least one expression cassette, the expression cassette comprising a polynucleotide encoding the heavy chain of the IL-7 binding protein described herein, and further comprising a polynucleotide encoding the light chain of the IL-7 binding protein described herein. Alternatively, a transformed, transfected, or transduced recombinant host cell may comprise at least one expression cassette, the first expression cassette comprising a polynucleotide encoding the heavy chain of the IL-7 binding protein described herein, and the second cassette comprising a polynucleotide encoding the light chain of the IL-7 binding protein described herein. A stably transformed host cell may comprise a vector comprising one or more expression cassettes encoding the heavy chain and / or light chain or fragments thereof of the IL-7 binding protein described herein. For example, such a host cell may comprise a first vector encoding the light chain and a second vector encoding the heavy chain.

[0141] These cells can be cultured under conditions that promote the expression of antigen-binding proteins using various apparatus such as shaking flasks, spinner flasks, and bioreactors. Polypeptides are recovered by conventional protein purification procedures. Protein purification procedures generally consist of a series of unit operations comprising various filtration and chromatographic steps developed to selectively concentrate and isolate antigen-binding proteins. The purified antigen-binding proteins can be formulated as pharmaceutically acceptable compositions.

[0142] Usage description In one embodiment, the IL-7 binding protein described herein is used in therapy. The IL-7 binding protein described herein can be used in the treatment of diseases or conditions for which IL-7 inhibitors are indicated, such as inflammatory diseases or autoimmune diseases. In some embodiments, IL-7 inhibition by the IL-7 binding protein described herein affects the survival, expansion, and function of autoreactive effector T cells while preserving regulatory T lymphocytes. In some embodiments, IL-7 inhibition by the IL-7 binding protein described herein inhibits the formation of ectopic lymphoid tissue. In some embodiments, IL-7 inhibition by the IL-7 binding protein described herein may help restore homeostasis by inhibiting the survival of innate lymphoid cells (ILCs).

[0143] In some embodiments, the IL-7 binding proteins disclosed herein can antagonize the biological effects of IL-7, and IL-7R-mediated T H 17 Expansion and T via IL-7R H It can antagonize at least one of the 17 survivals. The terms inhibit, antagonize, and neutralize are used synonymously herein. No term is intended to indicate the need for total neutralization, and partial neutralization (corresponding to reduction rather than complete elimination of the biological effect) is also intended.

[0144] At the molecular level, T HThe expansion and / or survival of 17 CD4+ T cell populations (or T H This can be observed by increased IL-17 production by the CD4+ T cell population. Therefore, in some embodiments, the IL-7 binding proteins disclosed herein reduce IL-17 production by the CD4+ T cell population. H 17 Expansion and survival also affect the CD4+ T cell population (or T H This can also be observed by increased IFN-γ production by the cell population (17). Therefore, in some embodiments, the IL-7 binding proteins disclosed herein antagonize (reduce) IFN-γ production by the CD4+ T cell population. At the molecular level, the IL-7 binding proteins disclosed herein may inhibit STAT-5 phosphorylation via the IL-7 receptor.

[0145] In some embodiments, at the molecular level, the blocking effect of the IL-7-binding proteins described herein can be observed and measured by assays such as those involving IL-7-induced P-STAT5 or Bcl-2. In some embodiments, at the cellular level, the blocking effect of IL-17 or IFNγ can be observed and measured by assays such as those involving IL-7. H The blockade of the effect can be observed and measured by assays such as secretion by 17. An exemplary assay is described in PCT application number PCT / US2009 / 053136 (WO2010 / 017468). In the exemplary pSTAT-5 assay, PBMCs can be stimulated with IL-7 in the presence and absence of the test drug. Then, the cells are stained for pSTAT-5 (for example, using a labeled anti-pSTAT-5 antibody, e.g., ALEXA FLUOR 647 mouse anti-Stat5 (pY694, BD[#612599])), and the pSTAT-5 levels are quantitatively evaluated by fluorescence-activated cell sorting. The level of phosphorylated STAT-5 can also be measured by ELISA. Drugs that reduce phosphorylated STAT-5 levels may be potential therapeutic candidates for autoimmune diseases.

[0146] In some embodiments, the Disclosure provides a method for treating an autoimmune disease in a human subject, comprising the step of administering to the subject an amount of IL-7 binding protein sufficient to reduce STAT-5 phosphorylation via IL-7R. In some embodiments, the IL-7 binding protein disclosed herein blocks or inhibits STAT-5 phosphorylation via IL-7 immediately downstream of IL-7R. In some embodiments, the IL-7 binding protein disclosed herein is activated T H This study downregulates the surface expression of activation markers and chemokine receptors that contribute to lymphocyte transport to the CNS in single cells.

[0147] Antagonists, such as antigen-binding proteins of this disclosure, can reduce the level of phosphorylated STAT-5 by at least 20%, 50%, 75%, 80%, 85%, 90%, 95%, or 100% compared to STAT-5 levels in the absence of the antagonist, or compared to negative controls or untreated cells. The antagonists can reduce IC50 μg / mL, ≤25 μg / mL, ≤10 μg / mL, ≤5 μg / mL, or ≤2 μg / mL. 50 It may have an IC of 1 μg / mL or less, 0.75 μg / mL or less, 0.5 μg / mL or less, 0.25 μg / mL or less, or 0.1 μg / mL or less. 50 It has. In one embodiment, the antagonist is IC50 ng / mL or less, 40 ng / mL or less, 30 ng / mL or less, 20 ng / mL or less, or 10 ng / mL or less. 50 It has. In one embodiment, the antagonist is 5 ng / mL IC 50 It holds.

[0148] Antagonists disclosed herein are T H 17. It may be particularly effective in inhibiting cell expansion. H The expansion of 17 cells is T H17 This can be determined by an expansion assay, which may involve stimulating a naive T cell population to expand in the presence and absence of the test drug, then stimulating these cells to produce IL-17, and evaluating the level of IL-17 produced by these cells in the presence and absence of the test drug. In an exemplary assay, human CD4+ T cells are stimulated by activation of the T cell receptor in the presence of IL-1, IL-6, and IL-23. H It can be differentiated into 17 cells. After differentiation on the 5th day, T H 17. CCR6+ cells can be selectively removed to create an enriched population. Next, this population can be stimulated with human IL-7, and the increase in IL-17 and IFN-γ in the supernatant can be determined. The presence of an antagonist to this interaction during the incubation period is T H Since this should inhibit the expansion of IL-17 cells and lead to a decrease in the production of IL-17 and IFN-γ, the ability of test agents such as the antigen-binding fragments of this disclosure to inhibit IL-7-mediated induction of IL-7R can be determined.

[0149] IL-7 binding proteins enable more than 20% inhibition of IL-17 secretion compared to negative controls in such assays. More generally, IL-7 binding proteins enable 50%, 75%, 85%, or 90% or greater inhibition of IL-17 secretion compared to controls. In some embodiments, IL-7 binding proteins have an IC50 μg / mL or less in this assay. 50 This may indicate that IC 50 The concentration may be 20 μg / mL, 10 μg / mL, or 5 μg / mL or less. In another embodiment, the present disclosure is a method for treating an autoimmune disease or inflammatory disorder, wherein the patient is given the IL-7 binding protein disclosed herein, and the patient's T H The present invention provides a method comprising the step of administering a dose sufficient to reduce the number of cells.

[0150] In some embodiments, the IL-7 binding proteins disclosed herein are intended for the treatment of a subject. The terms “individual,” “subject,” and “patient” are used interchangeably herein. The subject is generally human. The subject may also be a mammal such as a mouse, rat, or primate (e.g., marmoset or monkey). The subject may also be a non-human animal. The IL-7 binding protein may also have veterinary uses. The subject of treatment may be an agricultural animal, such as a cow or bull, sheep, pig, steer, goat, or horse, or a domestic animal such as a dog or cat. The animal may be of any age or may be a mature animal. In some embodiments, the treatment may be therapeutic, preventive, or avoidant. The subject may be one who requires it. Those requiring treatment may include individuals already suffering from a medical disease, as well as those who may develop the disease in the future.

[0151] Therefore, the IL-7 binding proteins described herein can be used for prophylactic or preventative measures. In this case, the IL-7 binding proteins described herein are administered to an individual to prevent or delay the onset of one or more embodiments or symptoms of the disease. The subject may be asymptomatic. The subject may have a genetic predisposition to the disease. In some embodiments, a prophylactically effective amount of IL-7 binding protein is administered to such an individual. In some embodiments, a prophylactically effective amount is an amount that prevents or delays the onset of one or more embodiments or symptoms of the disease described herein.

[0152] The IL-7 binding proteins described herein can also be used in therapy. The term “therapy” encompasses the alleviation, reduction, or avoidance of at least one aspect or symptom of a disease. For example, the IL-7 binding proteins described herein can be used to improve or reduce one or more aspects or symptoms of one or more aspects of the diseases described herein.

[0153] In some embodiments, the IL-7 binding proteins described herein are used in amounts effective for therapeutic, prophylactic, or preventative measures. In some embodiments, the therapeutically effective amount of the IL-7 binding proteins described herein is an amount effective to improve or alleviate one or more aspects or symptoms of a disease. In some embodiments, the IL-7 binding proteins described herein can also be used to treat, prevent, or cure the diseases described herein. In some embodiments, the IL-7 binding proteins described herein have generally beneficial effects on the health of the subject and can extend the expected lifespan of the subject.

[0154] The IL-7 binding proteins described herein do not need to affect complete cure or eradicate all symptoms or manifestations of the disease to constitute an effective therapeutic measure. As recognized in the relevant fields, a drug used as a therapeutic agent may reduce the severity of a given condition but does not need to eliminate all manifestations of the disease to be considered a useful therapeutic agent. Similarly, a therapeutic agent administered prophylactically does not need to be completely effective in preventing the onset of the disease to be an effective prophylactic agent. It is sufficient for the drug to simply reduce the effects of the disease (e.g., by reducing the number or severity of its symptoms, or by enhancing the effectiveness of another treatment, or by producing another beneficial effect), or to reduce the likelihood of the disease developing in a subject (e.g., by delaying the onset of the disease), or to reduce the likelihood of exacerbation.

[0155] In some embodiments, the IL-7 binding proteins described herein can be used in therapies to treat subjects having or suspected of having the diseases or conditions described herein. In some embodiments, the IL-7 binding proteins described herein are administered to subjects having or suspected of having the diseases or conditions described herein. In some embodiments, the IL-7 binding proteins described herein are used in multiple sclerosis (MS) and other autoimmune or inflammatory diseases, particularly pathogenic T11. HIt can be used in therapies involving cells. In some embodiments, the IL-7 binding proteins described herein can be used in the therapy of rheumatoid arthritis, psoriasis, Behçet's disease, diabetes (e.g., type 1 diabetes) and systemic lupus erythematosus (SLE).

[0156] Inhibition of IL-7-induced IL-7R-mediated signaling may be useful in treating inflammatory (non-autoimmune) diseases associated with elevated IL-17 or IL-2 levels, such as asthma. Therefore, inflammatory and / or autoimmune diseases that can be treated with the IL-7 binding proteins disclosed herein include: inflammatory skin diseases, e.g., psoriasis and atopic dermatitis; systemic sclerosis and inflammatory bowel disease (IBD); Crohn's disease; ulcerative colitis; ischemic-reperfusion injury, e.g., surgical tissue reperfusion injury; myocardial ischemia, e.g., myocardial infarction, cardiac arrest, postoperative reperfusion and postoperative systolemic coronary angioplasty; stroke and abdominal aortic aneurysm; stroke-related cerebral edema; cranial trauma, hypovolemic shock; asphyxiation; adult respiratory distress syndrome; acute lung injury; Behçet's disease; dermatomyositis; polymyositis; multiple sclerosis (MS); dermatitis; meningitis; encephalitis; uveitis; and osteoarthritis. Diseases include: lupus nephritis; autoimmune diseases, e.g., rheumatoid arthritis (RA), spondyloarthritis, Sjögren's syndrome, vasculitis; diseases with leukocytosis; inflammatory disorders of the central nervous system (CNS), septic-associated multiple organ injury syndrome or trauma-associated multiple organ injury syndrome; alcoholic hepatitis; bacterial pneumonia; antigen-antibody complex-mediated diseases, e.g., glomerulonephritis; sepsis; sarcoidosis; immunopathological responses to tissue / organ transplantation; inflammation of the lungs, e.g., pleurisy, alveolitis, vasculitis, pneumonia, chronic bronchitis, bronchiectasis, diffuse panbronchiolitis, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis (IPF), and cystic fibrosis; psoriatic arthritis; neuromyelitis optica, Guillain-Barré syndrome (GBS), COPD, and type 1 diabetes.

[0157] In particular, the IL-7 binding proteins disclosed herein may be useful in the treatment of all forms of multiple sclerosis, including neuromyelitis optica. In some embodiments, the IL-7 binding proteins disclosed herein are useful for the treatment of multiple sclerosis classified as clinically isolated syndrome (CIS); primary progressive (PPMS); relapsing-remitting (RRMS) and / or secondary progressive (SPMS). In some embodiments, treatment with the IL-7 binding proteins disclosed herein is predicted to be most effective when administered to an active inflammatory disease, i.e., when used in the treatment of clinically isolated syndrome or relapsing forms of MS. These disease stages can be defined clinically and / or by imaging diagnostic criteria such as gadolinium enhancement or other more sensitive techniques and / or by other yet-to-be-defined biomarkers of active disease. In particular, the IL-7 binding proteins disclosed herein can be used (by intravenous, subcutaneous, oral or intramuscular delivery) to treat RRMS when the subject is about to enter a relapse or has relapsed. In certain embodiments, the IL-7 binding proteins disclosed herein are administered to a subject at the time of occurrence of a relapse or within 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days or 10 days from the occurrence of the relapse.

[0158] In some embodiments, the autoimmune and / or inflammatory disease is selected from IBD, rheumatoid arthritis (RA), Sjögren's syndrome, Crohn's disease, diabetes (e.g., type I diabetes), systemic lupus erythematosus (SLE) and ulcerative colitis. In another embodiment, the autoimmune and / or inflammatory condition is rheumatoid arthritis (RA). In another embodiment, the autoimmune and / or inflammatory condition is Sjögren's syndrome. In another embodiment, the autoimmune and / or inflammatory condition is systemic lupus erythematosus (SLE). In another embodiment, the autoimmune and / or inflammatory condition is ulcerative colitis. In another embodiment, the autoimmune and / or inflammatory condition is diabetes, e.g., type I diabetes.

[0159] In this specification, in some embodiments, IL-7 binding proteins are provided for use in the treatment of diseases or conditions disclosed herein. In this specification, in some embodiments, IL-7 binding proteins are provided for use in the treatment of autoimmune diseases and / or inflammatory diseases. In this specification, in some embodiments, IL-7 binding proteins are provided for use in the treatment of multiple sclerosis (MS). In this specification, in some embodiments, IL-7 binding proteins are disclosed for use in the treatment of relapsing-remitting MS, secondary progressive MS and / or primary progressive MS. In this specification, in some embodiments, IL-7 binding proteins are provided for use in the treatment of rheumatoid arthritis (RA). In this specification, in some embodiments, IL-7 binding proteins are provided for use in the treatment of Sjögren's syndrome. In this specification, in some embodiments, IL-7 binding proteins are provided for use in the treatment of systemic lupus erythematosus (SLE). In this specification, in some embodiments, IL-7 binding proteins are provided for use in the treatment of ulcerative colitis. In this specification, in some embodiments, IL-7 binding proteins are provided for use in the treatment of diabetes, for example, type 1 diabetes.

[0160] In this specification, in some embodiments, the use of IL-7 binding proteins in the manufacture of pharmaceuticals for the treatment of diseases or conditions disclosed herein is provided. In this specification, in some embodiments, the use of IL-7 binding proteins in the manufacture of pharmaceuticals for the treatment of autoimmune diseases and / or inflammatory diseases is provided. In this specification, in some embodiments, the use of IL-7 binding proteins in the manufacture of pharmaceuticals for the treatment of multiple sclerosis is provided. In this specification, in some embodiments, the use of IL-7 binding proteins in the manufacture of pharmaceuticals for the treatment of rheumatoid arthritis (RA) is provided. In this specification, in some embodiments, the use of IL-7 binding proteins in the manufacture of pharmaceuticals for the treatment of Sjögren's syndrome is provided. In this specification, in some embodiments, the use of IL-7 binding proteins in the manufacture of pharmaceuticals for the treatment of systemic lupus erythematosus (SLE) is provided. In this specification, in some embodiments, the use of IL-7 binding proteins in the manufacture of pharmaceuticals for the treatment of ulcerative colitis is provided. In this specification, in some embodiments, the use of IL-7 binding proteins in the manufacture of pharmaceuticals for the treatment of diabetes, for example, type 1 diabetes.

[0161] Also provided are methods for treating autoimmune and / or inflammatory conditions in subjects requiring the treatment, comprising the step of administering to the subject a therapeutically effective amount of the IL-7 binding protein disclosed herein. In some embodiments, methods are provided for treating rheumatoid arthritis (RA) in subjects requiring the treatment, comprising the step of administering to the subject a therapeutically effective amount of the IL-7 binding protein disclosed herein. In some embodiments, methods are provided for treating Sjögren's syndrome in subjects requiring the treatment, comprising the step of administering to the subject a therapeutically effective amount of the IL-7 binding protein disclosed herein. In some embodiments, methods are provided for treating systemic lupus erythematosus (SLE) in subjects requiring the treatment, comprising the step of administering to the subject a therapeutically effective amount of the IL-7 binding protein disclosed herein. In some embodiments, methods are provided for treating ulcerative colitis in subjects requiring the treatment, comprising the step of administering to the subject a therapeutically effective amount of the IL-7 binding protein disclosed herein. In this specification, in some embodiments, a method is provided for treating multiple sclerosis in a subject in need thereof, comprising the step of administering to the subject a therapeutically effective amount of the IL-7 binding protein disclosed herein. In this specification, in some embodiments, a method is provided for treating diabetes, for example, type 1 diabetes, in a subject in need thereof, comprising the step of administering to the subject a therapeutically effective amount of the IL-7 binding protein disclosed herein.

[0162] In this specification, in some embodiments, a method is disclosed for treating multiple sclerosis in a patient, comprising the step of administering to the patient an IL-7 binding protein disclosed herein, wherein the patient has relapsing-remitting multiple sclerosis. In this specification, in some embodiments, a method is disclosed for treating an autoimmune disease or inflammatory disease in a human subject, comprising administering to the subject an IL-7 binding protein disclosed herein, H T against a single cell HA method is disclosed comprising the step of administering an amount effective in reducing the proportion of 17 cells. In some embodiments herein, a method for treating an autoimmune or inflammatory disease in a human subject is disclosed wherein the subject is given the IL-7 binding protein disclosed herein, (Foxp3+)T reg T cells H A method is disclosed that includes the step of administering a dose effective in reducing the cell ratio.

[0163] In some embodiments, treatment may include further monitoring of the disease or condition in question. Treatment may include a single treatment. Treatment may include repeated treatments. Treatment may include repeated treatments over the remainder of the subject's life. Treatment may include daily treatments. Treatment may include bi-weekly treatments. In some embodiments, treatment may be selected based on evaluation of the patient or a sample obtained from the patient.

[0164] Pharmaceutical composition / Route of administration / Dosage The IL-7 binding proteins described herein can be incorporated into pharmaceutical compositions for use in the treatment of human diseases described herein. In one embodiment, the pharmaceutical composition comprises the IL-7 binding protein in combination with one or more pharmaceutically acceptable carriers and / or excipients.

[0165] Such compositions comprise a pharmaceutically acceptable carrier as known and designated in accepted pharmaceutical practice. In one embodiment, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or excipient and an IL-7 binding protein exhibiting binding to IL-7 at an epitope comprising at least five consecutive amino acids from the sequence shown in SEQ ID NO: 12 or SEQ ID NO: 16.

[0166] The pharmaceutical compositions of this disclosure are available for use in therapeutic or prophylactic applications. In some embodiments, pharmaceutical compositions are provided comprising an IL-7 binding protein and a pharmaceutically acceptable carrier or excipient. In another embodiment, a pharmaceutical composition is provided comprising 1 to 500 mg of the IL-7 binding protein disclosed herein. In yet another embodiment, a pharmaceutical composition is provided comprising 20 to 300 mg of the IL-7 binding protein disclosed herein. In yet another embodiment, a pharmaceutical composition is provided comprising 50 to 200 mg of the IL-7 binding protein disclosed herein. Further embodiments of this specification provide a pharmaceutical composition comprising 50 to 200 mg of IL-7 binding protein, wherein the IL-7 binding protein is an antibody comprising the light chain amino acid sequence shown in SEQ ID NO: 3 and the heavy chain amino acid sequence shown in SEQ ID NO: 2. Further embodiments of this specification provide a pharmaceutical composition comprising 50 to 200 mg of IL-7 binding protein, wherein the IL-7 binding protein is an antibody comprising the light chain amino acid sequence shown in SEQ ID NO: 18 and the heavy chain amino acid sequence shown in SEQ ID NO: 19. In further embodiments of this specification, a pharmaceutical composition is provided comprising 50 to 200 mg of IL-7 binding protein, wherein the IL-7 binding protein comprises an antibody comprising the light chain amino acid sequence shown in SEQ ID NO: 20 and the heavy chain amino acid sequence shown in SEQ ID NO: 21. In further embodiments of this specification, a pharmaceutical composition is provided comprising 50 to 200 mg of IL-7 binding protein, wherein the IL-7 binding protein comprises an antibody comprising the light chain amino acid sequence shown in SEQ ID NO: 22 and the heavy chain amino acid sequence shown in SEQ ID NO: 23.In some embodiments, the pharmaceutical compositions described herein are 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, 70 mg, 71 mg It contains 72 mg, 73 mg, 74 mg, 75 mg, 76 mg, 77 mg, 78 mg, 79 mg, 80 mg, 81 mg, 82 mg, 83 mg, 84 mg, 85 mg, 86 mg, 87 mg, 88 mg, 89 mg, 90 mg, 91 mg, 92 mg, 93 mg, 94 mg, 95 mg, 96 mg, 97 mg, 98 mg, 99 mg, 100 mg, 101 mg, 102 mg, 103 mg, 104 mg, 105 mg, 106 mg, 107 mg, 108 mg, 109 mg, or 110 mg of the IL-7 binding protein disclosed herein.

[0167] In some embodiments, the therapeutic agent (IL-7 binding protein) of this disclosure is present in unit dose form in a pharmaceutical preparation. In some embodiments, the administration plan is determined by a healthcare professional and / or clinical factors. As is well known in medical technology, the dose for any one patient depends on many factors, including the patient's size, body surface area, age, the compound administered, sex, time and route of administration, health status, and other drugs administered concurrently. Exemplary doses may vary depending on the size and health status of the individual being treated, as well as the condition being treated. For example, in some embodiments, the disclosed antibody or functional fragment may be administered in doses of 1 to 100 mg / kg. In some embodiments, the disclosed IL-7 binding protein may be administered in doses of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mg / kg. In some embodiments, the pharmaceutical compositions disclosed herein may be administered in volumes exceeding approximately 5 mL, 10 mL, 15 mL, 20 mL, 25 mL, 30 mL, 35 mL, 40 mL, 45 mL, 50 mL, 60 mL, 70 mL, 80 mL, 90 mL, 100 mL, 110 mL, 120 mL, 130 mL, 140 mL, 150 mL, 200 mL, 300 mL, 400 mL, or 500 mL. In some embodiments, the pharmaceutical compositions disclosed herein are administered multiple times in these doses. In some embodiments, the dose is administered as a single dose or multiple times, for example, daily, weekly, bi-weekly, or monthly, hourly, or at the time of relapse, recurrence, or progression of the disease or condition being treated. In some embodiments, the dose may be administered by a slow, continuous infusion over a period of about 2 to about 24 hours, for example, about 2 to about 12 hours, or about 2 to about 6 hours.

[0168] In some embodiments, the pharmaceutical composition comprises a composition for parenteral, transdermal, intraluminal, intra-arterial, subarachnoid and / or intranasal administration, or a composition for direct injection into tissue. In some embodiments, the pharmaceutical composition is administered to the patient by infusion or injection. In one embodiment, a pharmaceutical composition comprising an IL-7 binding protein for intravenous administration is provided. In some embodiments, a pharmaceutical composition comprising an IL-7 binding protein for subcutaneous administration is provided. In some embodiments, the pharmaceutical compositions described herein are administered to a subject intra-arterial, subcutaneous, intradermal, intratumoral, intralymph node, intramedullary, intramuscular, intravenous (iv) injection, intravenous (iv) infusion, or intraperitoneal. In some embodiments, the IL-7 binding protein or its pharmaceutical composition is administered to a subject by intradermal or subcutaneous injection.

[0169] In some embodiments, the pharmaceutical composition is prepared by a method known to itself for the preparation of a pharmaceutically acceptable composition to be administered to a subject, and thus an effective amount of IL-7 binding protein is mixed with a pharmaceutically acceptable carrier. Suitable carriers are, for example, Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, 20 th This is described in (ed., Mack Publishing Company, Easton, Pa., USA, 2000). Based on this, compositions may include, but not exclusively, a solution of a substance associated with one or more pharmaceutically acceptable carriers or diluents, having an appropriate pH and contained in a buffer solution isotonic with physiological fluids. In some embodiments, the pharmaceutical compositions disclosed herein are acidic. In some embodiments, the pharmaceutical compositions disclosed herein are basic. In some embodiments, the pharmaceutical compositions may have about 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, or about 14.

[0170] In some embodiments, suitable pharmaceutically acceptable carriers include compositions that are essentially chemically inert and non-toxic and do not interfere with the efficacy of the bioactivity of the pharmaceutical composition. Examples of suitable pharmaceutical carriers, but not limited to, include water, physiological saline, glycerol solution, N-(1(2,3-dioleyloxy)propyl)N,N,N-trimethylammonium chloride (DOTMA), diolesylphosphotidyl-ethanolamine (DOPE), and liposomes. In some embodiments, such compositions contain a therapeutically effective amount of the IL-7 binding protein disclosed herein, together with a suitable amount of carrier to provide a form for direct administration to a subject.

[0171] Examples of pharmaceutical compositions include, but are not limited to, lyophilized powders or aqueous or non-aqueous sterile injection solutions or suspensions (which may further contain antioxidants, buffers, bacteriostatic agents, and solutes that substantially adapt to the tissues or blood of the recipient to whom the composition is intended). Other components that may be present in such compositions include, for example, water, surfactants (e.g., Tween), alcohols, preservatives, polyols, glycerin, and vegetable oils. Immediately formulated injection solutions and suspensions can be prepared from sterile powders, granules, tablets, or concentrated solutions or suspensions.

[0172] The pharmaceutical compositions disclosed herein may be formulated in various forms and administered by several different means. Pharmaceutical formulations may optionally contain conventionally acceptable carriers, adjuvants, and vehicles and may be administered orally, rectally, or parenterally. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, or intrasternal injection and infusion techniques. Administration includes injection or infusion (including intra-arterial, intracardiac, ventricular, intradermal, intraduodenal, intramedullary, intramuscular, intraosseous, intraperitoneal, subarachnoid, intravascular, intravenous, intravitreous, epidural, and subcutaneous), inhalation, transdermal, transmucosal, sublingual, oral, and topical administration (skin, dermal, enema, eye drops, ear drops, intranasal, and vaginal administration). In some exemplary embodiments, the route of administration is via injection, such as intramuscular, intravenous, subcutaneous, or intraperitoneal injection.

[0173] Liquid formulations include oral formulations, intravenous formulations, nasal formulations, ophthalmic formulations, optic nerve formulations, and aerosols. In certain embodiments, various combinations of formulations are administered. In certain embodiments, the composition is formulated for a sustained-release profile.

[0174] The pharmaceutical compositions of this disclosure may be administered in combination with other therapeutic agents or treatments. In some embodiments, the treatment for a subject may be surgery, nutritional therapy, physical activity, immunotherapy, pharmaceutical compositions, cell transplantation, blood fusion, or any combination thereof.

[0175] In some embodiments, the compositions / formulations disclosed herein are stable. In some embodiments, a “stable” formulation is one in which the IL-7 binding protein within it inherently retains physical and / or chemical stability and / or biological activity during storage. Various analytical techniques for measuring protein stability are available in the Art and are reviewed, for example, in Peptide and Protein Drug Delivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, NY, Pubs (1991) and Jones, A. Adv. Drug Delivery Rev. 10: 29-90 (1993). Stability can be measured at a selected temperature and for a selected period of time. In some embodiments, the formulation is stable for at least one month at ambient temperature or 40°C and / or stable for at least one to two years at 2–8°C. In some embodiments, the formulation is stable after freezing (e.g., -70°C) and thawing. In some embodiments, a protein “retains physical stability” in a formulation if it shows little change in aggregation, precipitation, and / or denaturation, as observed by visual inspection of color and / or clarity, or as measured by UV light scattering (measuring visible aggregates) or size exclusion chromatography (SEC). SEC measures soluble aggregates, which are not necessarily precursors to visible aggregates. In some embodiments, a protein “retains chemical stability” in a formulation if its chemical stability at a given time is considered to be such that the protein retains its biological activity. A chemically degraded species may be biologically active but chemically unstable. Chemical stability can be assessed by detecting and quantifying chemically altered forms of the protein. Chemical alterations may include size modifications (e.g., clipping), which can be assessed using, for example, SEC, SDS-PAGE, and / or matrix-assisted laser desorption / ionization / time-of-flight mass spectrometry (MALDI / TOF MS).Other types of chemical changes include charge changes (for example, those resulting from deamidation), which can be evaluated, for example, by ion exchange chromatography.

[0176] In some embodiments, the IL-7 binding protein described herein is a dimer at concentrations of at least about 2, 3, 4, and 5 mg / mL in acetate buffer, and a monomer at concentrations less than about 5, 4, 3, 2, and 1 mg / mL. In some embodiments, the IL-7 binding protein described herein is a dimer at a concentration of about 5 mg / mL in acetate buffer, and a monomer at a concentration of about 1 mg / mL. In some embodiments, the IL-7 binding protein is a reversible dimer. In some embodiments, the IL-7 binding protein is a dimer. In some embodiments, the IL-7 binding protein is a monomer.

[0177] In some embodiments, if the biological activity of the IL-7 binding protein at a given time is within approximately 10% (within the assay's error range) of the biological activity shown at the time the pharmaceutical formulation was prepared, as determined, for example by an antigen-binding assay, then the IL-7 binding protein "retains its biological activity" in the pharmaceutical formulation.

[0178] In some embodiments, the buffers disclosed herein refer to buffer solutions that resist pH changes due to the action of acid-based conjugate components. In some embodiments, the buffers may be phosphate buffers, citrate buffers, and other organic acid buffers. In some embodiments, the buffers are selected from the group consisting of sodium acetate buffer, sodium carbonate buffer, citrate buffer, glycylglycine buffer, histidine buffer, glycine buffer, lysine buffer, arginine buffer, sodium dihydrogen phosphate buffer, disodium hydrogen phosphate buffer, sodium phosphate buffer, sodium citrate buffer, sodium borate buffer, tris(hydroxymethyl)-aminomethane buffer, bicine buffer, tricine buffer, malate buffer, succinate buffer, maleate buffer, fumarate buffer, tartaric acid buffer, aspartate buffer, or mixtures thereof. The compositions disclosed herein may comprise antioxidants, including ascorbic acid and / or methionine. In some embodiments, the compositions disclosed herein may comprise preservatives. In some embodiments, the preservative is a compound that essentially reduces microorganisms, including bacterial activity, and therefore can be included in a formulation, for example, to help prepare a multi-use formulation.Examples of possible preservatives include octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl, or benzyl alcohol; alkylparabens, e.g., methylparaben or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol; low molecular weight (less than approximately 10 residues) polypeptides; proteins, e.g., serum albumin, gelatin, or immunoglobulin; hydrophilic polymers, e.g., polyvinylpyrrolidone Examples include: amino acids, such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, such as glucose, mannose, or dextrin; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants, such as TWEEN®, Pluronic S®, or polyethylene glycol (PEG).

[0179] In some embodiments, the compositions disclosed herein may further comprise chemotherapeutic agents, cytotoxic agents, cytokines, growth inhibitors, antihormone agents, and / or cardioprotective agents. Such molecules are preferably present in combination in amounts effective for the intended purpose.

[0180] In some embodiments, the IL-7 binding proteins disclosed herein can be encapsulated, for example, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) or macroemulsions, or in microcapsules prepared by coacervation techniques or interfacial polymerization, such as hydroxymethylcellulose microcapsules, gelatin microcapsules, and poly(methyl metasylate) microcapsules. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. Ed. (1980).

[0181] In some embodiments, the IL-7 binding proteins disclosed herein are prepared in sustained-release formulations. Preferred examples of sustained-release formulations include semipermeable matrices of solid hydrophobic polymers containing antibodies, these matrices in the form of molded articles, e.g., films or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl methacrylate) or poly(vinyl alcohol)), polylactides, copolymers of L-glutamic acid and γ-ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers, e.g., LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate) and poly-D-(-)-3-hydroxybutyrate.

[0182] In this specification, in some embodiments, pharmaceutical compositions comprising IL-7 binding protein present at concentrations of 1 mg / mL to 500 mg / mL are disclosed, and the compositions have a pH of 2.0 to 10.0. The compositions may further comprise a buffer system, a preservative, an isotonic agent, a chelating agent, a stabilizer, and a surfactant. In some embodiments, the pharmaceutical composition is an aqueous formulation, for example, a formulation comprising water. Such formulations are generally solutions or suspensions. In further embodiments, the pharmaceutical formulation is an aqueous solution. In some embodiments, the aqueous formulation is a formulation comprising at least 50% w / w water. In some embodiments, an aqueous solution is defined as a solution comprising at least 50% w / w water. In some embodiments, the pharmaceutical composition is a stable liquid aqueous pharmaceutical formulation comprising 20 to 150 mg / mL of the anti-human IL-7 binding protein described herein, an isotonic agent, a surfactant, and a buffer system with a pH of 4.0 to 8.0.

[0183] The pharmaceutical composition may also contain additional degradation inhibitors that can further enhance the stability of the therapeutically effective IL-7 binding protein. Examples of degradation inhibitors include, but are not limited to, methionine and EDTA (protecting polypeptides from methionine oxidation); and nonionic surfactants (protecting polypeptides from aggregation associated with freeze-thaw or mechanical shear). In some embodiments, the composition may further contain a surfactant.Surfactants include detergents, ethoxylated castor oil, polyglycolated glycerides, acetylated monoglycerides, sorbitan fatty acid esters, polyoxypropylene-polyoxyethylene block polymers (e.g., poloxamers, e.g., Pluronic F68, poloxamer 188 and 407, Triton X-100), polyoxyethylene sorbitan fatty acid esters, polyoxyethylene and polyethylene derivatives, e.g., alkylated and alkoxylated derivatives (tween, e.g., Tween-20, Tween (-40, Tween-80 and Brij-35), monoglycerides or their ethoxylated derivatives, diglycerides or their polyoxyethylene derivatives, alcohols, glycerols, lectins and phospholipids (e.g., phosphatidylserine, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, diphosphatidylglycerol and sphingomyelin), phospholipid derivatives (e.g., dipalmitoylphosphatidic acid) and lysophospholipids (e.g., palmitoyllysophosphatidyl-L-serine; and Ethanolamine, choline, serine or threonine (l-acyl-sn-glycero-3-phosphate esters), alkyl, alkoxyl (alkyl ester), and alkoxy (alkyl ether) derivatives of lysophosphatidylcholine, such as lauroyl and myristoyl derivatives of lysophosphatidylcholine, dipalmitoylphosphatidylcholine, and polar head groups, namely choline, ethanolamine, phosphatidic acid, serine, threonine, glycerol, inositol, and positively charged DODAC, DOTMA, DCP, BISHOP modifications, lysophosphatidylserine and lysophosphatidylthreonine, and glycerophospholipids (e.g., kephalin), glyceroglycolipids (e.g., galactopyranoside), sphingoglycolipids (e.g., ceramide, ganglioside), dodecylphosphocholine, chicken egg lysolecithin, fusidic acid derivatives (e.g., tauro-dihydrofusidic acid sodium), long-chain fatty acids and their salts, C6-C12 (e.g., oleic acid and caprylic acid), acylcarnitine and its derivatives, lysine, arginine or histidine N. a- A dipeptide comprising an acylated derivative, or a side-chain acylated derivative of lysine or arginine, lysine, arginine, or histidine, and any combination of a neutral or acidic amino acid. a -N of an acylated derivative, a tripeptide comprising any combination of a neutral amino acid and two charged amino acids a - Acylated derivatives, DSS (docusate sodium, CAS registry number [577-11-7]), docusate calcium, CAS registry number [128-49-4]), docusate potassium, CAS registry number [7491-09-0]), SDS (dodecyl sulfate sodium or lauryl sulfate sodium), sodium caprylate, cholic acid or its derivatives, bile acids and their salts and glycine or taurine conjugates, ursodeoxycholic acid, sodium cholate, sodium deoxycholate, sodium taurocholate, sodium glycocholate, N-hexadecyl-N,N-dimethyl-3-ammonio-l-propanesulfonate, anions (alkyl-aryl-sulfonates) The surfactant may be selected from monovalent surfactants, amphoteric surfactants (e.g., N-alkyl-N,N-dimethylammonium-l-propanesulfonate, 3-collamide-l-propyldimethylammonium-l-propanesulfonate), cationic surfactants (quaternary ammonium bases) (e.g., cetyl-trimethylammonium bromide, cetylpyridinium chloride), nonionic surfactants (e.g., dodecyl β-D-glucopyranoside), or poloxamine (e.g., tetronix), which is a tetrafunctional block copolymer derived by sequentially adding propylene oxide and ethylene oxide to ethylenediamine, or the surfactant may be selected from the group of imidazoline derivatives or mixtures thereof.

[0184] Diagnosis / Monitoring In some embodiments, the IL-7 binding proteins disclosed herein are used in diagnostic or prognostic methods. In some embodiments, diagnosis includes determining whether a subject has a disease or condition and / or determining the severity of the disease or condition. In some embodiments, prognosis includes predicting whether a subject will develop a disease or condition, whether treatment is required, what type of treatment the individual will need, whether they will respond to treatment, whether they will experience a disease episode, relapse or recurrence, and / or when, as well as the severity or duration of symptoms or disease episodes, relapses or recurrences. In some embodiments, the diagnostic or prognostic method may include, for example, selecting or recommending a treatment appropriate for the individual based on the diagnosis or prognosis. In some embodiments, the selected or recommended treatment or combination of treatments may then be administered to the subject.

[0185] In some embodiments, the IL-7 binding proteins disclosed herein are used in autoimmune or inflammatory diseases, particularly pathogenic T11. H IL-17 is used to diagnose or assess the prognosis of conditions involving IL-17 cells. Such diseases are associated with high levels of IL-17 expression. Elevated IL-17 levels have been reported in serum and CSF from MS patients (Matusevicius, D. et al.; Mult. Scler. 5, 101-104; 1999) and synovial fluid from rheumatoid arthritis patients. IL-17 has also been linked to psoriasis (Homey et al.; J. Immunol. 164(12):6621-32; 2000), while Hamzaoui et al. have reported high levels of IL-17 in Behçet's disease (Scand. J. Rhuematol.; 31:4, 205-210; 2002). Elevated IL-17 levels have also been observed in systemic lupus erythematosus (SLE) (Wong et al.; Lupus 9(8):589-93; 2000).

[0186] In some embodiments, the methods disclosed herein include measuring the level of IL-7 in a subject or in / in a sample obtained from a subject. In some embodiments, the measurement of IL-7 levels can be carried out by methods and assays known in the art. In some embodiments, the IL-7 level is compared to a reference level of IL-7. In some embodiments, the reference level is an indicator of normal, non-disease, disease, or disease stage. In some embodiments, the IL-7 level is measured multiple times in the subject or from multiple samples obtained from the subject. In some embodiments, the diagnostic or prognostic method can be carried out in combination with one or more other assays or tests to refine the diagnosis or prognosis. For example, other markers may be included in this analysis.

[0187] The assay of the target tissue sample can be performed at one or more time points. Separate tissue samples may be obtained from the subject for assay at each of the one or more time points. The assays at one or more time points may be performed on the same tissue sample. The assays at one or more time points may provide an evaluation of the efficacy of the drug, the course of the disease treatment plan over time, or a combination thereof. At each of the one or more time points, the tissue sample may be compared to the same reference. At each of the one or more time points, the tissue sample may be compared to a different reference. The one or more time points may be the same. The one or more time points may be different. The one or more time points may include at least one time point before drug administration, at least one time point after drug administration, at least one time point before a positive disease diagnosis, at least one time point after a disease remission diagnosis, at least one time point during the disease treatment plan, or a combination thereof.

[0188] The methods described herein can be used as a precautionary measure to monitor subjects at risk of developing a disease or condition. The methods described herein can be used alone for monitoring the effectiveness of diagnosis and / or treatment. The methods described herein can be used in combination with other assays for diagnosis or monitoring (such as cytological analysis or molecular profiling).

[0189] In some embodiments, an increase in the level of IL-7 or IL-7 receptor in a subject or sample compared to a reference sample or reference level indicates a positive diagnosis associated with the presence of a disease, e.g., that the individual has the associated disease or condition, or has a more severe disease. In some embodiments, subjects with a disease or condition include individuals suspected of having the disease or condition and / or individuals at risk of developing the disease or condition. For example, an individual may be suspected of having a disease or condition because of the presence of one or more symptoms, even if they have not been formally diagnosed. For example, IL-7 expression is increased in circulation in individuals with lymphopenia, and circulating IL-7 levels and CD4 + A strong inverse correlation exists between T cell count and lymphopenia (Mackall et al., 2011). In some embodiments, the IL-7 binding proteins disclosed herein are used to detect lymphopenia.

[0190] In some embodiments, a method for predicting a subject's response to treatment can be performed before administering the therapy. This prediction can then be considered when selecting or recommending a treatment appropriate for that individual. Alternatively, a method for predicting response to treatment can be performed after treatment with therapies and used to monitor and predict the subject's therapeutic response. For example, systemic levels of IL-7 may increase with the duration of the disease (Khaibullin et al., 2017), and an increase in circulating IL-7 has been identified as a potential predictive biomarker for response to IFN-β treatment in MS. In some embodiments, circulating IL-7 is increased in patients with Crohn's disease and ulcerative colitis, as well as in patients with SLE. In some embodiments, the disease or condition disclosed herein can be detected in a sample based on the level of IL-7 in the sample.

[0191] Samples obtained from the subject may include tissues, cells, cell fragments, cellular organelles, nucleic acids, genes, gene fragments, expression products, gene expression products, gene expression product fragments, or any combination thereof. Samples may be heterogeneous or homogeneous. Samples may include blood, urine, cerebrospinal fluid, semen, saliva, sputum, feces, lymph, tissue, mucus, or any combination thereof. Samples may be tissue-specific samples, such as those obtained from reproductive tissue (e.g., sperm or eggs), thyroid gland, skin, heart, lungs, kidneys, breasts, pancreas, liver, muscle, smooth muscle, bladder, gallbladder, colon, intestines, brain, esophagus, prostate, or any combination thereof. In some embodiments, samples may be cell-free samples.

[0192] As used herein, the term “cell-free” refers to the state of a nucleic acid sequence as it would be found in the body before the sample is obtained from the body. For example, circulating cell-free nucleic acid sequences in a sample may have arisen as cell-free nucleic acid sequences circulating in the bloodstream of the human body. In contrast, nucleic acid sequences extracted from solid tissue, such as a biopsy, are not generally considered “cell-free.” In some cases, cell-free DNA may consist of fetal DNA, maternal DNA, or a combination thereof. In some cases, cell-free DNA may consist of DNA fragments released into plasma. In some cases, cell-free DNA may consist of circulating DNA of tissue origin, disease, or pathological condition. Cell-free nucleic acid sequences can be isolated from blood samples. Cell-free nucleic acid sequences can be isolated from plasma samples.

[0193] Samples may be obtained from a subject by another individual or entity, such as a healthcare (or medical) professional or robot. Healthcare professionals include physicians, nurses, and medical technicians. In some cases, physicians may be specialists such as oncologists, surgeons, or endocrinologists. Medical technicians may be specialists such as cytologists, phlebotomists, radiologists, or pulmonary specialists. Healthcare professionals may take samples from a subject for testing or direct the subject to a testing center or laboratory for sample submission. Healthcare professionals may direct a testing center or laboratory to perform appropriate tests or assays on the sample, such as the methods of this disclosure, which involve determining gene sequence data, gene expression levels, sequence variant data, or any combination thereof. In some cases, healthcare professionals do not need to be involved in the initial diagnosis of a condition or disease or the initial sample acquisition. Alternatively, an individual, such as a subject, may be sampled using a commercially available kit. This kit may include a collection unit or device for taking samples as described herein, a storage unit for storing specimens prior to sample analysis, and instructions for using the kit.

[0194] kit A kit of parts containing a pharmaceutical composition is further provided along with instructions for use. For convenience, the kit of parts may contain a predetermined amount of reagent along with instructions for use.

[0195] In this specification, in some embodiments, kits comprising the IL-7 binding protein disclosed herein are disclosed. In some embodiments, the kit may be a diagnostic kit. In some embodiments, the kit comprises the IL-7 binding protein disclosed herein and instructions for use. In some embodiments, the kit comprises means for measuring the IL-7 level of a sample and instructions for use. The kit may provide a unit or device for obtaining a sample from a subject (e.g., a device comprising a needle connected to an aspirator). The kit may comprise a plurality of syringes, ampoules, foil packets, or blister packs containing single-dose doses of the kit components described herein. The kit containers may be airtight, water-resistant (e.g., impermeable to changes in moisture or evaporation), and / or light-shielding. The kit may comprise a device suitable for administering the components, e.g., a syringe, inhaler, pipette, forceps, measuring spoon, dropper (e.g., an eye dropper), swab (e.g., a cotton swab or wooden swab) or any such delivery device. In some embodiments, the device may be a medical implant device, for example, one packaged for surgical insertion. The kits disclosed herein may comprise one or more reagents or instruments that enable the implementation of the method. In some embodiments, the reagents or instruments comprise one or more of the following: a suitable buffer (aqueous solution), a support comprising wells on which a quantitative reaction can be performed. The kit may be a specific kit for a particular tissue sample. Furthermore, the kits disclosed herein may comprise a control.

[0196] In addition to the components described above, instructions for use may be provided with the kit. These instructions may be present in the kit in various forms, such as printed information on a suitable medium or support (e.g., one or more pieces of paper on which the information is printed), on the kit packaging, or as inserts in the packaging. In some embodiments, instructions for use may be provided on a computer-readable medium on which the information is recorded (e.g., a jump / thumb drive, CD, etc.), or as a website address that can be used to access the website information via the Internet.

[0197] device Another aspect of this disclosure provides a pre-filled syringe or auto-injector device comprising an IL-7 binding protein or composition as described herein. In some embodiments, the composition stored in the container, pre-filled syringe, injector or auto-injector device contains an IL-7 binding protein as disclosed herein.

[0198] array This specification discloses supports comprising the IL-7 binding protein disclosed herein. The support may be a solid-phase support. The support may have a variety of configurations, from simple to complex, depending on the intended use of the support. The support may have an overall slide or plate configuration, such as rectangular or disc-shaped. A standard microplate shape may also be used. In some embodiments, the surface may be smooth, substantially planar, or have irregularities such as depressions or ridges. In some embodiments, the support may have a length of about 10–200 mm, 40–150 mm, or 75–125 mm; a width of about 10–200 mm, 20–120 mm, or 25–80 mm; and a thickness of about 0.01–5.0 mm, 0.1–2 mm, or 0.2–1 mm.

[0199] In some embodiments, the support may be organic or inorganic; metallic (e.g., copper or silver) or nonmetallic; polymer or nonpolymer; conductive, semiconducting or nonconductive (insulating); reflective or nonreflective; porous or nonporous. Supports described herein can be formed from any suitable material, including metals, metal oxides, semiconductors, polymers (in particular organic polymers in any suitable form, including woven fabrics, nonwoven fabrics, molded articles, extruded articles, castings, etc.), silicon, silicon oxide, and composites thereof. The support may be an array. In some embodiments, the support comprises an array. The array may comprise an ordered spatial arrangement of two or more discrete regions. The array may comprise IL-7 binding proteins located in known or unknown discrete regions. The row and column arrangement of the array may be chosen because it is relatively simple to construct such an arrangement. However, the spatial arrangement may be in any form selected by the user, and may optionally be a pattern. The array region may be any convenient shape, including circular, oval, elliptical, ring, or other similar curved shapes, and the shape may be the result of a particular method employed to manufacture the array in a particular embodiment.

[0200] In some embodiments, the support may be planar. In some cases, the support may be spherical. In some cases, the support may be bead-shaped. In some cases, the support may be magnetic. In some embodiments, the magnetic support may comprise magnetite, maghemitite, FePt, SrFe, iron, cobalt, nickel, chromium dioxide, ferrite, or mixtures thereof. In some embodiments, the support may be nonmagnetic. In some embodiments, the nonmagnetic support may comprise polymers, metals, glass, alloys, inorganic materials, or mixtures thereof. In some cases, the nonmagnetic material may be a coating around the magnetic support. In some cases, the magnetic material may be distributed in a continuous phase of the magnetic material. In some embodiments, the support comprises a magnetic material and a nonmagnetic material. In some cases, the support may comprise a combination of a magnetic material and a nonmagnetic material. In some embodiments, the IL-7 binding protein disclosed herein is associated directly or indirectly with the support disclosed herein.

[0201] Computer control system This disclosure provides a computer-controlled system programmed to perform the methods of this disclosure. In some embodiments, the computer system is programmed to interface with a device configured to detect the binding of IL-7 and / or IL-7-binding proteins disclosed herein to a site, or otherwise configured. The computer system may be a computer system located remotely from a user's electronic device. The electronic device may be a mobile electronic device.

[0202] In some embodiments, the computer system includes a central processing unit (CPU, also referred herein as “processor” and “computer processor,” which may be a single-core or multi-core processor, or multiple processors for parallel processing). In some embodiments, the computer system also includes memory or memory locations (e.g., random-access memory, read-only memory, flash memory), electronic storage devices (e.g., hard disks), communication interfaces for communicating with one or more other systems (e.g., network adapters), and peripherals (e.g., caches, other memory, data storage, and / or electronic display adapters). In some embodiments, the memory, storage devices, interfaces, and peripherals communicate with the CPU via a communication bus, such as a motherboard. In some embodiments, the storage devices may be data storage devices (or data repositories) for storing data. In some embodiments, the computer system is operably coupled to a computer network ("network") with the help of a communication interface. In some embodiments, the network may be the Internet, the Internet and / or extranet, or an intranet and / or extranet communicating with the Internet. In some embodiments, the network is a telecommunications network and / or data network. The network may include one or more computer servers that enable distributed computing, such as cloud computing. In some embodiments, the network may implement a peer-to-peer network, possibly with the help of a computer system, which allows devices connected to the computer system to act as clients or servers. In some embodiments, the CPU executes a machine-readable sequence of instructions, which can be embodied in a program or software. The instructions may be stored in a storage location, such as memory. The instructions can instruct the CPU, which can then be programmed or otherwise configured to perform the methods of this disclosure.Examples of operations performed by the CPU may include fetching, decoding, executing, and writing back. In some embodiments, the CPU may be part of a circuit, such as an integrated circuit. One or more other components of the system may be included in the circuit. In some cases, the circuit is an application-specific integrated circuit (ASIC). In some embodiments, a storage device may store files such as drivers, libraries, and saved programs. The storage device may also store user data, such as user settings and user programs. In some cases, the computer system may include one or more additional data storage devices located outside the computer system, such as those located on a remote server communicating with the computer system via an intranet or the internet. In some embodiments, the computer system communicates with one or more remote computer systems over a network. For example, the computer system may communicate with a user's remote computer system. Examples of remote computer systems include personal computers (e.g., portable PCs), slate PCs or tablet PCs, smartphones, or personal digital assistants. Users may access the computer system over the network.

[0203] The methods described herein can be implemented by machine-executable code (e.g., a computer processor) stored in an electronic storage location of a computer system, such as memory or an electronic storage device. The machine-executable code or machine-readable code can be provided in software form. During use, the code can be executed by the processor. In some cases, the code may be retrieved from storage and stored in memory for immediate access by the processor. In some cases, machine-executable instructions may be stored in memory without the use of electronic storage devices. In some embodiments, the code may be pre-compiled and configured for use in a machine with a processor adapted to execute the code, or it may be compiled during runtime. The code may be supplied in a programming language that can be selected to allow the code to be executed in pre-compiled fashion or as-compiled fashion.

[0204] Embodiments of systems and methods provided herein, such as computer systems, can be embodied through programming. Various embodiments of this technology can typically be considered as “products” or “manufactured goods” in the form of machine (or processor) executable code and / or associated data, either mounted on or embodied in a machine-readable medium. Machine-executable code can be stored in electronic storage devices such as memory (e.g., read-only memory, random-access memory, flash memory) or hard disks. “Storage” media can include any or all of the tangible memory of a computer, processor, or its associated modules, such as various semiconductor memories, tape drives, disk drives, etc., which can at any time provide non-temporary storage for software programming. All or part of the software may be communicated over the Internet or various other telecommunication networks. Such communication enables the loading of software from one computer or processor to another, for example, from a management server or host computer to an application server computer platform. Thus, other types of media that can contain software elements include light, electricity, and electromagnetic waves, used through physical interfaces between local devices, such as wired and optical fixed-line networks and various air links. Physical elements that transmit such waves, such as wired or wireless links and optical links, can also be considered media that contain software. As used herein, terms such as computer or machine-readable media refer to any medium involved in providing instructions to a processor for execution, and are not limited to non-temporary tangible “storage” media.

[0205] Machine-readable media, such as computer executable code, can take many forms, but are not limited to, tangible storage media, carrier media, or physical transmission media. Non-volatile storage media include optical or magnetic disks, such as any storage device, including any computer, which may be used to implement a database as shown in the drawing. Volatile storage media include dynamic memory, such as the main memory of such a computer platform. Tangible transmission media include coaxial cables; copper wires and optical fibers, including wires that make up a bus in a computer system. Carrier media can take the form of electrical or electromagnetic signals, or acoustic or optical waves, such as those generated during radio frequency (RF) and infrared (IR) data communications. Therefore, common forms of computer-readable media include, for example, hard disks, magnetic tapes, any other magnetic media, CD-ROMs, DVDs or DVD-ROMs, any other optical media, punched card paper tapes, any other physical storage media having a pattern of holes, RAM, ROMs, PROMs and EPROMs, FLASH-EPROMs, any other memory chips or cartridges, carriers for transmitting data or instructions, cables or links for transmitting such carriers, or any other media from which a computer can read programming code and / or data. Many of these forms of computer-readable media may be involved in carrying one or more sequences of one or more instructions to a processor for execution.

[0206] In some embodiments, the computer systems disclosed herein may include, or communicate with, electronic displays constituting a user interface (UI) for providing, for example, one or more results (immediate results or archived results from previous experiments), one or more user inputs, reference values ​​from a library or database, or a combination thereof. Examples of UIs, but not limited to, include graphical user interfaces (GUIs) and web-based user interfaces.

[0207] Furthermore, the methods and systems of this disclosure can be implemented by one or more algorithms. The algorithms may be implemented by software methods when executed by a central processing unit. The algorithms may determine optimized conditions through supervised learning to optimize conditions such as buffer type, buffer concentration, temperature, incubation period, threshold, and diagnostic / prognostic indicator for the methods disclosed herein. [Examples]

[0208] Example 1: DRSPAI-L7B of the cynomolgus macaque This study was conducted to evaluate DRSPAI-L7B in cynomolgus monkeys. In Part 1, three single IV injections at 0.1, 1, and 10 mg / kg were evaluated. In Part 2, repeated administration of 30 mg / kg (four SC injections) was performed on the vehicle control animals from Part 1. Blood samples were collected to assess the pharmacodynamic activity of DRSPAI-L7B by measuring the drug's PK, free and total IL-7 levels, and STAT5 phosphorylation.

[0209] Total antibody level Total antibody levels were measured using the GYROLAB general-purpose antigen capture detection method. The maximum peak serum concentration detected (C) max ) and the time (T) at which it was observed maxThe ) was determined by examining the obtained data. Furthermore, AUC, total serum clearance (CL), steady-state volume of distribution (Vss), and terminal half-life (t1 / 2) were calculated using a non-compartmental PK model (Table 3).

[0210] [Table 3]

[0211] No target-mediated pharmacokinetics (TMDD) were observed, and the increase in serum Cmax and AUC was dose-proportional with dose increases from 0.1 to 10 mg / kg. DRSPAI-L7B was slowly eliminated, with a mean half-life of approximately 17 ± 3.9 days, and repeated administration resulted in a 2.8-fold increase in drug accumulation. The data are shown in Figures 1A, 1B, and 1C.

[0212] To assess the presence of anti-drug antibodies (ADAs), an acid-dissociation bridging assay using DRSPAI-L7B was employed for capture. ADAs were not detected in either Part 1 or Part 2 of the study.

[0213] Further studies were conducted in cynomolgus monkeys to measure the pharmacokinetic (PK) and pharmacokinetic (PD) effects of DRSPAI-L7B after subcutaneous (SC) administration. Four single IV injections at doses of 0.1, 1, 3, and 10 mg / kg were evaluated. These doses were administered once via SC injection on day 1.

[0214] The total body exposure to DRSPAI-L7B is measured by the area under the serum concentration-time curve (AUC) from the start of administration to the last quantifiable time point. 0-t The peak serum concentration (C) was determined by calculating it using the linear up / log down trapezoidal method. max ) and the time it was seen (T max The decision was made via PK SUBMIT.

[0215] [Table 4]

[0216] At the maximum dose of 10 mg / kg, the average C for each sex was max The concentration was 119 μg / mL (range 108-128 μg / mL), and the mean AUC was 119 μg / mL. 0-t The value was 60200 μg.h / mL (range 52700~69700 μg.h / mL).

[0217] A dose-dependent increase in total IL-7 levels was observed at all dose levels, indicating the involvement of DRSPAI-L7B in targeting. In addition, doses of 1 mg / kg or higher resulted in dose-dependent inhibition of IL-7-induced STAT5 phosphorylation in both Th and Tc lymphocytes, and doses of 3 mg / kg or higher resulted in a dose-dependent decrease in Bcl-2 expression in Th lymphocytes.

[0218] Low levels of anti-DRSPAI-L7B antibody were detected in two of the three monkeys administered 1.0 mg / kg. In one male monkey, this resulted in decreased target association and decreased AUC.

[0219] Example 2: Binding affinity of DRSPAI-L7B to IL-7 The binding dynamics and affinity of DRSPAI-L7B to human and cynomolgus monkey IL-7 were evaluated by surface plasmon resonance (SPR) using a Biacore 8K instrument at 25°C and 37°C. The affinity of DRSPAI-L7B to human IL-7 was approximately 34 pM at 25°C and 67 pM at 37°C (Table 5). The affinity of DRSPAI-L7B to cynomolgus monkey IL-7 was approximately 53 pM at 25°C and approximately 75 pM at 37°C (Table 5).

[0220] [Table 5]

[0221] Example 3: Inhibition of IL-7 signaling (functional assay) All human samples were obtained with informed consent from patients in accordance with ICH GCP, under protocols approved by the national, regional, or clinical trial site's ethics committee or Institutional Review Board (IRB) approved protocols. Disease-specific personal cell cultures (PBMCs) were supplied by approved external human tissue suppliers. PBMCs were stored frozen at -80°C until use.

[0222] Blood from healthy volunteers was provided by a blood donation center: blood was collected by venipuncture and transferred to a pot or blood bag containing heparin sodium (1 U / mL). Blood was collected and used for whole blood assay or PBMC separation within 1 hour. A different donor was used for each experiment. Cells were removed from -80°C storage, thawed, and immediately placed in a 37°C water bath. After transferring the cell suspension to a 15 mL centrifuge tube, warm medium (RPMI + 10% heat-inactivated FCS, 1% penicillin / streptomycin, and 1% GlutaMax) was added very slowly to gradually decrease the DMSO concentration. The volume was increased to 10 mL, the cells were centrifuged, washed again, and counted, with a count of 5 × 10⁶ cells per mL. 6 The cells were resuspended in an appropriate amount of assay medium to form individual cells.

[0223] All antibodies were aliquoted upon arrival for long-term storage at -80°C. For experimental purposes, antibody aliquots were thawed and stored at 4°C for up to 8 weeks.

[0224] [Table 6]

[0225] All antibody treatments and rhIL-7 stimulations were mixed in a 1:1 ratio in culture medium to a 4-fold final assay concentration (FAC), and incubated at room temperature for 5 minutes. If neither antibody nor IL-7 stimulation was present, culture medium was added.

[0226] About whole blood: 100 μL of antibody:IL-7 mixture was dispensed into a FACS tube, followed by 100 μL of whole blood. The tube was gently mixed by vortexing and incubated at 37°C in a humidified incubator for 20 minutes. At the end of the stimulation period, 2.5 mL of pre-warmed Phosflow lysis buffer (1x) was added, and the sample was incubated at 37°C for a further 10 minutes. 2 mL of PBS was added to the suspension, and the tube was centrifuged to pellet the cells (300 × g, room temperature for 5 minutes). The supernatant was discarded, and the cells were washed twice more with PBS. After the final wash, the cells were resuspended in 500 μL of Perm buffer III (pre-cooled to -20°C) and mixed by vortexing. The tube was incubated on ice for 30 minutes, followed by a single wash with 3 mL of PBS. The cells were resuspended in 100 μL of PBS and transferred to a 96-well round-bottom culture plate for staining.

[0227] Regarding PBMC processing: 50 μL of antibody:IL-7 mixture was added to each well of a 96-well round-bottom tissue culture plate. 50 μL of PBMC suspension was added to each treated well (2.5 × 10⁻⁶). 5 Cells / well). After gently mixing the plate with a rotary plate shaker, incubate in a humidified incubator at 37°C for 20 minutes. At the end of the stimulation period, add 250 μL of pre-warmed Phosflow lysis buffer (1x) and incubate the sample at 37°C for a further 10 minutes. After fixation, pelletize the cells by centrifugation (300 × g, 5 minutes at room temperature) and wash twice with 200 μL of PBS. Resuspend the cell pellet in 100 μL of Perm buffer III (pre-cooled to -20°C) and mix by pipetting up and down. Incubate the cells on ice for 30 minutes, wash once with 200 μL of PBS, and resuspend in PBS.

[0228] For all samples: After permeabilization, the plate was centrifuged (300 × g, 5 minutes at room temperature), and the cell pellet was resuspended in 25 μL of FcR blocking reagent diluted 1:5 in PBS with 3% BSA. After incubating the cells at room temperature for 10 minutes, 2.5 μL of anti-CD3 (BV510), 2.5 μL of anti-CD4 (PerCP / Cy5.5), 2.5 μL of anti-CD8 (FITC), 7.5 μL of anti-pSTAT5 (PE), and 35 μL of flow cytometry staining buffer (50 μL total per sample) were added. If no staining was used for control, the same amount of staining buffer was added instead. The plate was gently mixed with a rotary plate shaker and incubated on ice in the dark for 30 minutes. The cells were washed with 200 μL of staining buffer, resuspended in 200 μL of staining buffer, and analyzed on the same day using FACS Canto II.

[0229] The instrument's performance was verified using cytometer setup tracking (CST) beads. This is a QC check of the instrument, where a baseline is set and the voltage of each laser is optimized before use. The calibration results are stored in the instrument's CST software.

[0230] Instrument calibration was performed using anti-mouse IgG,κ / negative control calibration beads according to the manufacturer's instructions. The relevant antibodies used to stain cells during the experiment were used to label the appropriate calibration bead type. Experimental calibration was performed using appropriately labeled beads with the automated calibration function available in the FACS Diva software. After analysis of the calibration samples, the appropriate calibration settings were calculated and applied to each experimental staining panel. pSTAT5 FACS analysis: Cells were acquired in FSC-A vs. FSC-H plots, and doublets were excluded. Single cells were acquired in FSC-A vs. SSC-A plots and gated to live lymphocytes. These were acquired in AmCyan vs. FSC-A plots and gated to the CD3+ population. CD3 + Then, a PerCP-Cy5.5 vs. FITC plot was created, and CD4 + and CD8 +We identified the populations. For pSTAT5, we created PE fluorescence histograms for each subset. The positive gate was set based on unstimulated samples, and a PE positivity rate statistic was used for data analysis.

[0231] The data was analyzed using FlowJo software (version 10), and the results were created in Microsoft Excel (2010) spreadsheet format using the batch analysis function of FlowJo software. Cell populations were aggregated in the Excel spreadsheet as a percentage of parent cells. This was converted to response percentages by normalizing it to the non-stimulated control, or to inhibition percentages by normalizing it to the non-stimulated control and subtracting this value from 100 (theoretical maximum response rate).

[0232] Once a concentration-response graph is created, the data for each donor is fitted using a nonlinear logistic curve-fitted regression, and the IC of all donors is calculated. 50 The mean (mean and median), range, standard deviation (SD), and search-encoded magnitude (SEM) were calculated using GraphPad Prism (version 6). Where statistical tests were performed, a two-way ANOVA with Sidac correction for multiple comparisons was applied. A p-value < 0.05 was considered statistically significant. * p<0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** This indicates that p ≤ 0.0001.

[0233] In whole blood assays, STAT5 phosphorylation was determined by flow cytometry after 20 minutes of stimulation with 1 ng / mL recombinant human IL-7 (rhIL-7; 58 pM) and CD4 + Evaluation was performed using T cells. As shown in Figure 2A and Table 6, DRSPAI-L7B inhibited STAT5-mediated IL-7 signaling in a concentration-dependent manner, and IC 50 The median was 34 pM (5.1 ng / mL). A1290 inhibited IL-7 signaling via STAT5 in a concentration-dependent manner, and IC 50The median was 18 pM (0.00275 μg / mL). A1291 inhibited STAT5-mediated IL-7 signaling in a concentration-dependent manner, and IC 50 The median was 16 pM (0.00246 μg / mL). A1294 inhibited STAT5-mediated IL-7 signaling in a concentration-dependent manner, and IC 50 The median was 76 pM (0.0114 μg / mL). Immortalized T lymphoblasts (CCRF-CEM cells) were stimulated with 34 pg / mL (2 pM) recombinant human IL-7 (rhIL-7) in the presence or absence of DRSPAI-L7B. STAT5 phosphorylation was evaluated using MSD of the cell lysates. DRSPAI-L7B strongly blocked IL-7-induced pSTAT5 (Table 6; IC). 50 <1 pM).

[0234] [Table 7]

[0235] IL-7-induced phosphorylation of STAT5 in healthy and diseased T cells PBMCs from healthy donors or IBD patients (two with Crohn's disease and one with ulcerative colitis) were stimulated with rhIL-7 in the presence of DRSPAI-L7B or anti-RSV antibody (isotype control). The stimulated cells were fixed and CD8 + (Figure 2B), CD4 + (Figure 2C) and CD3 + (Figure 2D) STAT5 phosphorylation in T cells was evaluated by flow cytometry. Data are shown as an increase in pSTAT5 compared to the unstimulated state. Mean ± SD, n=3. * p<0.05, ** p ≤ 0.01, *** Paired two-way ANOVA with p ≤ 0.001 and Sidac's multiple comparison correction. Figures 2B, 2C, and 2D.

[0236] Example 4: Dynamic Light Scattering Assay Dynamic light scattering (DLS) analysis was performed on DRSPAI-L7B, A1290, A1291, and A1294 to characterize higher-order agglomeration species and sample heterogeneity.

[0237] Each antibody was concentrated to 10 mg / mL or higher, and after buffer exchange with 50 mM sodium phosphate pH 7.5 or 50 mM sodium acetate pH 5.0 buffer by dialysis, it was standardized to 10 mg / mL and filtered using a 0.22 μm syringe filter. After filtration, all samples were stressed at a target concentration of 10 mg / mL at 40°C for 2 weeks. The samples were incubated in two types of buffer under stressed and unstressed conditions before evaluation. Using a 96-well Corning Costar 3635 plate sealed with Corning 6575 seals, 100 μL of sample was measured in 3 replicates at 25°C using a Wyatt DynaPro DLS plate reader.

[0238] The data were analyzed using DYNAMICS v7.1.9 software. The data were distributed across the following peaks: Peak 1 = 0.1–1 nm, Peak 2 = 1–10 nm, Peak 3 = 10–100 nm, Peak 4 = 100–1000 nm, Peak 5 = 1000–10000 nm. The data were filtered using the following criteria: amplitude must be between 0 and 1, baseline limit 1 ± 0.01, and sum of total squares (SOS) must be less than 100. Rh greater than 8 nm and average mass% of Peak 2 less than 98% were associated with a significant aggregation risk.

[0239] A1290, A1291, and A1294 showed a significant risk of aggregation, all exhibiting hydrodynamic radius (Rh) values ​​exceeding 8 nm. DRSPAI-L / B did not show this risk of aggregation because its Rh value was less than 8 nm. [Table 8]

[0240] Example 5: Effect of DRSPAI-L7B on cytokine production in human PBMCs We investigated the role of IL-7 in the function and differentiation of Th1 and Th17 cells using DRSPAI-L7B. We evaluated the effect of DRSPAI-L7B on cytokine secretion from healthy PBMCs stimulated with IL-7 in the presence of a CD3 agonist antibody.

[0241] Blood from healthy volunteers was provided by the blood donation center: the blood was collected by venipuncture and transferred to a pot or blood bag containing heparin sodium (1 U / mL). The blood was collected and used for PBMC separation.

[0242] Blood was diluted 2-fold with PBS and overlaid on 15 mL of Ficol in an AccuSpin tube. The mixture was centrifuged at 800 rcf for 20 minutes without braking. The plasma was carefully removed with a pipette, and the layer containing the PBMCs was carefully transferred to a 50 mL tube. The PBMCs were washed twice with 50 mL of PBS (250 rcf, 10 minutes), then resuspended in 50 mL of RPMI + 10% FCS + L-glutamine, and counted using Vi-cell XR.

[0243] PBMC 5x10 6 Cells were resuspended in culture medium at a concentration of cells / mL. Antibody dilutions of anti-RSV antibody (isotype control) and DRSPAI-L7B were prepared in culture medium at 2.5 times the required final concentration. Equal volumes of cell suspension and antibody dilution (150 μL) were mixed and incubated at room temperature for 30 minutes. IL-7 was prepared in culture medium at 5 times the final concentration, and 20 μL was added to the required wells of a 96-well U-bottom polystyrene plate pre-coated with 10 μg / mL anti-CD3 overnight at 4°C. Culture medium was added to all remaining wells. 80 μL of mixed cell suspension / antibody dilution (2 × 10⁶) 6 Cells (per well) were added to each well of a 96-well plate and incubated at 37°C and 5% CO2 for 48 hours.

[0244] After 48 hours, the plate was centrifuged at 300 rcf for 5 minutes, and the supernatant was collected without disturbing the pellet and transferred to a new 96-well U-bottom plate. The supernatant was either used immediately for ELISA / MSD or stored at -80°C until further use.

[0245] The stock solution concentration of anti-RSV IgG1 was 2.8 mg / mL. It was thawed on the day of use and diluted to the appropriate concentration. The stock solution concentration of DRSPAI-L7B was 11.33 mg / mL. It was thawed on the day of use and diluted to the appropriate concentration. Recombinant human IL-7 was purchased from R&D systems. The lyophilized protein was resuspended in sterile PBS + 0.1% bovine serum albumin to a concentration of 25 μg / mL, and 50 μL aliquots were stored at -20°C. It was thawed on the day of use and diluted to the appropriate concentration. The stock solution of anti-CD3 clone HIT3a was 1 mg / mL. It was diluted to the appropriate concentration on the day of use.

[0246] [Table 9]

[0247] ECL signals were obtained from the MSD instrument and converted to concentrations using the standard curve for each analyte. In the normalized graph, anti-CD3 + The mean of the IL-7 sample was set to 100%, and all other values ​​were normalized relative to it. Antibody concentrations were logarithmically transformed and plotted against cytokine concentrations. For comparison, samples without IL-7 (anti-CD3 only) are also shown in each graph. For curve fitting, the following nonlinear fit was used in Graphpad Prism: log(inhibitor) vs. response (3 parameters), IC2. 50 The values ​​were calculated using Graphpad Prism.

[0248] DRSPAI-L7B inhibited the secretion of IFN-γ (Figure 3A) and IL-10 (Figure 3B) in a concentration-dependent manner (IFN-γ mean IC50). 50 =195.8±101pM; IL-10 mean IC 50(=207.2 ± 86 pM). Data represent the mean ± SEM of n=6 independent donors evaluated in three independent experiments. Figures 3C, 3D, 3E, 3F, and 3G show the inhibition of IL-2 by DRSPAI-L7B in the presence of rhIL-7 and anti-CD3. Increased IL-2 production was observed in five donors after IL-7 stimulation. This increase was completely inhibited by DRSPAI-L7B.

[0249] Example 6: DRSPAI-L7B inhibits cytokine production by memory T cells. To accurately determine the role of IL-7 in Th17 cell function and differentiation, a "poised Th17" assay was used to profile the secretion of Th17-related cytokines. mem The cells were isolated and incubated with IL-7 in the presence of DRSPAI-L7B.

[0250] Human whole blood was collected from donors at blood donation centers (BDUs). Typically, 200 mL was collected venipuncture from each donor, and the anticoagulant citrate-glucose solution (ACD, Sigma, catalog number C3821) was immediately added to each sample. ACD was added at a 15% concentration (e.g., 30 mL of ACD added to 200 mL of blood). Within two hours of collection, the blood was evenly dispensed into pre-filled LEUCOSEP tubes (Greiner, catalog number 227288) at a maximum of 30 mL per tube using a microbiological safety cabinet. This blood was centrifuged at 800 × g for 15 minutes at room temperature using a swing bucket rotor without braking. PBMCs were washed with PBS (500 × g, 10 minutes), then resuspended in 10 mL of PBS and counted using a NucleoCounter. The cells were again centrifuged at 500 × g, and the cell pellet was divided into 5 × 10⁶ cells. 7 The cells were resuspended in FACS buffer at a concentration of cells / mL.

[0251] Human CD4 + Memory T cells (T mem50 μL / mL of EasySep concentrated cocktail was added to the cell suspension. After incubating the cells at room temperature for 10 minutes, 50 μL / mL of EasySep magnetic particles were added. The suspension was incubated again at room temperature for 10 minutes, and then the cell suspension was placed on an EasySep magnet for 10 minutes. Subsequently, to ensure negative selection, the cell suspension was transferred to a new tube while still in the magnet. The cells were centrifuged at 500 × g for 10 minutes and resuspended in cell culture medium. Cell counts were determined using a NucleoCounter.

[0252] The cells were left to rest overnight in culture medium at 37°C and 5% CO2. The next day, the cells were centrifuged and measured 2.5 × 10⁶. 5 The cells were resuspended in assay medium at a concentration of cells / mL. Recombinant hIL-7 was added to the cells at a final concentration of 20 ng / mL. The cells were then incubated in the presence of DRSPAI-L7B at 37°C and 5% CO2 for 4 days, and subsequently stimulated with 10 nM PMA and 1 μM ionomycin at 37°C and 5% CO2 for 16 hours.

[0253] Detection of IL-17 from supernatant using MSD After 16 hours of PMA and ionomycin stimulation, cells were centrifuged, and 40 μL of supernatant was transferred to MSD plates pre-blocked with 0.5% Blocker B. These MSD plates were coated with anti-IL-17A capture antibody. After incubating the samples at room temperature for 2 hours with shaking, the plates were washed with PBS and 0.05% Tween-20. Then, 10 μL of IL-17-specific detection antibody labeled with MSD SULFO-TAG reagent was added, and the samples were incubated at room temperature for a further 2 hours with shaking. The plates were washed three more times with PBS and 0.05% Tween-20, and 2× Read Buffer T was added to the samples. The plates were read using a Sector Imager.

[0254] Detection of other cytokines A U-Plex MSD kit was designed to enable the investigation of the effects of DRSPAI-L7B on the secretion of IL-6, IL-10, IFN-γ, TNF-α, and CCL3. MSD U-Plex plates were prepared by coating the plates with linker-bound capture antibodies. Each capture antibody was biotinylated and assigned a unique linker. The supernatant was diluted 1 / 100 and transferred to an MSD plate. The sample was incubated at room temperature for 1 hour with shaking, and then the plate was washed with PBS and 0.05% Tween-20. Subsequently, 50 μL of specific detection antibody labeled with MSD SULFO-TAG reagent was added, and the sample was incubated at room temperature for another 1 hour with shaking. The plate was washed three more times with PBS and 0.05% Tween-20, and 2× Read Buffer T was added to the sample. The plate was read with a Sector Imager.

[0255] The DRSPAI-L7B antibody was prepared at a stock concentration of 11.33 mg / mL in 20 mM histidine, 180 mM trehalose, 40 mM arginine, 8 mM methionine, and 0.05 mM EDTA at pH 6.0. The antibody was diluted to a concentration of 20 μg / mL in assay medium. Next, 1:3 serial dilutions were performed in assay medium to create a 10-point dose-response curve. The dilutions were transferred to assay plates to achieve a maximum final assay concentration of 10 μg / mL.

[0256] BRL-54319MM (rapamycin) was used as a positive control for the assay at a final assay concentration of 1 μM in the assay medium.

[0257] Recombinant human IL-7 was resuspended in sterile PBS at 25 μg / mL, and 50 μL aliquots were stored at -20°C. These aliquots were thawed and diluted to the appropriate concentration on the day of use.

[0258] [Table 10]

[0259] FACS buffer: Sterile PBS containing 2% heat-inactivated FBS. Cell culture medium: 450 mL IMDM, 50 mL FBS, 5 mL Penstrep, 5 mL L-glutamine, 5 mL non-essential amino acids, and 5 mL sodium pyruvate. Assay medium: 500 mL Xvivo 15, 5 mL Penstrep, 5 mL L-glutamine, 5 mL HEPES, 5 mL sodium pyruvate.

[0260] All data were normalized to the mean values ​​of the eight high-value control wells and eight low-value control wells for each plate. Next, a four-parameter curve fit of the following form was applied.

number

[0261] In the formula, a is the minimum value, b is the Hill gradient, c is XC50, and d is the maximum value. The data is the average IC. 50 This is shown as the standard deviation of the mean of n experiments.

[0262] CD4 isolated from the blood of a healthy donor + T mem Cells were incubated with IL-7 in the presence of DRSPAI-L7B for 4 days, and then stimulated with PMA / ionomycin for 16 hours before harvesting. Cytokine secretion into the supernatant was evaluated by MSD. DRSPAI-L7B treatment stimulated IL-17 (Figure 4A, IC). 50 =270±31.59pM), TNFα (Figure 4B, IC 50 =127.1±89.83pM), IL-6 (Figure 4C, IC 50 =202.07±99.64pM), IL-10 (Figure 4D, IC 50 =197.48±148.91), INFγ (Figure 4E, IC 50 =157.98±89.55) and CCL3 (Figure 4F, IC 50(=163.83±85.96) This resulted in concentration-dependent inhibition of secretion. Dose-dependent inhibition was also observed for IL-6, IL-10, IFNγ, TNFα, and CCL3. Inhibition of these cytokine productions is expressed as a percentage of what was achieved in the rapamycin (1 μM)-positive control.

[0263] Example 7: Analysis of T cell population Considering the central role of T cells in MS, we analyzed the T cell population in PBMCs of RRMS, PPMS, and SPMS patients.

[0264] All human samples were obtained with informed consent from patients in accordance with ICH GCP, under protocols approved by the national, regional, or clinical trial site's ethics committee or Institutional Review Board (IRB) approved protocols.

[0265] Healthy PBMCs were isolated from BDU blood and cryopreserved in liquid nitrogen until use. Diseased PBMCs were supplied from approved external human tissue suppliers. Healthy control blood was collected by venous puncture and transferred to a container containing heparin sodium anticoagulant (1 U / mL). Blood was collected and used for PBMC isolation within one hour.

[0266] Pre-prepared and frozen healthy control human PBMCs were used. PBMCs were prepared by layering blood in 15 mL of Ficol. The tube was centrifuged at 800 g for 20 minutes without braking. The mononuclear cell layer at the interface was transferred to a 50 mL Falcon tube, washed with PBS up to 45 mL as a top layer, and centrifuged at 300 g for 10 minutes. The pellet was resuspended in 5% of the original blood volume in frozen medium A (60:40 FCS:medium), and then the same volume of frozen medium B (80:20 FCS:DMSO) was added dropwise to reduce osmotic shock. The cells were transferred to cryovials (1 mL / vial (approximately 1 × 10⁶)). 7 The cells were frozen in a Mr Frosty freezing container at -80°C for up to one week, and then transferred to liquid nitrogen for long-term storage.

[0267] PBMC recovery The cells were removed from liquid nitrogen storage and thawed, then immediately placed in a 37°C water bath to further thaw. The cell suspension was transferred to a 50 mL centrifuge tube, and the DMSO concentration was gradually decreased by very slowly adding the culture medium (RPMI + 10% heat-inactivated FCS, 1% penicillin / streptomycin and 1% glutamine). When the volume reached 30 mL, the cells were centrifuged at 300 g for 10 minutes, resuspended in 5 mL of medium and counted, and the volume was increased to 15 mL of medium. The cells were then centrifuged again in the same manner as above, and 5 × 10⁶ cells were obtained. 6 The cells were resuspended in an appropriate amount of culture medium to a concentration of 1 mL / cell.

[0268] In each of the five individual experiments, donor PBMC samples from two healthy controls (HC), two recurrent rheumatoid arthritis (RRMS), one patient with peritoneal malformation (PPMS), and one patient with paraplegia (SPMS) were thawed as described above, and the cells were processed as follows. Different donors were used in each experiment, and the HCs were roughly matched in age and sex to the disease patient donors used.

[0269] T-cell phenotypic analysis flow cytometry assay PBMC 5x10 6 After resuspending the cells in culture medium at 1 mL / mL, 100 μL of cells were transferred to a FACS tube (for complete staining), and an additional 50 μL of HC sample (for FMO control tube) was transferred. The cells were washed with 2 mL of FACS buffer, centrifuged at 300 g for 5 minutes, and the pellet was resuspended in the remaining solution. 5 μL of human FcX Trustain block was added for 10 minutes, followed by the addition of 100 μL of antibody staining cocktail, and the cells were incubated at room temperature for 30 minutes. The cells were washed with 2 mL of FACS buffer, centrifuged at 300 g for 5 minutes, and the pellet was resuspended in the remaining solution. 500 μL of diluted Live / Dead Fixable Aqua Dead Cell Stain was added, and the cells were incubated at room temperature for 25 minutes. The cells were washed with 2 mL of FACS buffer, centrifuged at 300 g for 5 minutes, and the pellet was resuspended in the remaining solution. 200 μL of FACS buffer was added, and the samples were analyzed on the same day using BD FACS Canto II.

[0270] The instrument's performance was verified using cytometer setup tracking (CST) beads. This is a QC check of the instrument, where a baseline is set and the voltage of each laser is optimized before use. The calibration results are stored in the instrument's CST software.

[0271] Instrument calibration was performed using UltraComp calibration beads, following the manufacturer's instructions. The relevant antibodies used to stain cells during the experiment were used to label the calibration beads. Experimental calibration was performed using the automated calibration function available in the FACS Diva software, with appropriately labeled beads. After analysis of the calibration samples, calibration settings were calculated and applied to each experimental staining panel.

[0272] [Table 11]

[0273] Samples were acquired using a BD FACS Canto II flow cytometer with BD BioSciences FACS Diva software (v8.0.1). The resulting corrected .fcs files were analyzed with FlowJo software (v10.0.8), and the results were created in Excel using the Batch Analysis function within the software.

[0274] T cell populations were analyzed in PBMCs of RRMS, PPMS, and SPMS patients. Data were compiled from patients in whom all patients were receiving treatment (10 / 10 RRMS patients were receiving natalizumab, and all progressive MS patients were receiving steroids and / or symptomatic treatment). reg A decrease in cells was observed. CD4 levels were compared between healthy controls and MS patients. + (Figure 5A), CD8 + (Figure 5B) and regulatory T cells (Figure 5C) were profiled by flow cytometry based on the expression of CD45RO, CCR7, CD127, and CD25 on the cell surface. + or CD8 +No differences were observed between healthy individuals and diseased T cell populations in any of the subsets. reg The population was significantly reduced compared to HC, but T in SPMS patients reg No significant difference was observed in the numbers. When tested using a one-way ANOVA with Dunnett's multiple comparison test, *** 0 < 0.0001, * 0 < 0.05. The data represents the mean ± SEM values ​​of n=5-10 donors in each group, analyzed in five independent experiments. Effector memory = CD45RO + CCR7 - Central memory = CD45RO + CCR7 + Naive = CD45RO - CCR7 + Effect pedal = CD45ROCCR7 - , T reg =CD127 low / - CD25 + .

[0275] Example 8: Phosphorylation of STAT5 All human samples were obtained with informed consent from patients in accordance with ICH GCP, under protocols approved by the national, regional, or clinical trial site's ethics committee or Institutional Review Board (IRB) approved protocols.

[0276] Healthy PBMCs were isolated from BDU blood and cryopreserved in liquid nitrogen until use. Diseased PBMCs were supplied from approved external human tissue suppliers.

[0277] Healthy control blood was collected by venous puncture and transferred to a container containing heparin sodium anticoagulant (1 U / mL). The collected blood was used for PBMC isolation within one hour.

[0278] Pre-prepared and frozen healthy control human PBMCs were used. PBMCs were prepared by layering blood in 15 mL of Ficol. The tube was centrifuged at 800 g for 20 minutes without braking. The mononuclear cell layer at the interface was transferred to a 50 mL Falcon tube, washed with PBS up to 45 mL as a top layer, and centrifuged at 300 g for 10 minutes. The pellet was resuspended in 5% of the original blood volume in frozen medium A (60:40 FCS:medium), and then the same volume of frozen medium B (80:20 FCS:DMSO) was added dropwise to reduce osmotic shock. The cells were transferred to cryovials (1 mL / vial (approximately 1 × 10⁶)). 7 The cells were frozen in a Mr Frosty freezing container at -80°C for up to one week, and then transferred to liquid nitrogen for long-term storage.

[0279] The cells were removed from liquid nitrogen storage and thawed, then immediately placed in a 37°C water bath to further thaw. The cell suspension was transferred to a 50 mL centrifuge tube, and the DMSO concentration was gradually decreased by very slowly adding the culture medium (RPMI + 10% heat-inactivated FCS, 1% penicillin / streptomycin and 1% glutamine). When the volume reached 30 mL, the cells were centrifuged (300 g for 10 minutes), resuspended in 5 mL of medium and counted, and the medium was added up to 15 mL. The cells were then centrifuged again in the same manner as above, and 5 × 10⁶ cells were obtained. 6 The cells were resuspended in an appropriate amount of culture medium to achieve a cell / mL ratio.

[0280] In each of the five individual experiments, donor PBMC samples from two healthy controls (HC), two recurrent steroid-mediated stenosis (RRMS), one patient-mediated steroid-mediated stenosis (PPMS), and one patient-mediated steroid-mediated stenosis (SPMS) were thawed as described above, and the cells were processed as follows. A different HC donor was used in each experiment, and the age and sex were roughly matched to those of the disease-affected donors used.

[0281] Inhibition of IL-7-induced pSTAT5 in T cells by DRSPAI-L7B. 5 x 10 6After resuspending PBMCs at a concentration of / mL in culture medium, 450 μL of cells were transferred to a 15 mL Falcon tube and incubated with 5 mL of PBS containing 5 μL of Near InfraRed live / dead stain. The cells were washed with 9 mL of complete culture medium, centrifuged (300 g, 5 minutes), and the cell pellet was transferred to AIM V serum-free culture medium in a 5 × 10⁶ cubic meter. 6 Cells were resuspended at a concentration of 1 / mL. All antibody treatments and rhIL-7 stimulations were diluted to four times the final assay concentration in AIM V serum-free culture medium, then mixed 1:1 (IL-7:mAb) and incubated at room temperature for 10 minutes. Culture medium was added if neither antibody nor IL-7 stimulation was present. The final concentration of IL-7 used was 1 ng / mL (57 pM). The final concentration of mAb used was 500 ng / mL (3.33 nM).

[0282] 100 μL of PBMC suspension was added to four FACS tubes for each donor (5 × 10⁻⁶). 5 Cells / Tests). 100 μL of antibody:IL-7 mixture was added to a suitable FACS tube (medium only, IL-7 only, IL-7 + DRSPAI-L7B, or IL-7 + anti-RSV isotype control antibody). After gently mixing the tubes, they were incubated at 37°C for 20 minutes in a humidified incubator. At the end of the stimulation period, the cells were centrifuged at 300 g for 5 minutes to resuspend the cell pellet, and 250 μL of pre-warmed PHOSFLOW fixation buffer (1x) was added. The samples were incubated at 37°C for a further 10 minutes. After fixation, the cells were pelletized by centrifugation (300 g, 5 min) and washed with 2 mL of PBS. The cell pellet was resuspended in 100 μL of ice-cold Perm buffer III and gently vortexed. After incubating the cells on ice for 30 minutes, they were washed once with 1 mL of PBS and centrifuged (300 g, 5 min). The cells were washed with 2 mL of PBS and then centrifuged (300 g, 5 minutes).

[0283] After permeabilization, the cell pellet was resuspended in 25 μL of FcR blocking reagent diluted 1:5 with FACS buffer. After incubating the cells at room temperature for 10 minutes, the detection antibody staining cocktail was added: 5 μL of anti-CD3 (PerCP / Cy5.5), 5 μL of anti-CD4 (AF488), 5 μL of anti-CD8 (APC), 20 μL of anti-p-STAT5 (PE), and 15 μL of FACS buffer (50 μL total per test). If staining was not performed for FMO control, the same amount of FACS buffer was added instead. The tubes were gently mixed and incubated at room temperature (RT) for 30 minutes in the dark. The cells were washed with 2 mL of FACS buffer, centrifuged (300 g, 5 minutes), and the pellet was resuspended in 100 μL of FACS buffer for analysis using a FACS Canto II flow cytometer on the same day.

[0284] The performance of the FACS Canto II instrument was verified using cytometer setup tracking (CST) beads. This is a QC check of the instrument, where a baseline is set and the voltage of each laser is optimized before use. The calibration results are stored in the instrument's CST software.

[0285] Instrument calibration was performed using UltraComp calibration beads, following the manufacturer's instructions. The relevant antibodies used to stain cells during the experiment were used to label the appropriate calibration bead type. For live / dead cell dye calibration, 1 μL of undiluted dye was added to one drop of ArcAmine-reactive bead, incubated for 30 minutes, washed, and then ArcAmine-negative beads were added before immediately performing sample measurements. Experimental calibration was performed using the automated calibration function available in the FACS Diva software, with appropriately labeled beads. After analysis of the calibration samples, calibration settings were calculated and applied to each experimental staining panel.

[0286] Antibodies and reagents For the experiment, antibody aliquots were thawed and stored at 4°C for up to 8 weeks. DRSPAI-L7B (anti-IL-7) and anti-RSV isotype controls were used.

[0287] [Table 12]

[0288] Samples were acquired using a BD FACS Canto II flow cytometer with BD BioSciences FACS Diva software (v8.0.1). The resulting corrected .fcs files were analyzed with FlowJo software (v10.0.8), and the results were created in Excel using the Batch Analysis function within the software.

[0289] To measure the ability of affected cells to respond to IL-7 and to confirm the efficacy of DRSPAI-L7B in samples from MS patients, PBMCs isolated from either healthy controls or MS patient donors were stimulated with 1 ng / mL (58 pM) of IL-7 in the presence of DRSPAI-L7B or an unsaturated (IC90 = 500 ng / mL (3.3 nM)) anti-RSV IgG1κ isotype control antibody.

[0290] PBMCs from healthy donors or MS patients (10 healthy individuals, 10 RRMS, 5 PPMS, and 5 SPMS) were stimulated with rhIL-7 in the presence of DRSPAI-L7B or anti-RSV antibody (isotype control). CD4 + T cells (Figure 6A) and CD8 + Phosphorylation of STAT5 in T cells (Figure 6B) was evaluated by flow cytometry. IL-7 stimulation was 1 ng / mL (58 pM, approximately 200 times higher than that reported for the disease), and CD4 cells derived from healthy donors and MS patients were used. + T cells and CD8 + STAT5 phosphorylation was induced in T cells. IL-7 stimulation was almost completely neutralized by DRSPAI-L7B at 500 ng / mL, i.e., 3.3 nM (unsaturated concentration). The data shown are normalized for IL-7 treatment conditions. Mean ± SEM. * p<0.05, ** p ≤ 0.01, *** p ≤ 0.001, ****p<0.0001. One-way ANOVA with Tukey's multiple comparison correction. Similar results were observed with IL-7 stimulation of PBMCs derived from IBD patients.

[0291] Example 9: IL-7 levels in disease All human samples were obtained with informed consent from patients in accordance with ICH GCP, under protocols approved by the national, regional, or clinical trial site's ethics committee or Institutional Review Board (IRB) approved protocols. Samples were stored at -80°C until use.

[0292] IL-7 levels were measured according to the SOP method. Briefly, this method follows the MSD kit protocol, which involves diluting the sample 1:2 with Diluent 43. After incubation of the diluted sample on a pre-coated IL-7 MSD plate, it was detected with rutenyl anti-IL-7 antibody. The IL-7 level in the plasma sample is directly proportional to the resulting ECL signal, which was read using an MSD Sector Imager 6000 Reader. The IL-7 method uses the MSD V-PLEX Human IL-7 Kit (catalog number K151RCD).

[0293] ECL signals for standards, controls, and unknown samples were derived from the MSD instrument and exported to Softmax Pro GxP for analysis. Inverse concentrations for each method were interpolated using a standard curve and a four-parameter curve-fitting model with 1 / y² weighting. The IL-7 concentration summaries were transferred to Microsoft Excel.

[0294] All data was transferred from Microsoft Excel 2016 to GraphPad Prism v.6 for graphing and statistical analysis. The data was copied to Prism's "Columns" based on the sample matrix (serum) and analyte (IL-7). Column statistics tests, including the Shapiro-Wilk normality test, were performed on each dataset to determine if they were normally distributed. If the data were not normally distributed, the distribution was normalized by transforming the data using the formula y=log(y). Column statistics tests were then performed again on the transformed data to confirm normality.

[0295] For serum samples, one-way analysis of variance (ANOVA) was used for group comparisons. The data distribution was tested using the Shapiro-Wilk normality test on column statistics. For non-normally distributed data, group differences were evaluated using Kruskal-Wallis nonparametric analysis with Dunn's multiple comparison test to compare the mean ranks of each column. In addition, the data was transformed using y=log(y) to normalize the data distribution. After transformation, the Shapiro-Wilk test was performed using column statistics to confirm that the transformation resulted in a normal distribution of the data. The transformed normally distributed data was then evaluated for statistically significant differences using a standard one-way, nonparametric ANOVA with Tukey's multiple comparison test to compare the means of each column.

[0296] IL-7 levels were quantified in serum samples from healthy controls (HC, n=10), Crohn's disease (n=15), ulcerative colitis (UC, n=15), systemic lupus erythematosus (SLE, n=15), and primary Sjögren's syndrome (pSS, n=15). IL-7 levels were significantly elevated in Crohn's disease, UC, and SLE compared to healthy controls (7.3, 9.44, and 5.53 times, respectively). A slight increase in IL-7 was also observed in the pSS cohort (3.55 times compared to HC). Data are mean ± SD. ** p ≤ 0.01, *** p ≤ 0.001, ****p ≤ 0.0001; serum was analyzed using one-way ANOVA with Dunn's multiple comparison correction. Figures 7A and 7B.

[0297] Example 10: Preparation of DRSPAI-L7B Cell lines were transfected with plasmids. These plasmids contained codon-optimized DRSPAI-L7B heavy and light chain genes, each under the transcriptional regulation of a different human EF1α promoter. The light chain constant region was human κ, and the heavy chain constant region was human IgG1 with a LAGA substitution. The LAGA substitution corresponds to L235A / G237A. The transfected cell lines were expanded and sorted based on DRSPAI-L7B expression.

[0298] Example 11: Epitope binding Device Waters Synapt G2-Si mass spectrometer Acquity M Class UPLC LEAP H / DX PAL Liquid Handling Robot

[0299] solution Quench solution: 400 mM potassium phosphate, 6 M guanidine hydrochloride, 0.5 M TCEP pH 2.5 (This pH is achieved after mixing the sample with a quench buffer whose pH has been adjusted with NaOH in a 1:1 ratio.) Dilution buffer: 50 mM sodium phosphate, 100 mM NaCl, pH 7.0 (in H2O)

[0300] protein: IL7: Concentration: 0.68 mg / mL (33 μM) (in PBS). Sequence before processing (SEQ ID NO: 1): [ka] Secretory leader (underlined above)

[0301] DRSPAI-L7B was produced using HEK cells and used at a concentration of 15 mg / mL (100 μM) in PBS.

[0302] HDX The dilution buffers were as follows: Non-deuterated: 50 mM sodium phosphate, 100 mM NaCl, pH 7.0 in H2O Deuterated: 50 mM sodium phosphate, 100 mM NaCl in D2O, pD6.6

[0303] In the initial trial, DRSPAI-L7B was tested as a single dose to confirm the quality of digestion and signal intensity.

[0304] In the HDX experiment, the IL7:mAb mixture was prepared as follows. The "Apo" sample consisted of 20 μL of concentrated IL7, 15 μL of PBS, and 25 μL of dilution buffer. The "mAb" sample consisted of 20 μL of concentrated IL7, 15 μL of DRSPAI-L7B, and 25 μL of dilution buffer. This resulted in a final nominal concentration of 50 μM for IL7 and 25 μM for DRSPAI-L7B. Samples were prepared on ice and kept at 0°C until analysis.

[0305] In the mAb binding experiment, samples were subjected to a standard deuteration method using a LEAP H / DX PAL robot and a 10-fold dilution in deuterated buffer. Protein samples were placed in a rack at 0°C. 6 μL of protein sample was transferred to a vial maintained at 20°C, and then 54 μL of dilution buffer (non-deuterated at time 0, deuterated at other time points) was added to initiate hydrogen exchange. After incubation for an appropriate time, 50 μL of this sample was aspirated and transferred to a pre-cooled vial (0°C) containing 50 μL of quench solution (400 mM sodium phosphate, 6 M guanidine hydrochloride, 0.5 M tris-carboxyethylphosphine [pH 2.5 after mixing with sample]). After mixing and incubation for 1 minute, 90 μL of this sample was re-aspirated and transferred to an HDX manager, and injected at 50 μL / min through a 100 μL loop into an immobilized pepsin column (Enzymate BEH, 2.1 × 30 mm, Waters #186007233, held at 15°C). The resulting peptide was eluted with 0.2% formic acid and captured on a Vanguard BEH C18 pre-column (2.1 × 5 mm; Waters #186003975). The capture column was then switched inline to an analytical reverse-phase column (BEH C18, 1 × 100 mM, Waters #186002346), and the peptide was eluted using the following gradient: A = water, 0.2% formic acid, 0.03% trifluoroacetic acid, B = 0.2% formic acid in acetonitrile:

[0306] [Table 13]

[0307] During the gradient phase, the pepsin column was washed at 25 μL / min with pepsin washing buffer (2M guanidine-HCl, 0.8% formic acid, 5% acetonitrile, 5% propane-2-ol, pH 2.5) at 2 × 80 μL, and returned to 0.2% formic acid at 25 μL / min in preparation for the next sample. The eluate from the analytical column was analyzed using a Waters Synapt G2-Si mass spectrometer operating in positive, separation mode with ESI-MS, while acquiring continuous data. Rock spray data including leucine-enkephalin ions and Glu-Fib ions was also acquired. For peptide identification samples, MSe data was acquired (alternating between low-energy and high-energy conditions within a collision cell) to obtain fragmentation data useful for reliable peptide identification. For HDX samples, a single low-energy acquisition (+ rock spray) was performed.

[0308] The first sample was MS to create a peptide search list using ProteinLynx Global Server v3.0.2 (Waters). e The process was run in a specific mode. HDX samples were run in two replicates with deuteration times of 0, 0.5, and 5 minutes. The peptide search list was imported into DynamX v3.0 (Waters) and filtered to obtain high-quality peptides (minimum intensity > 10,000, peptide score > 7.0) to search for in the HDX samples. Next, the data from the HDX samples was taken in and processed to determine deuteration for each identified peptide in each sample. Peptide and ion assignments were manually verified and refined as necessary.

[0309] To interpolate peptide-level data into residue-level data (to enable heatmaps and structural displays), we used the algorithm that DyanamX uses to generate heatmaps, and for each residue, we used data from the shortest duplicate peptide (if the two duplicate peptides were the same length, we used the peptide closest to the N-terminus).

[0310] result Two peptides in the region of residues 67-81 (code number of the full-length untreated construct) showed strong protection in the presence of the mAb. (Sequence ID 12-FKRHICDANKEGMFL) (Sequence ID 16-FKRHICDANKEGMF)

[0311] Here too, the region spanning residues 67–81 showed a clear protective signal. Furthermore, heatmap data was mapped to the available 3D structure of IL7 (complexed with IL7Rα) and the protective region (FKRHICDANKEGMFL) spanning residues 67–81. This region was distal to the region of IL7 that interacts with the receptor IL7Rα. The epitope is adjacent to the interaction site between IL7Rα and the γ chain on the folded protein.

[0312] Embodiment Other aspects and embodiments of this disclosure will become apparent from the following exemplary embodiments.

[0313] Embodiments: Embodiment 1 An IL-7 binding protein that binds to one or more amino acid residues in the amino acid sequence of human IL-7, as shown in Sequence ID No. 12.

[0314] Embodiment 2 The IL-7 binding protein of Embodiment 1, which protects IL-7 residues 67-81 (SEQ ID NO: 12) from deuterium exchange in HDX-MS analysis.

[0315] Embodiment 3 The IL-7 binding protein of Embodiment 1 protects residues 67-80 (SEQ ID NO: 16) of IL-7 from deuterium exchange during HDX-MS analysis.

[0316] Embodiment 4 An IL-7 binding protein or its IL-7 binding fragment with a KD of 100 nM or less that binds to human IL-7 adjacent to the IL-7Rα binding site and inhibits the binding of IL-7 to IL-7R when measured by an in vitro competitive binding assay.

[0317] Embodiment 5 An IL-7 binding protein according to any one of Embodiments 1 to 4, comprising at least one of the following: (a) a heavy chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 6, (b) a heavy chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 7, or (c) a heavy chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 8.

[0318] Embodiment 6 An IL-7 binding protein according to any one of Embodiments 1 to 5, comprising at least one of the following: (a) a light chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 9, (b) a light chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 10, or (c) a light chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 11.

[0319] Embodiment 7 An IL-7 binding protein according to any of Embodiments 1 to 6, comprising a variable region light chain having at least 80% identity with the amino acid sequence shown in Sequence ID No. 5.

[0320] Embodiment 8 An IL-7 binding protein or an IL-7 binding fragment thereof, comprising a variable region light chain having at least 95% identity with the amino acid sequence shown in Sequence ID No. 5.

[0321] Embodiment 9 The IL-7 binding protein of Embodiment 8 comprises at least one of the following: (a) a heavy chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 6, (b) a heavy chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 7, or (c) a heavy chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 8.

[0322] Embodiment 10 An IL-7 binding protein or an IL-7 binding fragment thereof, comprising a heavy chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 6, a heavy chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 7, and a heavy chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 8.

[0323] Embodiment 11 An IL-7 binding protein or an IL-7 binding fragment thereof, comprising a light chain CDR1 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 11.

[0324] Embodiment 12 An IL-7 binding protein of Embodiment 10 or 11, comprising a variable region light chain having at least 80% identity with the amino acid sequence shown in Sequence ID No. 5.

[0325] Embodiment 13 An IL-7 binding protein according to any of Embodiments 1 to 12, comprising a variable region light chain having the amino acid sequence shown in Sequence ID No. 5.

[0326] Embodiment 14 An IL-7 binding protein according to any of Embodiments 1 to 13, comprising a heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 6, a heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 7, and a heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 8.

[0327] Embodiment 15 An IL-7 binding protein according to any of Embodiments 1 to 14, comprising a light chain CDR1 having the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR2 having the amino acid sequence shown in SEQ ID NO: 10, and a light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11.

[0328] Embodiment 16 An IL-7 binding protein according to any of Embodiments 1 to 15, comprising a variable region heavy chain having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 4.

[0329] Embodiment 17 An IL-7 binding protein according to any of Embodiments 1 to 16, comprising a variable region heavy chain having the amino acid sequence shown in Sequence ID No. 4.

[0330] Embodiment 18 An IL-7 binding protein according to any of Embodiments 1 to 17, comprising a light chain having at least 80% identity with the amino acid sequence shown in Sequence ID No. 3.

[0331] Embodiment 19 An IL-7 binding protein according to any of Embodiments 1 to 18, comprising a light chain having the amino acid sequence shown in Sequence ID No. 3.

[0332] Embodiment 20 The IL-7 binding protein according to any one of embodiments 1 to 19, wherein the IL-7 binding protein includes a constant region such that the IL-7 binding protein has reduced ADCC and / or complement activation or reduced effector function.

[0333] Embodiment 21 The IL-7 binding protein according to Embodiment 20, wherein the IL-7 binding protein comprises a heavy chain Fc domain having alanine residues at positions 235 and 237 according to EU numbering.

[0334] Embodiment 22 An IL-7 binding protein according to any of Embodiments 1 to 21, comprising a heavy chain having at least 80% identity with the amino acid sequence shown in Sequence ID No. 2.

[0335] Embodiment 23 An IL-7 binding protein according to any of Embodiments 1 to 22, comprising a heavy chain having the amino acid sequence shown in Sequence ID No. 2.

[0336] Embodiment 24 An IL-7 binding protein according to any of Embodiments 1 to 23, comprising a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 2 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 3.

[0337] Embodiment 25 An IL-7 binding protein according to any of Embodiments 1 to 24, wherein the IL-7 binding protein is an antibody or its antigen-binding portion.

[0338] Embodiment 26 The IL-7 binding protein of embodiment 25, wherein the antibody is a monoclonal antibody.

[0339] Embodiment 27 The IL-7 binding protein of embodiment 26, wherein the monoclonal antibody is IgG1.

[0340] Embodiment 28 An IL-7 binding protein according to any of Embodiments 1 to 27, wherein the IL-7 binding protein is a human, humanized, or chimeric antibody.

[0341] Embodiment 29 An IL-7 binding protein according to any of Embodiments 1 to 28, wherein the IL-7 binding protein is a humanized antibody.

[0342] Embodiment 30 An IL-7 binding protein according to any of Embodiments 1 to 29, wherein the IL-7 binding protein is a human antibody.

[0343] Embodiment 31 An IL-7 binding protein according to any of Embodiments 1 to 30, wherein the IL-7 binding protein binds to and neutralizes IL-7.

[0344] Embodiment 32 An IL-7 binding protein according to any of embodiments 1 to 31, wherein the IL-7 binding protein binds to native IL-7.

[0345] Embodiment 33 An IL-7 binding protein according to any of embodiments 1 to 32, wherein the IL-7 binding protein binds to circulating IL-7.

[0346] Embodiment 34 The IL-7 binding protein is an isolated IL-7 binding protein, as of any of Embodiments 1 to 33.

[0347] Embodiment 35 It binds to IL-7 and inhibits IL-7-dependent IFN-γ or IL-10 secretion from peripheral blood mononuclear cells to an IC of less than 1 nM. 50 An IL-7 binding protein of any of embodiments 1 to 34 that inhibits the IL-7 binding protein.

[0348] Embodiment 36 It binds to IL-7 and induces IL-7-dependent STAT5 phosphorylation in CD4+ T cells at IC50 below 1 nM. 50 An IL-7 binding protein of any of embodiments 1 to 35 that inhibits the IL-7 binding protein.

[0349] Embodiment 37 An IL-7 binding protein according to any of embodiments 1 to 36, wherein the IL-7 binding protein is a reversible dimer.

[0350] Embodiment 38 An IL-7 binding protein according to any of embodiments 1 to 37 that inhibits signaling, activation, cytokine production, and proliferation of CD4+ T cells and / or CD8+ T cells.

[0351] Embodiment 39 A nucleic acid encoding an IL-7 binding protein according to any of Embodiments 1 to 38.

[0352] Embodiment 40 A nucleic acid of embodiment 39, comprising a sequence having at least 80% identity with the nucleic acid sequence shown in sequence number 13, which codes for a light chain.

[0353] Embodiment 41 A nucleic acid of embodiment 39 or 40, comprising the nucleic acid sequence shown in sequence number 13 which codes for a light chain.

[0354] Embodiment 42 A nucleic acid according to any of embodiments 39 to 41, comprising a sequence having at least 80% identity with the nucleic acid sequence shown in Sequence ID No. 14 which codes for a heavy chain.

[0355] Embodiment 43 A nucleic acid according to any of embodiments 39 to 42, comprising the nucleic acid sequence shown in Sequence ID No. 14 which encodes a heavy chain.

[0356] Embodiment 44 A nucleic acid according to any of embodiments 39 to 43, further comprising a sequence having at least 80% identity with the nucleic acid sequence shown in Sequence ID No. 15 which encodes a signal peptide.

[0357] Embodiment 45 A vector comprising the nucleic acid described in any one of embodiments 39 to 44.

[0358] Embodiment 46 A vector according to embodiment 45, further comprising a promoter that functions in mammalian cells.

[0359] Embodiment 47 A host cell comprising a nucleic acid of any of embodiments 39 to 44, or a vector of embodiment 45 or 46.

[0360] Embodiment 48 The host cells of embodiment 47 are CHO cells.

[0361] Embodiment 49 A method for producing an IL-7 binding protein according to any of Embodiments 1 to 38, comprising the steps of: maintaining host cells according to Embodiment 47 or 48 in a culture medium to produce an IL-7 binding protein; and isolating or purifying the IL-7 binding protein produced by the host cells.

[0362] Embodiment 50 IL-7 binding protein produced by the method of Embodiment 49.

[0363] Embodiment 51 An IL-7 binding protein that competes for binding to IL-7 with any of the IL-7 binding proteins of Embodiments 1 to 38.

[0364] Embodiment 52 A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an IL-7 binding protein or an IL-7 binding fragment thereof, wherein the IL-7 binding protein or the IL-7 binding fragment exhibits binding to IL-7 at an epitope comprising at least five consecutive amino acids from the sequence shown in Sequence ID No. 12.

[0365] Embodiment 53 The pharmaceutical composition of Embodiment 52, wherein the IL-7 binding protein is one of the IL-7 binding proteins of Embodiments 1 to 38.

[0366] Embodiment 54 A pharmaceutical composition comprising an IL-7 binding protein according to any of Embodiments 1 to 38 and a pharmaceutically acceptable carrier or excipient.

[0367] Embodiment 55 A pharmaceutical composition according to any one of embodiments 52 to 54, further comprising at least one additional therapeutic agent.

[0368] Embodiment 56 A pharmaceutical composition according to any of embodiments 52 to 55, having a pH of 4.5 to 7.0.

[0369] Embodiment 57 A pharmaceutical composition according to any of embodiments 52 to 56, having a pH of 5.5, 6.0, 6.2, or 6.5.

[0370] Embodiment 58 An IL-7 binding protein according to any of embodiments 1 to 38 for use in therapy.

[0371] Embodiment 59 A method for treating an autoimmune and / or inflammatory condition in a subject requiring such treatment, comprising the step of administering to the subject a therapeutically effective amount of an IL-7 binding protein of any of embodiments 1 to 38 or a pharmaceutical composition of embodiments 52 to 57.

[0372] Embodiment 60 The method of Embodiment 59, wherein the administration is via arterial, subcutaneous, intradermal, intratumor, intralymph node, intramedullary, intramuscular, intravenous, or intraperitoneal administration.

[0373] Embodiment 61 The method according to Embodiment 60, wherein the administration is by subcutaneous injection.

[0374] Embodiment 62 A method according to any of Embodiments 59 to 61, wherein the therapeutically effective dose is at least about 0.1 mg / kg, 0.5 mg / kg, 1 mg / kg, 3 mg / kg, 5 mg / kg, 10 mg / kg, 20 mg / kg, 30 mg / kg, or 40 mg / kg.

[0375] Embodiment 63 A method according to any of embodiments 59 to 62, wherein the therapeutically effective dose is approximately 3 mg / kg.

[0376] Embodiment 64 A method according to any of embodiments 59 to 63, wherein a therapeutically effective amount is administered to the subject at least once every approximately 1 to 60 days.

[0377] Embodiment 65 A method according to any of embodiments 59 to 64, wherein a therapeutically effective dose is administered to the subject once every four weeks.

[0378] Embodiment 66 A method according to any of embodiments 59 to 65, wherein the autoimmune and / or inflammatory condition is Sjögren's syndrome.

[0379] Embodiment 67 A method according to any of embodiments 59 to 65, wherein the autoimmune and / or inflammatory condition is rheumatoid arthritis.

[0380] Embodiment 68 A method according to any of embodiments 59 to 65, wherein the autoimmune and / or inflammatory condition is multiple sclerosis.

[0381] Embodiment 69 The method of Embodiment 68, wherein multiple sclerosis is clinically isolated syndrome, relapsing-remitting, primary progressive, or secondary progressive.

[0382] Embodiment 70 A method according to any of embodiments 59 to 65, wherein the autoimmune and / or inflammatory condition is Crohn's disease.

[0383] Embodiment 71 A method according to any of embodiments 59 to 65, wherein the autoimmune and / or inflammatory condition is ulcerative colitis.

[0384] Embodiment 72 A method according to any of embodiments 59 to 65, wherein the autoimmune and / or inflammatory condition is lupus erythematosus.

[0385] Embodiment 73 Use of any IL-7 binding protein of Embodiments 1 to 38 in the manufacture of a pharmaceutical product for the treatment of autoimmune and / or inflammatory conditions.

[0386] Embodiment 74 Use of Embodiment 73, wherein the autoimmune and / or inflammatory condition is Sjögren's syndrome.

[0387] Embodiment 75 Use of Embodiment 73, in which the autoimmune and / or inflammatory condition is rheumatoid arthritis.

[0388] Embodiment 76 Use of Embodiment 73, in which the autoimmune and / or inflammatory condition is multiple sclerosis.

[0389] Embodiment 77 Use of Embodiment 76, wherein multiple sclerosis is clinically isolated syndrome, relapsing-remitting, primary progressive, or secondary progressive.

[0390] Embodiment 78 Use of Embodiment 73, in which the autoimmune and / or inflammatory condition is Crohn's disease.

[0391] Embodiment 79 Use of Embodiment 73, wherein the autoimmune and / or inflammatory condition is ulcerative colitis.

[0392] Embodiment 80 Use of Embodiment 73, in which the autoimmune and / or inflammatory condition is lupus erythematosus.

[0393] Embodiment 81 An IL-7 binding protein of any of Embodiments 1 to 38 for use in the treatment of autoimmune and / or inflammatory conditions.

[0394] Embodiment 82 An IL-7 binding protein for use in Embodiment 81, wherein the autoimmune and / or inflammatory condition is Sjögren's syndrome.

[0395] Embodiment 83 An IL-7 binding protein for use in Embodiment 81, wherein the autoimmune and / or inflammatory condition is rheumatoid arthritis.

[0396] Embodiment 84 An IL-7 binding protein for use in Embodiment 81, wherein the autoimmune and / or inflammatory condition is multiple sclerosis.

[0397] Embodiment 85 IL-7 binding protein for use in Embodiment 84, where multiple sclerosis is a clinically isolated syndrome, relapsing-remitting, primary progressive, or secondary progressive.

[0398] Embodiment 86 An IL-7 binding protein for use in Embodiment 81, wherein the autoimmune and / or inflammatory condition is Crohn's disease.

[0399] Embodiment 87 An IL-7 binding protein for use in Embodiment 81, wherein the autoimmune and / or inflammatory condition is ulcerative colitis.

[0400] Embodiment 88 An IL-7 binding protein for use in Embodiment 81, wherein the autoimmune and / or inflammatory condition is lupus erythematosus.

[0401] Embodiment 89 Use of IL-7 binding proteins according to any of embodiments 1-38 or 50-51 for the diagnosis of a disease or condition.

[0402] Embodiment 90 A composition comprising an IL-7 binding protein according t...

Claims

1. An IL-7 binding protein that binds to one or more amino acid residues within the amino acid sequence of human IL-7 shown in SEQ ID NO:

12.

2. 2. The IL-7 binding protein of claim 1, which protects residues 67-81 (SEQ ID NO: 12) of IL-7 from deuterium exchange in HDX-MS analysis.

3. 2. The IL-7 binding protein of claim 1, which protects residues 67-80 (SEQ ID NO: 16) of IL-7 from deuterium exchange in HDX-MS analysis.

4. An IL-7 binding protein that binds human IL-7 adjacent to the IL-7Rα binding site with a KD of about 100 nM or less as measured by a surface plasmon resonance assay.

5. 5. The IL-7 binding protein of claim 4, which inhibits binding of IL-7 to IL-7R as measured in an in vitro competitive binding assay determined using a surface plasmon resonance assay.

6. 6. An IL-7 binding protein according to claim 1, comprising one or more of CDRH1 as set forth in SEQ ID NO:6, CDRH2 as set forth in SEQ ID NO:7, CDRH3 as set forth in SEQ ID NO:8, CDRL1 as set forth in SEQ ID NO:9, CDRL2 as set forth in SEQ ID NO:10 and / or CDRL3 as set forth in SEQ ID NO:

11.

7. An IL-7 binding protein comprising a CDRH1 set forth in SEQ ID NO:6, a CDRH2 set forth in SEQ ID NO:7, a CDRH3 set forth in SEQ ID NO:8, a CDRL1 set forth in SEQ ID NO:9, a CDRL2 set forth in SEQ ID NO:10 and a CDRL3 set forth in SEQ ID NO:

11.

8. V having at least 90% identity with the amino acid sequence set forth in SEQ ID NO:4 H Domain and / or V having at least 90% identity with the amino acid sequence shown in SEQ ID NO:5 L 8. The IL-7 binding protein of claim 7, comprising a domain.

9. V shown in SEQ ID NO:4 H Domain and V shown in SEQ ID NO:5 L 9. The IL-7 binding protein of claim 8, comprising a domain.

10. 10. The IL-7 binding protein of any one of claims 1 to 9, wherein the IL-7 binding protein comprises a constant region such that the IL-7 binding protein has reduced ADCC and / or complement activation or reduced effector function.

11. 11. The IL-7 binding protein of claim 10, wherein the IL-7 binding protein comprises a heavy chain Fc domain having alanine residues at positions 235 and 237 according to EU numbering.

12. 12. The IL-7 binding protein of any one of claims 1 to 11, wherein the IL-7 binding protein comprises a scaffold selected from human IgG1 and human IgG4 isotypes.

13. 13. The IL-7 binding protein of claim 12, wherein the IL-7 binding protein is a human IgG1 isotype.

14. The IL-7 binding protein of any one of claims 1 to 13, wherein the IL-7 binding protein is a monoclonal antibody.

15. The IL-7 binding protein of claim 14, wherein the monoclonal antibody is a human, humanized or chimeric antibody.

16. 16. An IL-7 binding protein according to any one of claims 7 to 15, comprising a heavy chain having at least 90% identity with the amino acid sequence shown in SEQ ID NO:2 and a light chain having at least 90% identity with the amino acid sequence shown in SEQ ID NO:

3.

17. 17. The IL-7 binding protein of claim 16, comprising a heavy chain as set forth in SEQ ID NO:2 and a light chain as set forth in SEQ ID NO:

3.

18. 18. An IL-7 binding protein according to any one of claims 1 to 17, which binds to IL-7 with a KD of 50 nM or less, 10 nM or less, 1 nM or less, or 0.1 nM or less.

19. binds to IL-7, and (i) IC of 1 nM or less 50 and / or (ii) inhibits IL-7-dependent IFN-γ or IL-10 secretion from peripheral blood mononuclear cells at an IC 50 19. An IL-7 binding protein according to any one of claims 1 to 18, which inhibits IL-7-dependent STAT5 phosphorylation in CD4+ T cells at 100-fold increase in IL-7 activity.

20. CD4 + T cells and / or CD8 + 20. An IL-7 binding protein according to any one of claims 1 to 19, which inhibits T cell signalling, activation, cytokine production and proliferation.

21. A nucleic acid encoding an IL-7 binding protein according to any one of claims 1 to 20.

22. 22. An expression vector comprising the nucleic acid sequence of claim 21.

23. 23. A host cell comprising a nucleic acid sequence according to claim 21 or an expression vector according to claim 22.

24. 24. An IL-7 binding protein expressed by the host cell of claim 23.

25. 21. A method for making an IL-7 binding protein according to any one of claims 1 to 20, comprising the steps of maintaining a host cell according to claim 23 in a culture medium to produce said IL-7 binding protein, and isolating or purifying the IL-7 binding protein produced by said host cell.

26. 25. An IL-7 binding protein that competes with an IL-7 binding protein according to any one of claims 1 to 20 or 24 for binding to IL-7.

27. A pharmaceutical composition comprising a pharma- ceutical acceptable carrier or excipient and an IL-7 binding protein, said IL-7 binding protein exhibiting binding to IL-7 at an epitope comprising at least 5 consecutive amino acids of the sequence set forth in SEQ ID NO:12 or SEQ ID NO:

16.

28. A pharmaceutical composition comprising an IL-7 binding protein according to any one of claims 1 to 20 and 24, and a pharma- ceutically acceptable carrier or excipient.

29. The pharmaceutical composition of claim 28 for use in the treatment of autoimmune and / or inflammatory conditions.

30. The pharmaceutical composition of claim 29, wherein the autoimmune and / or inflammatory condition is multiple sclerosis, Sjogren's syndrome, rheumatoid arthritis, Crohn's disease, ulcerative colitis or lupus erythematosus.

31. The pharmaceutical composition described in claim 30, wherein the multiple sclerosis is clinically isolated syndrome, relapsing-remitting, primary progressive or secondary progressive.

32. 25. Use of an IL-7 binding protein according to any one of claims 1 to 20 or 24 in the manufacture of a medicament for the treatment of an autoimmune and / or inflammatory condition.

33. 33. Use of an IL-7 binding protein according to claim 32, wherein the autoimmune and / or inflammatory pathology is multiple sclerosis, Sjogren's syndrome, rheumatoid arthritis, Crohn's disease, ulcerative colitis or lupus erythematosus.

34. 34. The use of an IL-7 binding protein according to claim 33, wherein the multiple sclerosis is clinically isolated syndrome, relapsing-remitting, primary progressive or secondary progressive.

35. A kit comprising an IL-7 binding protein according to any one of claims 1 to 20 or 24 and instructions for use.